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ABSTRACT
The United States is facing a shortage of neurologists with severe conse-
quences: a) average wait-times to see neurologists are increasing, b) patients
with chronic neurological disorders are unable to receive diagnosis and care
in a timely fashion, and c) there is an increase in neurologist burnout leading
to physical and emotional exhaustion. Present-day neurological care relies
heavily on time-consuming visual review of patient data (e.g., neuroimaging
and electroencephalography (EEG)), by expert neurologists who are already
in short supply. As such, the healthcare system needs creative solutions that
can increase the availability of neurologists to patient care. To meet this need,
this dissertation develops a machine-learning (ML)-based decision support
framework for expert neurologists that focuses the experts’ attention to ac-
tionable information extracted from heterogeneous patient data and reduces
the need for expert visual review. Specifically, this dissertation introduces a
novel ML framework known as domain-guided machine learning (DGML) and
demonstrates its usefulness by improving the clinical treatments of two major
neurological diseases, epilepsy and Alzheimer’s disease. In this dissertation,
the applications of this framework are illustrated through several studies con-
ducted in collaboration with the Mayo Clinic, Rochester, Minnesota. Chapters
3, 4, and 5 describe the application of DGML to model the transient abnormal
discharges in the brain activity of epilepsy patients. These studies utilized the
intracranial EEG data collected from epilepsy patients to delineate seizure
generating brain regions without observing actual seizures; whereas, Chapters
6, 7, 8, and 9 describe the application of DGML to model the subtle but
permanent changes in brain function and anatomy, and thereby enable the
early detection of chronic epilepsy and Alzheimer’s disease. These studies
utilized the scalp EEG data of epilepsy patients and two population-level
multimodal imaging datasets collected from elderly individuals.
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Over the past twenty centuries, the field of medicine has seen major advance-
ments in surgical treatments, systematic training of physicians, understanding
of anatomy, development of public health measures, and evidence-based clin-
ical research. These advancements, along with developments in chemistry,
genetics, and lab technology (such as the x-ray) led to modern medicine. It
is clear that the recent advancements in medicine have moved hand in hand
with technological advancements. The inventions of noninvasive imaging
technology and next-generation sequencing technology are great examples
of new technology that greatly reduced the burden of diagnosing complex
illnesses. However, despite those monumental advancements in medical prac-
tice, the rates and costs of chronic disease are rising globally. Our current
medical model works well for acute illnesses and trauma, but is not ade-
quately equipped to reverse or prevent chronic and degenerative illness. To
make things worse, developed countries like the United States are facing
significant shortages of physicians, particularly in rural settings [1]. Such
shortages have led to several alarming consequences: a) average wait-times
to see physicians are increasing, b) patients with chronic diseases are unable
to receive diagnosis and care in a timely fashion, and c) there is a profound
increase in physician burnout leading to physical and emotional exhaustion,
and loss of enthusiasm for clinical practice. With continuing deficits predicted
over the next several years, the problem can only worsen as populations age.
Tackling this multifaceted problem requires advancements in many areas
including medical training, healthcare cost, and human resource management.
This dissertation focuses on using analytical approaches to enable additional
clinical decision support which can increase the availability of physicians
to patient care. Recent advancements in fast computing capabilities and
machine learning methods have enabled the ability to process large amounts
of heterogeneous medical data in real time and develop predictive models
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that can assist physicians in clinical decision making. Specifically, it ap-
pears that the abilities to a) predict the onset of chronic diseases well in
advance, b) characterize the unique profile of an individual’s disease from
multimodal biomarker data, c) model the longitudinal evolution of disease
etiology, and d) develop personalized treatments can greatly enhance our
ability to treat chronic illnesses. However, significant research gaps related to
model correctness, ground truth, availability of data, multimodality of data,
and interpretability remain unaddressed.
1.1 Research Gaps in Machine Learning for Healthcare
Availability of data: The accuracy and generalizability of machine learning
(ML)-based predictive models are dictated by the amount of data available
for training and testing [2]. Figure 1.1 illustrates the relationship between the
amount of training data available and the performance of the predictive model
trained using that data. Deep learning-based approaches have a distinctive
advantage when a large amount of training data is available because of
their ability to learn high-dimensional nonlinear discriminative functions.
However, a major bottleneck in developing ML tools for healthcare is that the
preliminary data available for developing a predictive model is usually limited.
Therefore, the advantage of deep learning is unfortunately not applicable in
the majority of the problems involving healthcare data. On the other hand,
classical ML approaches (e.g., logistic regression, support vector machine)
are generally at least as good as neural network-based approaches when the
available training data is small. As such, classical ML approaches are preferred
in small-data problems over neural network-based approaches because of their
simplicity and interpretability. However, regardless of the ML approach used,
small datasets generally limit the ability to learn accurate and generalizable
decision schemes. Therefore, a shift in the general design of ML methods is
necessary to achieve the desired accuracy levels when the data available for
training is limited.
Multimodality of data: A clinician considers multiple sources of informa-
tion when assessing a patient’s condition, such as medical history, genetic
information, imaging data, electrophysiological data, blood measurements,





Figure 1.1: Illustration of training data and accuracy requirement in health
analytics.
ML-based predictive models to utilize all the available information to provide
accurate predictions and add value to clinical decisions. However, a simple
concatenation of the features is often not sufficient to describe the complex
biological dependence between the different information sources. It appears
that the sources should be combined in a way that is meaningful from a
biological perspective using domain knowledge. One might argue that such
relationships could be learned when sufficient training data is available. How-
ever, since data is scarce in healthcare, intelligent ways to combine multimodal
healthcare data can greatly assist in the development of high-performance
machine learning models for healthcare.
Interpretability: A major bottleneck in translating artificial intelligence
(AI) technology from experimental projects to actual implementations in
clinical workflows is their uninterpretable nature. A model does not add value
to a clinician’s assessment of a medical condition when the reason for the
model’s prediction is unclear, and this fact is true regardless of the accuracy
the model. Especially, modern ML approaches based on deep learning are
much harder to interpret than classical ML approaches. Although classical
ML approaches are easier to interpret, the accuracy level achieved by such
approaches is typically insufficient, and they are not well suited for complex
models that integrate multimodal information. Furthermore, recent work in
assigning attributions to input data based on the predictions made by deep
learning models is a promising step [3]; however, these approaches do not
provide high-level decision rules that are interpretable for a clinician.
Ground truth: Unambiguous ground truth is necessary for developing
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accurate predictive models. However, generating ground truth in healthcare
is costly and time consuming because it involves a lot of manual effort. As a
result, large datasets with well-curated ground truth information are difficult
to obtain, and often the ground truth data are error-prone. A recent study
has shown that the ground truth data generated by expert ophthalmologists
in grading retinal fundus images demonstrate a significant level of ambiguity
[4]. An approach that has been historically successful in handling errors
in ground truth is generating multiple instances of ground truth via crowd
sourcing. However, this is unfortunately not a feasible option in healthcare
analytics because of the added cost and the inability to distribute sensitive
healthcare data. Hence, it is necessary to develop predictive models that are
less reliant on the ground truth data but have a firm biological foundation.
Such models enable the development of generalizable predictive models despite
being trained on very little and/or ambiguous ground truth.
Model correctness: The need for highly accurate predictive models in
healthcare is indisputable. However, the definition of model correctness is
beyond simply the accuracy of a model, and is a topic of intense debate in clin-
ical practice. Model correctness comprises many aspects, including accuracy,
trust, and fairness, and ultimately boils down to the value a predictive model
adds to a clinician’s assessment. Accuracy metrics such as area under receiver
operating characteristics (AUROC) curve and area under precision-recall
curves (AUPRC) describe only the average performance of a predictive model,
and their scopes are limited to the training and testing datasets. On the other
hand, to ensure the model’s broader applicability, trust and fairness focus on
the model’s performance on inputs that are outside of the training and testing
datasets. Specifically, the aspects of trust and fairness attempt to answer
queries such as whether the model produces stable results when provided with
arbitrarily random inputs, and whether the model demonstrates an inherent
bias towards a particular set of inputs. Although there is extensive literature
on improving model accuracy, the aspects of trust and fairness have only
recently started receiving interest in the scientific community.
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1.2 Domain-guided Machine Learning
This dissertation introduces a novel framework known as “Domain-guided
Machine Learning” (DGML) to address some of the aforementioned research
gaps. Specifically, this dissertation focuses on developing novel machine
learning models that integrate analytical concepts and domain-specific insights.
At its core, DGML uses probabilistic graphical models to represent the domain-
driven relationships between different information sources and transforms
them into discriminative models to infer the state of an underlying biological
phenomenon. In the process, this dissertation also addresses the following
methodological challenges to enable the successful clinical translation of the
developed models. Those challenges include 1) extracting correlates of diseases
mechanisms from heterogeneous data (e.g., imaging, electrophysiological
signals, omics, clinical records), 2) inferring spatial and temporal patterns
of biomarkers by leveraging data types of different spatial and temporal
granularities, 3) elucidating causal factors that are involved in the disease
pathophysiology, and 4) developing reliable predictive models with limited
sample sizes and longitudinal information.
DGML framework: The core of this framework is the development of a
knowledge graph that represents the relationships between different informa-
tion sources. Such a graph is generated by gathering scientifically established
relationships between the variables of interest via interacting with clinicians
and reviewing literature. After this crucial first step, the second step involves
defining the relationships explicitly, based either on domain knowledge or
using parameteric functions that can be learned from data. Since the gen-
erality of the model relies on the ability to customize the definitions of the
dependencies described by the model, we have adopted a factor graph setting
to represent the model. A factor graph is a bipartite graph that expresses how
a global function of several variables factors into a product of local functions.
Factor graphs subsume many other graphical models, including Bayesian
networks, Markov random fields, and Tanner graphs [5].
We represent the interactions between the variables of interest as a dynamic
graph G = (V,E), where V is the set of variables and E is the set of undirected
links between the variables. The variable associated with the feature k is
denoted by xk and the values of all the variables are denoted by the vector x.
Furthermore, we use Xk to denote the set of all possible values that xk can
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take. Depending on the nature of the feature k, xk could be a scalar or a
vector and discrete or continuous.
For example, the Figure 1.2a describes four random variables (x1, x2, x3, x4)
and some dependencies between them, and the Figure 1.2b illustrates the
representations of such dependencies using factor functions. The function fij
defines the relationship between variables xi and xj. Now suppose that the
variables x1, x2, and x3 are observable and we are interested in estimating
the variable x4. The likelihood of the variables given the graph G is defined
as in Eq. 1.1, where Z is a normalizing factor.
P (x|G) = 1
Z
f12(x1, x2)× f13(x1, x3)× f24(x2, x4)× f34(x3, x4) (1.1)
Therefore, we define the following predictive function (Eq. 1.2) for inferring
x4 with the highest likelihood per Eq. 1.1, i.e., x̂4.
x̂4 = arg max
x4∈X4
f12(x1, x2)× f13(x1, x3)× f24(x2, x4)× f34(x3, x4) (1.2)
Finding an x4 that maximizes this objective function involves an optimization
over the space X4, which becomes a classification or regression task depending















(b) Dependencies as factor functions.
Figure 1.2: An example of the dependencies between four random variables
and a representative factor graph model.
Addressing research gaps using DGML: DGML addresses several of
the previously explained research gaps. Because DGML is based on domain
expertise, the development of a DGML-based predictive model is less reliant on
data volume. In other words, the domain-based design provides a meaningful
initialization for the model, and such a model can then be fine-tuned using
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the limited data available. This allows DGML-based models to achieve
desired performance levels even with a small number of training data samples.
Furthermore, by design, the DGML framework allows the integration of
multimodal healthcare data taking their inter-dependencies also into account.
In fact, such inter-dependencies are derived from domain expertise, and the
model is designed in such a way that the combination of multiple data sources
is meaningful from a biological perspective. In addition, DGML-based models
are easily interpretable for clinicians because clinical intuitions are the basis
for the development of a DGML-based model. Because DGML models have
firm biological foundations, they also allow the development of accurate
predictive models even when the available ground truth information is limited
or error-prone.
1.3 DGML in Practice
Up to 1 billion people, nearly one in seven of the world’s population, suf-
fer from neurological disorders, from Alzheimer’s and Parkinson’s disease,
strokes, multiple sclerosis, and epilepsy to migraine, brain injuries, and neuro-
infections, with some 6.8 million dying of the maladies each year. Although
neurological diseases are the primary cause of disability and mortality around
the world, advancements in neurological disease care have been slow-moving
because of the complex nature of the human brain. Furthermore, the con-
sequences of physician shortages are exacerbated in the field of neurology
because the present-day neurological care relies extensively on visual interpre-
tation of patient data (e.g., neuroimaging, electroencephalography (EEG)),
which are unfortunately relegated to expert neurologists. The burden of
having to visually review and interpret patient data not only reduces the avail-
ability of neurologists to patient care, but also introduces reviewer bias and
potential errors in clinical decisions. As such, the field of neurology is facing a
multitude of problems related to timely patient care, physician burnout, and
quality of clinical care, and cannot sustain without creative solutions. This
dissertation demonstrates applications of the DGML approach in augmenting
the treatments for neurological diseases (see Figure 1.3), working closely with














Figure 1.3: Overarching analytic theme and specific applications. This
dissertation empirically demonstrates the DGML approach in 1) seizure
forecasting and control, 2) delineation of seizure onset zones, 3) brain
stimulation for enhancing verbal memory, and 3) early detection of
Alzheimer’s disease.
1.4 Contributions
1.4.1 Modeling Instantaneous Changes Brain Activity
Analyzing electroencephalograms (EEG) is an essential part of studies that
seek to understand the human brain. Different neural events observed in
EEGs characterize different kinds of instantaneous brain activity, and the
temporal disposition and spatial similarities of such events describe locally
synchronized neurophysiological processes in both time and space. Although
these aspects have been separately explored extensively in the EEG literature,
a unified model that describes all three (instantaneous, spatial, and temporal)
aspects has not been developed. Such a model is important for accurately
interpreting the underlying neurophysiological phenomena and for deriving
electrophysiology-based therapeutics for neurological disorders. The first part
of this dissertation describes methods that encapsulate instantaneous obser-
vational, temporal, and spatial dependencies in brain activity for augmenting
and individualizing the treatment for epilepsy.
Clinical relevance: The most significant epilepsy-related disability is the
uncertainty in the occurrence of seizures [6]. Patients take continuous medi-
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cation and refrain from engaging in risky activities (e.g., swimming, driving)
because of the uncertainty in experiencing a seizure episode at any time. The
ability to predict seizures in a timely manner enables the providers to warn
the patients and treat only when required. In addition, the most common
treatments for the epilepsy patients who are not responsive to pharmacother-
apies are brain stimulation and epilepsy surgery. While the ability to predict
seizures is essential for brain stimulation, both epilepsy surgery and electric
stimulation also require fairly accurate localization of epileptic regions in the
brain. Hence, the ability to accurately localize the epileptic regions in the
brain could help in improving the therapeutic benefits of the two methods.
Predicting temporal abnormalities: Prior to this dissertation, our team
developed algorithms using intracranial EEG data to predict epileptic seizures
sufficiently ahead of time. The work described in [7] develops a machine
learning-based individualized seizure prediction framework using neurophysio-
logical signals collected from canine subjects with naturally occurring epilepsy.
This framework for seizure prediction performed significantly better (73%-
92% area under the ROC curve) than a random predictor, with a 90-minute
prediction window. Furthermore, a preseizure analysis produced evidence
supporting the existence of a distinct identifiable preictal state and hence
supporting the idea of individualizing the treatment for epilepsy.
Detecting spatial abnormalities and localization: In addition, our team
also developed algorithms for localizing seizure-generating brain regions by
leveraging the spatio-temporal dependencies. The work described in [8] devel-
ops a novel belief propagation approach based on unsupervised clustering and
Bayesian filtering to capture the evolution of spatial and temporal character-
istics in an EEG recording; whereas, [9] describes a factor graph-based model
to encode spatial and temporal dependencies between EEG channels using
exponential functions and used that model to detect transient abnormal elec-
trophysiological events with substantially higher accuracy relative to previous
approaches. Furthermore, using those detected events, a markedly improved
approach was developed to localize epileptic brain regions without recording
actual seizures, while the current standard is to perform such localization
using seizure recordings.
Combining multiple sources of information: Furthermore, [10] showed
that combining multiple electrophysiological biomarkers in a carefully designed
analytic approach can reduce the variability in model performance across
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multiple patients. This work also showed that recording durations as short
as two hours of non-seizure intracranial EEG are sufficient for successful
localization. This framework was retrospectively validated using the data of
82 epilepsy patients who underwent epilepsy surgery at the Mayo Clinic.
1.4.2 Modeling Long-term Changes in Brain Health
Brain health refers to the overall health of an individual’s brain, taking
both the structural and the functional aspects into account. The brain
health of a healthy adult declines gradually with age as the age-related
neuronal loss and gliosis result in gradual depreciation of brain structure and
functions. Many neurological diseases including epilepsy and Alzheimer’s
disease (AD) impact brain health via different mechanisms and can increase
the course of brain health decline at abnormal rates. Brain monitoring
methods such as neuroimaging and EEG are useful in understanding the
decline of brain health. Particularly, structural magnetic resonance imaging
(SMRI) is useful in understanding decline of brain structure, and EEG is
useful in understanding decline in brain activity. This dissertation developed
models to describe brain health using imaging and electrophysiological data,
and used those models to identify individuals who had the potential for
neurological diseases.
Clinical relevance: Chronic neurological diseases are devastating because
they impact many aspects of the patients’ daily lives and continue to worsen
their brain health. The ability to detect the presence of chronic neurological
diseases at the earliest possible time is crucial to a) to reduce the damage
to brain health and b) identify the most suitable intervention. For instance,
currently available interventions for AD such as cognitive training, physical
exercise, diet, etc. are more likely to be effective when the patients are
intervened during the early stages of the AD continuum. In addition, drug
resistant epilepsy (DRE) is the most severe form of epilepsy, and the patients
go through multiple phases of drug trials before DRE is diagnosed and
interventions such as epilepsy surgery and brain stimulation are considered.
During those drug trials, the patients continue to have seizures that cause
irreversible damage to their brains. Therefore, the potential to diagnose DRE
at an earlier time can help the providers determine the correct intervention
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and reduce the damage to the patients’ brain health.
Modeling brain health using EEG: The work described in [11] developed
a model of brain health in young individuals using EEG-based features.
This work describes a simple graph-based model that combined alpha rhythm
related features from scalp EEG recorded from major brain regions to quantify
the brain health of health individuals. This work showed that deviations in
the EEG features representing brain health of healthy individuals, such as
the alpha rhythm, can indicate the potential for epilepsy and help lateralize
seizure focus, even when commonly recognized epileptiform features are absent.
Hence, a machine learning-based approach that utilizes alpha rhythm-related
features was used to classify 1) whether an EEG was recorded from an epilepsy
patient, and 2) if so, the seizure-generating side of the patient’s brain. When
evaluated using “normal” scalp EEGs of 48 patients with drug-resistant focal
epilepsy and 144 healthy individuals, this approach achieved area under ROC
curve (AUC) values of 0.81 and 0.72 for the respective classification tasks.
This finding is significant because the ability to diagnose epilepsy at the
earliest possible time can avoid significant delays in treatment, and can more
efficiently triage patients to costly in-hospital monitoring studies. In that
context, this study presents a promising research direction in the treatment
of epilepsy.
Modeling brain health using neuroimaging: The work described in
[12] developed a model of brain aging in older individuals using structural
neuroimaging data. Brain aging refers to the neuroanatomical changes that
occur as an individual gets old. The study of brain aging can help identify
individuals who have accelerated neurodegenerative trajectories. Brain aging
models are typically developed using the data of healthy individuals to predict
a measure of brain aging known as brain age. These models lack the ability
to generalize when they are used to predict the brain ages of individuals
with neurodegenerative diseases because such models have not been exposed
to extreme levels of neurodegeneration. The difficulty of developing a more
generalizable model lies in including the data from individuals with neurode-
generative diseases because their ground truth brain ages are unreliable. By
leveraging the relationship between brain age, brain structure, and cognition,
this study developed a multitask learning-based joint model of brain age and
cognition that exposed the brain aging model to a larger dynamic range of
neurodegeneration. This model proved to be more generalizable in brain-
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age prediction and was able to differentiate neurodegenerative patients from
healthy individuals with much better accuracy.
Early prediction of AD progression: Furthermore, based on the afore-
mentioned findings, a machine learning model for predicting short-term
dementia progression using multiple biomarkers was also developed [13]. The
goal of this project was to develop a generalizable model that integrated
high-dimensional data (multimodal neuroimaging and cerebrospinal fluid
biomarkers, genetic factors, and measures of cognitive resilience) for identifi-
cation of mild cognitive impairment (MCI) individuals who progressed to AD
within three years. Specifically, it was necessary to assess model generaliz-
ability and develop an interpretable model to ensure the successful clinical
translation of this approach. The main contributions of this work were a)
developed generalizable models based on a support vector machine classifier
with a clinically relevant accuracy ( 93%) for identifying MCI individuals
who progress to AD within three years; b) developed a unique strategy to
compare generalizability against model complexity; and c) discovered that
the expression of CR1 (complement receptor 1), an AD susceptibility gene
involved in immune pathways, uniquely added independent predictive value.
This work highlighted the value of optimized machine learning approaches for
analyzing multimodal patient information for making predictive assessments.
1.4.3 Methodological Contributions
In addressing the aforementioned problems, this dissertation also makes
the following contributions to the field of neural data analysis.
1. The evolutions of different neurological disorders occur in different time
scales, i.e., epileptic seizures are rapidly evolving; whereas, Alzheimer’s
disease is slowly progressing. Hence, it is commonplace to monitor
instantaneous neuronal activity in the case of epilepsy and long-term
structural, metabolic, and protein-level changes in the case of AD
to capture disease-specific physiological mechanisms. Therefore, the
extraction of useful features related to the patho-physiology of these
diseases requires a deep understanding of the monitoring mechanisms
and a variety of feature-engineering techniques. This research demon-
strates expertise in time-series signal processing, image processing, and
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omic-expression analysis to successfully address this challenge.
2. The present-day brain-monitoring mechanisms, unfortunately, cannot
provide simultaneous spatial and temporal coverages at similar gran-
ularities. Therefore, the ability to infer complementary information
(both in space and time) from a variety of data sources (EEG, imaging,
omics, clinical, etc.) is necessary to advance the understanding of the
highly heterogeneous etiologies of these diseases. This research utilizes
probabilistic graphical models as the primary vehicle to combine the
complementary predictive values shared across different measurements
taken from the brain.
3. Although modern machine learning approaches (primarily deep-learning)
have surpassed human-level performance in many applications, their
applicability is generally limited to very focused prediction tasks. How-
ever, complex problems like disease progression and risk stratification
require not only the ability to make predictions with high accuracy,
but also the ability to longitudinally track relevant biomarkers. This
research demonstrates that an amalgamation of supervised learning
and graphical models can be used to make accurate predictions about
disease stages and to longitudinally track disease progression that aids
real-time prognostics and healthcare delivery.
1.5 Thesis Organization
The rest of this thesis is organized as follows. Chapter 2 covers some
related work in the machine learning for healthcare domain and introduces
some background knowledge on the diseases epilepsy and Alzheimer’s disease
and brain monitoring mechanisms such as EEG and magnetic resonance
imaging. Chapter 3 introduces the types of instantaneous variations that can
be observed in brain activity in the presence of epilepsy disorder, and then
discusses an application in which methods on modeling such instantaneous
variations will be demonstrated. Chapter 4 describes the factor graph-based
model of brain activity and its application to seizure onset localization in
epilepsy. Chapter 5 describes another model that combines the predictive
values of multiple electrophysiological biomarkers to improve the accuracy of
13
seizure onset localization. Those chapters also describe the studies conducted
using the intracranial EEG data collected from patients with epilepsy at the
epilepsy division of the Mayo Clinic at Rochester, Minnesota to demonstrate
the proposed models. Chapter 6 describes the long-term changes that can
be observed in brain activity and anatomy, their relation to brain health
decline, different ways to measure long-term brain changes, and the clinical
implications of modeling brain health. Chapter 7 describes an EEG-based
model of brain health and its application for diagnosing epilepsy. Chapter
7 also describes the demonstration of this model using the scalp EEG data
collected at the epilepsy division of Mayo Clinic at Rochester, Minnesota and
the Max Plank Institute at Leipzig [14]. Chapter 8 describes a neuromaging-
based model of brain health in elderly individuals and its application for early
detection of cognitive impairment. This model was demonstrated using the
data collected as part of the Mayo Clinic Study of Aging [15]. Finally, Chapter
9 describes a machine learning-based approach for predicting progression from
mild cognitive impairment to dementia using multiple sources of information.
This approach was demonstrated using the data collected as part of the




2.1 Machine Learning in Healthcare
Application of machine learning in healthcare has received a lot of inter-
est recently. The abundance of biomedical data and the advancements in
computing capabilities have created a huge surge in solving modern clinical
problems using data-driven approaches, particularly using machine learning.
The range of medical data used in machine learning applications includes
physiological signals, medical imaging, bioinformatics, electronic medical
records, and sensor measurements from wearable devices, and the applica-
tions range from direct clinical needs such as diagnosis, prognosis, surgery
guidance, adverse event prediction, and personalized treatments, to indirect
contributions such as image segmentation and reconstruction, drug discovery,
genome-wide association studies, and other scientific discoveries.
Early work in machine learning for healthcare utilized classical approaches
such as graphical models, logistic regression, support vector machine, and
shallow neural networks. However, in recent times, the focus has shifted
to deep learning and its derivations such as convolutional neural networks,
recurrent neural networks, and deep-reinforcement learning. While classical
approaches relied on features extracted from raw medical data using domain
knowledge, modern approaches based on deep learning are able to learn
meaningful representations from the raw data itself. Although this is a major
advantage of deep learning-based approaches, as it allows the discovery of
previously unknown features, such abilities come at the price of having to
create extremely large datasets. For that reason, classical approaches are still
used in healthcare applications when there are only small datasets available.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ML in neurology. The use of machine learning for improving neurological
disease care has been a very popular topic of research in recent years [49].
The majority of the literature has focused on neuroimaging: classification,
risk assessment, segmentation tasks, diagnosis, prognosis, and even prediction
of therapy responses [50, 51, 52, 53, 54]. On the other hand, the application
of deep learning to time-series data such as EEG has been limited by the
unavailability of large datasets [55]. Nonetheless, several recent studies have
applied deep learning-based methods to intracranial and scalp EEG data for
the application of seizure forecasting [56, 57]. However, a common theme
across those studies is the inability to reproduce the results due to inter-
site data variability and the lack of standard preprocessing routines [58].
Furthermore, the existing deep learning-based studies have employed popular
model architectures that were historically developed for computer vision
applications [56]. As such, they lack the ability to fully exploit the specific
spatio-temporal dynamics present in neural data, particularly EEG.
2.2 Epilepsy
Epilepsy1 has been considered as a superficial mental disorder for centuries.
However, today, epilepsy is identified as a neurological disorder of the central
nervous system. The underlying physiological phenomena that cause epilepsy
still remain unknown. However, it is widely observed that epilepsy is common
among those who had undergone brain-related injuries or diseases. In children
and young adults, genetic disorders, congenital abnormalities, and birth
trauma affecting the brain are commonly considered as the causes of epileptic
symptoms. On the other hand, in mature adults and the elderly, strokes,
tumors, and cerebrovascular disease are considered the causes.
Although epilepsy is an increasingly worsening disorder (i.e., each seizure
damages the brain), patients with epilepsy are capable of a standard career
and family lives. However, they are not advised to engage in activities such
as driving, swimming, etc., during which the occurrence of a seizure episode
could lead to death. Furthermore, the side effects of antiepileptic medication,
recurring episodes of loss of consciousness and motor control, and the general
misconception about the disorder create clinical and psychological barriers.
1This review of epilepsy was adapted from [59].
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2.2.1 Seizures
A seizure can be described as a combination of unintentional changes in
behavior, movement, sensation and consciousness as a result of abnormal
brain activity. Seizures can be epileptic seizures or non-epileptic seizures.
Epileptic seizures occur as a result of an abnormal brain activity characterized
by synchronized abnormal and excessive electrical activity. On the other
hand, non-epileptic seizures occur in response to an external disturbance to
the central nervous system such as alcohol withdrawal, drug abuse, acute
illness, sleep deprivation, or in the context of psychological trauma. Different
treatments are needed for each type of seizure, and thus the ability to
distinguish among them is crucial. Two major types of seizures are partial
seizures and generalized seizures. While partial seizures are localized to a
part of the brain, generalized seizures involve the entire brain.
Partial seizures: In a partial seizure, epileptic activity is contained in one
part of the brain. Partial seizures that do not affect consciousness are classified
as simple partial seizures, while those that do are classified as complex partial
seizures. A simple partial seizure that originates in the somatosensory area of
the brain is called a simple partial sensory seizure, while one that originates
from the motor cortex is called a simple partial motor seizure.
Generalized seizures: In a generalized seizure, epileptic activity involves
the entire brain from the onset. Generalized seizures which lead to irregular
muscular movements are classified as generalized convulsive seizures, while
those that do not, are classified as generalized nonconvulsive seizures. Depend-
ing on the state of consciousness after the seizure, we can further categorize
convulsive seizures into the myoclonic, clonic, tonic, and tonic-clonic types.
Nonconclusive seizures that result in the loss of consciousness, eye blinking,
staring, and other minor facial movements are called absence seizures. Gener-
alized nonconclusive seizures that do not lead to a loss of consciousness are
called atonic seizures.
2.2.2 Treatment of Epilepsy
Epilepsy affects individuals with variable degrees of severity. Between 70%-
80% of epilepsy patients suffer from seizures whose severity and frequency can
be limited with the use of antiepileptic drugs, each of which essentially limits
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the capacity of neurons to fire at excessive rates. The correct classification
of these patients’ seizures is crucial since different seizure types require
specific drug regiments. In fact, the use of the wrong antiepileptic drug may
exacerbate certain types of seizures. The remaining 20%-30% of epilepsy
patients suffer from seizures that are refractory to medication. These patients
seek alternative treatment options that include surgery, cortical stimulation,
deep-brain stimulation, vagus nerve stimulation, and ketogenic diets.
2.3 Alzheimer’s Disease
Alzheimer’s disease (AD)2 is a neurodegenerative disease causing severe
personal and societal burdens. As of 2020, 5.8 million3 people in the United
States and more than 50 million4 people in the world are affected by AD. The
clinical disease stages of AD have been divided into three phases. First is a
pre-symptomatic phase in which individuals are cognitively normal but some
have AD pathological changes. Second is a prodromal phase of AD, commonly
referred to as mild cognitive impairment (MCI)[61] which is characterized
by the onset of the earliest cognitive symptoms (typically deficits in episodic
memory) that do not meet the criteria for dementia. The severity of cognitive
impairment in the MCI phase of AD varies from the earliest appearance
of memory dysfunction to more widespread dysfunction in other cognitive
domains. The final phase in the evolution of AD is dementia, defined as
impairments in multiple domains that are severe enough to produce loss of
function.
The abnormal protein deposits that characterize AD pathologically are
well known: Aβ plaques and neurofibrillary tangles (NFTs) formed by hyper-
phosphorylated tau. Neurodegeneration is as important as these hallmark
pathological lesions of AD, and manifests as atrophy, neuron loss, and gliosis,
which are routinely noted in post-mortem examinations.




2.3.1 Biomarkers of AD
There are five most widely studied biomarkers of AD pathology, based on
the current literature: decreased CSF Aβ42, increased CSF tau, decreased
fluorodeoxyglucose uptake on PET (FDG-PET), PET amyloid imaging, and
structural MRI measures of cerebral atrophy. Each of these five biomarkers
is validated well enough to be used in currently active therapeutic trials and
large multisite observational studies.
Biomarkers of Aβ-plaque deposition: Both CSF Aβ42 and amyloid PET
imaging are biomarkers of brain Aβ plaque deposition. Nearly all patients
who have a clinical diagnosis of AD have positive amyloid imaging studies
[62].
Biomarkers of neurodegeneration: CSF tau is an indicator of tau patho-
logical changes and associated neuronal injury. Although phosphotau might
be a more specific indicator of AD, concentrations of both phosphotau and to-
tal tau increase in AD [63]. Increased CSF tau is not specific for AD, but does
correlate with clinical disease severity, with higher concentrations associated
with greater cognitive impairment in individuals on the normal–MCI–AD
cognitive spectrum [64]. In general, increases in CSF tau seem to indicate
neuronal damage, and are seen in ischemic and traumatic brain injury [65].
FDG-PET is used to measure net brain metabolism, which, although
including many neural and glial functions, largely indicates synaptic activity
[66]. Brain glucose metabolism measured with FDG-PET is highly correlated
with post-mortem measures of the synaptic structural protein synaptophysin
[67]. In the context of AD, decreased FDG-PET uptake is an indicator of
impaired synaptic function.
Structural MRI can provide measures of cerebral atrophy, which is caused
by dendritic pruning and loss of synapses and neurons [68]. Volumetric or
voxel-based measures of brain atrophy show a strong correlation between
the severity of atrophy and the severity of cognitive impairment in patients
along the continuum from normal cognitive status to AD dementia [69]. Thus,
rates of neuronal and synaptic loss indicated by the progressive rate of brain
atrophy correlate with rates of cognitive decline [70].
Temporal ordering of biomarkers: Biomarkers of Aβ deposition be-
come abnormal early, before neurodegeneration and clinical symptoms occur.
Biomarkers of neuronal injury, dysfunction, and neurodegeneration become
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abnormal later in the disease. Cognitive symptoms are directly related to
biomarkers of neurodegeneration rather than biomarkers of Aβ deposition.
2.3.2 Treatment of AD
Alzheimer’s disease requires precise diagnosis, early if possible, and adequate
etiological treatment, and, as an incurable age-related neurodegenerative dis-
order, its particular pathophysiology needs to be considered. The therapeutic
options have focused on ameliorating the symptoms as well as reducing the
rate of progression of damage, although this has not significantly reversed the
disease, so prevention is a better solution for this public health problem.
The toxic conformations of Aβ or tau in the brain are thought to spread
the disease, and blocking the generation of these peptides may be part of
useful treatments. Nevertheless, the current treatments of this disease are
based on cholinesterase inhibitors and a glutamate antagonist, providing
only symptomatic relief, while evidence for the complexity and multicausality
of this dementia is recognized in basic and clinical studies [71]. Efforts
in etiology-based treatment are currently underway in clinical trials, and
complement preventive treatments such as physical activity, proper diet,
cognitive stimulation, and the management of comorbidity.
2.4 Electroencephalography
The perpetual activity of the cerebral cortex is largely supported by the
variety of oscillations the brain generates, spanning a number of frequencies
and anatomical locations, as well as behavioral correlates [72]. Electroen-
cephalograms are very useful in measuring brain activity because of their
ability to cover a large range of brain oscillation frequencies. While conven-
tional EEG measures the brain’s electrical activity from outside the skull,
electrocorticography (ECoG), or intracranial electroencephalography (iEEG),
uses electrodes placed directly on the exposed surface of the brain to record
such activity from the cerebral cortex. ECoG may be performed either in the
operating room during surgery (intraoperative ECoG) or outside of surgery
(extraoperative ECoG). Because a craniotomy (a surgical incision into the
skull) is required to implant the electrode grid, ECoG/iEEG is an invasive
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procedure. However, the typical characteristics of EEG and ECoG/iEEG are
identical except that ECoG/iEEG is a much cleaner representation of the
brain activity due to the fact that it is less susceptible to external interference.
Thus, the typical constituents on a EEG recordings can also be observed in
ECoG/iEEG.
2.4.1 EEG Brain Rhythms
A typical EEG recording contains the following different rhythms charac-
terized by their frequency ranges. The brain’s baseline activity constitutes
these rhythms in more or less fixed proportions.
• Delta rhythm - EEG activity with a frequency below 3 Hz and am-
plitudes that exceed those of all other rhythms; it is most prominent
frontally in adults and posteriorly in children in the third and fourth
stages of sleep.
• Theta rhythm - EEG activity with frequency between 4-7 Hz; this
activity is abnormal in awake adults, but commonly observed in sleep
and children below the age of 13 years.
• Alpha rhythm - EEG activity with frequency between 8-13 Hz that is
prominent in the occipital regions of normal, relaxed adults whose eyes
are closed.
• Beta rhythm - EEG activity with frequency between 14-30 Hz that is
most prominently observed in the frontal and central regions in adults,
but may also be generalized.
• Gamma rhythm - EEG activity with frequency between 30-80 Hz.
Gamma rhythms are thought to represent binding of different popula-
tions of neurons together into a network for the purpose of carrying out
a certain cognitive or motor function.
However, many of the most interesting changes in brain activities from
perception to action occur in relatively short time windows such as subseconds
rather than minutes or hours; therefore, these short windows are the most
relevant for the investigation of brain dynamics involved in cognitive activity.
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Examined from such a temporal perspective, the brain patterns that charac-
terize these cognitive moments may have some non-oscillatory or irregular
components, but are typically largely oscillatory in nature and return reliably
to the baseline after the information is processed. Such irregular changes can
occur as part of normal physiological phenomena or because of neurological
diseases. Typically, the irregular activity associated with neurological dis-
eases can be characterized by the absence or deviation of normal EEG from
well-documented limits on frequency, amplitude, morphology, localization,
and reactivity. The following are some irregular changes that can be observed
in brain activity.
• Lambda waves - Transient sharp waves lasting for a duration of approx-
imately 0.25 seconds that occur in the occipital region whenever an
adult scans a visual field with horizontal eye movement.
• Sleep-spindles, K-complexes, and vertex waves - These are unique
waveforms observed only during the different stages of sleep
• Spike and sharp waves - Spike waves are transients with pointed peaks
exhibiting durations between 20-70 milliseconds; sharp waves are similar
to spike waves, but exhibit longer durations typically between 70-200
milliseconds.
• Periodic discharges - Periodic discharges refer to time-limited bursts
that are repeated at a certain rate; bursts may exhibit a variety of
durations, frequencies, amplitudes, morphologies, and localizations.
• Rhythmic hyper synchrony - Rhythmic hyper synchrony refers to rhyth-
mic activity emerging from a quiescent background and exhibiting
unusual frequency, amplitude, morphology, and localization of any
degree; rhythmic activity may either be continuous or intermittent.
• Electro cerebral inactivity - Electro cerebral inactivity refers to a variable
length period, not caused by instrumental or physiological artifacts, that
exhibits extreme attenuation of the EEG relative to a patient-specific
baseline.
• High-frequency oscillations (HFOs) - Spontaneous events occurring in
EEG, defined as at least four oscillations with frequencies higher than 80
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Hz, which distinctively stand out from the background signal. HFOs are
divided into three subgroups: ripples (80–250 Hz), fast ripples (250–500
Hz), and very-fast ripples with frequencies exceeding even 500 Hz.
2.5 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a medical imaging technique used in
radiology to form pictures of the anatomy and the physiological processes of
the body. MRI scanners use strong magnetic fields, magnetic field gradients,
and radio waves to generate images of the organs in the body. MRI does not
involve x-rays or the use of ionizing radiation, which distinguishes it from CT
and PET scans. MRI is a medical application of nuclear magnetic resonance
(NMR). NMR can also be used for imaging in other NMR applications, such
as NMR spectroscopy.
While the hazards of ionizing radiation are now well controlled in most
medical contexts, an MRI may still be seen as a better choice than a CT scan.
MRI is widely used in hospitals and clinics for medical diagnosis and staging
and follow-up of disease without exposing the body to radiation. An MRI
may yield different information compared with CT. Risks and discomfort may
be associated with MRI scans. Compared with CT scans, MRI scans typically
take longer and are louder, and they usually need the subject to enter a
narrow, confining tube. In addition, people with some medical implants or
other non-removable metal inside the body may be unable to undergo an
MRI examination safely.
MRI was originally called NMRI (nuclear magnetic resonance imaging),
but “nuclear” was dropped to avoid negative associations [73]. Certain atomic
nuclei are able to absorb and emit radio-frequency energy when placed in
an external magnetic field. In clinical and research MRI, hydrogen atoms
are most often used to generate a detectable radio-frequency signal that is
received by antennas close to the subject being examined. Hydrogen atoms
are naturally abundant in humans and other biological organisms, particularly
in water and fat. For this reason, most MRI scans essentially map the location
of water and fat in the body. Pulses of radio waves excite the nuclear spin
energy transition, and magnetic field gradients localize the signal in space.
By varying the parameters of the pulse sequence, different contrasts may be
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generated between tissues based on the relaxation properties of the hydrogen
atoms therein.
Since its development in the 1970s and 1980s, MRI has proven to be a
versatile imaging technique. While MRI is most prominently used in diagnostic
medicine and biomedical research, it also may be used to form images of
non-living objects. MRI scans are capable of producing a variety of chemical
and physical data, in addition to detailed spatial images. The sustained
increase in demand for MRI within health systems has led to concerns about
cost effectiveness and overdiagnosis [74, 75].
2.5.1 Construction and Physics
In most medical applications, hydrogen nuclei, which consist solely of a
proton, that are in tissues create a signal that is processed to form an image of
the body in terms of the density of those nuclei in a specific region. Given that
the protons are affected by fields from other atoms to which they are bonded,
it is possible to separate responses from hydrogen in specific compounds.
To perform a study, the person is positioned within an MRI scanner that
forms a strong magnetic field around the area to be imaged. First, energy
from an oscillating magnetic field is temporarily applied to the patient at the
appropriate resonance frequency. Scanning with X and Y gradient coils causes
a selected region of the patient to experience the exact magnetic field required
for the energy to be absorbed. The excited atoms emit a radio-frequency
(RF) signal, which is measured by a receiving coil. The RF signal may be
processed to deduce position information by looking at the changes in RF
level and phase caused by varying the local magnetic field using gradient
coils. As these coils are rapidly switched during the excitation and response
to perform a moving line scan, they create the characteristic repetitive noise
of an MRI scan as the windings move slightly due to magnetostriction. The
contrast between different tissues is determined by the rate at which excited
atoms return to the equilibrium state. Exogenous contrast agents may be
given to the person to make the image clearer [73].
The major components of an MRI scanner are the main magnet, which
polarizes the sample, the shim coils for correcting shifts in the homogeneity
of the main magnetic field, the gradient system, which is used to localize
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the region to be scanned, and the RF system, which excites the sample and
detects the resulting NMR signal. The whole system is controlled by one or
more computers.
MRI requires a magnetic field that is both strong and uniform to a few
parts per million across the scan volume. The field strength of the magnet
is measured in teslas – and while the majority of systems operate at 1.5
T, commercial systems are available between 0.2 and 7 T. Most clinical
magnets are superconducting magnets, which require liquid helium. Lower
field strengths can be achieved with permanent magnets, which are often used
in “open” MRI scanners for claustrophobic patients [76]. Recently, MRI has
been demonstrated also at ultra-low fields, i.e., in the microtesla-to-millitesla
range, where sufficient signal quality is made possible by prepolarization (on
the order of 10 to 100 mT) and by measuring the Larmor precession fields at
about 100 µT with highly sensitive superconducting quantum interference
devices (SQUIDs) [77].
2.5.2 T1 and T2
Each tissue returns to its equilibrium state after excitation by the indepen-
dent relaxation processes of T1 (spin-lattice; that is, magnetization in the
same direction as the static magnetic field) and T2 (spin-spin; transverse to
the static magnetic field). To create a T1-weighted image, magnetization is
allowed to recover before measuring the MR signal by changing the repetition
time. This image weighting is useful for assessing the cerebral cortex, identi-
fying fatty tissue, characterizing focal liver lesions, and in general obtaining
morphological information, as well as for post-contrast imaging. To create
a T2-weighted image, magnetization is allowed to decay before measuring
the MR signal by changing the echo time. This image weighting is useful
for detecting edema and inflammation, revealing white matter lesions, and
assessing zonal anatomy in the prostate and uterus.
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CHAPTER 3
MODELING TRANSIENT EEG FEATURES
This chapter is organized as follows. It first introduces the transient changes
in EEG-based brain activity that can be observed in epilepsy patients. It
then introduces a clinical treatment of epilepsy, i.e., epilepsy surgery, and
describes how it can be improved by accurately modeling some specific
irregularities in the brain activity of epilepsy patients. Finally, it summarizes
two contributions based on the DGML framework to improve the current
state of epilepsy surgery and describes the experimental setup utilized for
demonstration purposes. Following this chapter, Chapters 4 and 5 describe
those two DGML-based contributions in more detail.
3.1 Instantaneous Brain Activity Variations in
Epilepsy
The spontaneous occurrence of an epileptic seizure is the defining feature of
the epileptic brain. In patients being evaluated for epilepsy and animal models
of epilepsy, electrophysiological recordings are regularly carried out to capture
seizures to identify the existence of epilepsy, a specific type of epileptic seizure,
or epilepsy syndrome. In most cases, recordings are made from the scalp, but
can also be obtained directly from brain tissue. Epileptic seizures themselves
are a specific biomarker of epileptogenesis and epileptogenicity (the presence
and severity of an epileptic condition), although owing to their unpredictable
nature and irregular rate of occurrence, seizure EEG recordings are not ideal in
terms of time, cost, or risk for evaluating, for example, the efficacy of existing or
new anti-seizure drugs, potential antiepileptogenic interventions, or presurgical
evaluation. However, EEG recordings in individuals with epilepsy contain
other transient electrophysiological disturbances that occur between seizure
episodes (i.e., interictally) that can occur more frequently than seizures, such
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as interictal epileptiform discharges (IEDs) and pathological high-frequency
oscillations (HFOs). HFOs with spectral frequencies between 250 and 600 Hz,
termed fast ripples, are found in brain areas capable of generating spontaneous
seizures [78]. It is believed that HFOs reflect population-level spikes arising
from abnormal synchronously bursting principal neurons within local areas
[79]. On the other hand, IEDs consist of electrographic waves or complexes
distinguished from background activity on the EEG, and during IEDs, a large
percentage of neurons discharge a high-frequency burst of action potentials
[80].
3.2 Clinical Application: Epilepsy Surgery
Epilepsy surgery involves resection of a portion of a patient’s brain, and it
is an irreversible procedure that can reduce and often eliminate seizures in
patients [81]. The success of resective surgery depends on accurately localizing
seizure-generating brain regions [82]. Intracranial electroencephalography
(iEEG), which involves placement of electrodes (or channels) in direct contact
with brain tissues, has been widely used to identify seizure-generating brain
tissue and guide epilepsy surgery [83]. Typically, the electrodes that are in
the seizure onset zone (SOZ) are identified based on visual inspection of the
iEEG captured at the time of seizures. Some tissue around these electrodes
is removed during a following surgical procedure. However, this process is
time consuming, costly, and associated with potential morbidity.
Interictal localization of SOZ: As such, localizing the SOZ based on
interictal (non-seizure) iEEG recordings is considered as an alternative, or
possibly a complementary, procedure [82, 83]. Electrodes placed directly on or
close to a seizure onset zone exhibit different forms of transient pathological
electrophysiologic events (or abnormal events) between seizure recordings,
i.e. interictally [84]. Time and/or spectral domain features extracted from
iEEG data are used to capture such events. Based on the observed rate of the
abnormal events, a group of channels (which represent a certain area in the
brain spanned by the sensors) is identified as a SOZ. Since ictal recordings are
not required in this approach, localization of SOZ channels is performed as
an integral part of the surgical procedure involving 1) electrode implantation,
2) SOZ determination, and 3) epileptic tissue removal, all without requiring
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longer iEEG monitoring. Hence, this approach reduces the time, cost, and
morbidity for the patients.
Using interictal biomarkers of epilepsy for localizing SOZs: A com-
mon practice undertaken in the literature investigating interictal SOZ localiza-
tion is to compare the incidence rates (events/time) of putative pathological
electrophysiological events associated with epileptic brain tissue detected in
iEEG recorded from individual electrodes against the gold-standard SOZ
electrodes determined from spontaneous seizures. Among the potential elec-
trophysiological biomarkers, HFOs and IEDs have been the most widely
investigated. Phase-amplitude coupling (PAC) and other forms of cross-
frequency coupling (CFC) have more recently been investigated as promising
clinical biomarkers for epilepsy [85].
3.2.1 Research Gaps in Interictal SOZ Localization
Artifacts in biomarker detection: Most of the existing studies have
utilized a simple counting of the above biomarkers (detected either manually
or using software) in fixed durations to classify the electrodes that are in the
SOZ [86]. Such simple counting of biomarkers can produce uncertain results
when there are artifacts in the data. These artifacts include physiological
events and other signal abnormalities.
Temporal variations: In addition, there is evidence that behavioral states
play a role in altering the temporal patterns of epileptiform activity in the
brain [87, 88, 89]. As a result, the occurrence of the biomarkers exhibits
temporally varying rates when long EEG recordings with mixed behavioral
states are considered [90]. Hence, the common practice of simply counting
HFOs or IEDs for a fixed duration and using an average rate to determine
the SOZ is likely suboptimal.
Inter-patient variability: Furthermore, these approaches have predomi-
nantly utilized a single biomarker to identify SOZs and have not considered
the inter-patient variability nor the temporal dynamics of the epileptic activ-
ity [86]. As a result, they have not been able to generalize across multiple
patients, and their overall accuracies have been insufficient to bring them into
clinical practice [91, 92].
In that context, the aim of this part of the dissertation was to develop
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domain-guided approaches that leveraged the spatial and temporal character-
istics of interictal biomarkers of epilepsy and the complementary predictive
values of multiple interictal electrophysiological biomarkers (e.g., HFO, IED,
and PAC) for interictal electrode classification and mapping of SOZs.
3.3 Solutions: Domain-guided Approaches
This section summarizes two DGML-based applications we developed to
address the aforementioned research gaps.
EEG-Graph: a factor graph-based model of EEG brain activity:
Interictal epileptic events, which are localized to the SOZ, exhibit significant
spatial correlation among channels in the SOZ and temporal repetition.
Based on this observation, this study built on the hypothesis that the spatial
and temporal patterns of the biomarkers could be utilized to reduce the
contribution of artifacts since the artifacts are generally random. Hence, a
graphical-model-based approach was developed to capture and utilize the
spatial and temporal correlations of interictal biomarkers of epilepsy and
thereby improve interictal localization of SOZs.
A multi-biomarker approach for addressing inter-patient variability
in interictal SOZ localization: The reasons for inter-patient variability
might include electrode placement, false-positive detections of biomarkers,
signal artifacts, the varied etiology of focal epilepsy, or the fact that some
biomarkers are incident in both physiologic and pathologic states [93, 94].
Thus, utilizing a single biomarker to identify SOZs of patients with potentially
heterogeneous epileptogenic mechanisms may result in unsatisfactory accuracy
for some individuals. This study hypothesized that it may be possible to reduce
inter-patient variability by combining the complementary values contained
within different electrophysiological biomarkers and thereby improve SOZ
localization potential. To that end, an approach that combined the predictive
values of the most common interictal biomarkers of epilepsy: HFOs, IEDs,
and PAC, was developed to reduce inter-patient variability and improve the
overall accuracy of interictal SOZ localization.
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3.4 Experimental Setup
The EEG data used to demonstrate the aforementioned methods were
recorded from patients undergoing evaluation for epilepsy surgery at the Mayo
Clinic, Rochester, Minnesota. The Mayo Clinic Institutional Review Board
approved this study, and all subjects provided informed consent. Subjects
underwent intracranial depth electrode implantation as part of their evaluation
for epilepsy surgery whenever non-invasive studies could not adequately
localize the SOZ. To provide an unbiased dataset for analysis, we took 2 hours
of continuous iEEG data (during some period between 12:00 and 3:00 AM)
on the night after surgery.
Subjects: Data from 82 subjects with focal epilepsy were investigated. All
subjects were implanted with intracranial depth arrays, grids, and/or strips.
Subjects underwent multiple days of iEEG and video monitoring to record
their habitual seizures.
Electrodes and anatomical localization Depth electrode arrays (from
AD-Tech Medical Inc., Racine, WI) were 4- and 8-contact electrode arrays
consisting of a 1.3-mm-diameter polyurethane shaft with platinum/iridium
(Pt/Ir) macroelectrode contacts. Each contact was 2.3 mm long, with 10-mm
or 5-mm center-to-center spacing (with a surface area of 9.4 mm2 and an
impedance of 200–500 ohms). Grid and strip electrodes had 2.5-mm-diameter
exposed surfaces and 1-cm center-to-center spacing of adjacent contacts.
Anatomical localization of electrodes was achieved using post-implant CT
data co-registered to the patient’s MRI using normalized mutual information
[95]. Electrode coordinates were then automatically labeled by the SPM
Anatomy toolbox, with an estimated accuracy of 0.5 mm [96].
Signal recordings: All iEEG data were acquired with a common reference
using a Neuralynx Cheetah electrophysiology system. (It had a 9-kHz an-
tialiasing analog filter, and was digitized at a 32-kHz sampling rate, filtered
by a low-pass, zero-phase-shift, 1-kHz, low-pass Bartlett-Hanning window,
and down-sampled to 5 kHz.)
Clinical SOZ localization: The SOZ electrodes and time of seizure onset
were determined by visually identifying the electrodes with the earliest iEEG
seizure discharges. Seizure onset times and zones were determined by visual
identification of a clear electrographic seizure discharge, followed by looking
back at earlier iEEG recordings for the earliest electroencephalographic change
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contiguously associated with the visually definitive seizure discharge. The
same approach has been used previously to identify neocortical SOZs [97] and
medial temporal lobe seizures [88]. The identified SOZ electrodes were used
as the gold standard to test and validate our analyses.
Data: Continuous 2-hour interictal segments of iEEG data, sufficiently sepa-
rated from seizures, were chosen for all 82 patients to represent a monitoring
duration that could be achieved during surgery. A total of 4966 electrodes
were implanted across the 82 subjects, and 911 of them were identified to be
in SOZs via ictal localization performed by clinical epileptologists caring for
the patients.
Data preprocessing: Prior to analysis, continuous scalp and intracranial
EEG recordings were reviewed using a custom MATLAB viewer [98]. Elec-
trode channels and time segments containing significant artifacts or seizures
were not included in subsequent analyses. All iEEG recordings were filtered
to remove 60-Hz power-line artifacts.
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CHAPTER 4
A GRAPHICAL MODEL OF EEG BRAIN
ACTIVITY
This chapter describes the application of a domain-guided model to capture
the transient abnormalities in the brain activity of epilepsy patients. Specifi-
cally, it describes a graphical-model-based approach to capture the spatial,
temporal, and observational dependencies of such transient abnormalities,
and evaluates the efficacy of that approach by applying it to a real EEG
dataset collected from patients who underwent epilepsy surgery at the Mayo
Clinic, Rochester, Minnesota.
4.1 Introduction
Studying the neurophysiological processes within the brain is an impor-
tant step toward understanding the human brain. Techniques such as elec-
troencephalography are exceptional tools for studying the neurophysiological
processes, because of their high temporal and spatial resolution. An elec-
troencephalogram (EEG) typically contains several types of rhythms and
discrete neurophysiological events that describe instantaneous brain activity.
On the other hand, the neural activity taking place in a brain region is very
likely dependent on activities that took place in the same region at previous
time instances. Furthermore, some EEG channels show inter-channel corre-
lation due to their spatial arrangement [99]. Those three characteristics are
related, respectively, to the observational, temporal, and spatial dependencies
observed in time-series EEG signals.
The majority of the literature focuses on identifying and developing detec-
tors for features relating to the different rhythms and discrete neurophysiolog-
ical events in the EEG signal [88]. Some effort has been made to understand
the inter-channel correlations [100] and temporal dependencies [101] observed
in an EEG. However, very little effort has been made to combine those depen-
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dencies into a single model. Since those dependencies possess complementary
information, using only one of them generally results in poor understanding
of the underlying neurophysiological phenomena. Hence, a unified framework
that jointly captures all three dependencies in EEG addresses an important
research problem in electrophysiology.
Solution: Graphical models in general are useful for representing dependen-
cies between random variables. Factor graphs are a specific type of graphical
models that have random variables and factor functions as the vertices in the
graph [102]. A factor function is used to describe the relationship between
two or more random variables in the graph. Factor graphs are particularly
useful when custom definitions of the dependencies, such as in our case,
need to be encoded in the graph. Hence, we have chosen to adopt a factor
graph-based model to represent the three kinds of dependencies described
previously. These dependencies are represented via three different factor
functions, namely observational, spatial, and temporal factor functions. We
assess the applicability of this model in localization of seizure onset zones
(SOZ), which is a critical step in treating patients with epilepsy [103]. In
particular, our model is utilized to isolate those neural events in an EEG that
are associated with the SOZ, and are eventually used to deduce the location
of the SOZ. However, in a general setting, with appropriate definitions of
factor functions, one can utilize our model to describe other neural events of
interest.
Study summary: Our study establishes the feasibility of the factor graph-
based model and demonstrates its application in SOZ localization on a real
EEG dataset collected from epilepsy patients who underwent epilepsy surgery.
Our results indicate that utilizing the spatial and temporal dependencies in
addition to observations made in the EEG provides a 5–7% improvement in
the AUC (0.72, 0.67, 0.65) and outperforms alternative approaches utilized
for SOZ localization. Furthermore, our experiments demonstrate that the
lightweight graph inference technique provides a considerable improvement
(3–10%) in SOZ localization compared to sampling-based alternatives (AUC:
0.72, 0.62, 0.69). Major contributions of this study are the following.
1. A framework based on factor graphs that jointly represents instantaneous
observation-based, temporal, and spatial dependencies in EEG. This is
the first attempt to combine these three aspects into a single model in
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the context of EEG analysis.
2. A lightweight and exact graph inference technique based on customized
definitions of factor functions. Exact graph inference is typically in-
tractable in most graphical-model representations because of exponen-
tially growing state spaces.
3. A markedly improved technique for localizing SOZ based on the factor
graph-based model developed in this study. Existing approaches utilize
only the observations made in the EEG to determine the SOZ and do
not utilize spatial and temporal dependencies.
4.2 Model Description
Here we provide a mathematical description of the model and the inference
procedure. In a nutshell, we are interested in inferring the presence of a
neurophysiological phenomenon of interest by observing rhythms and discrete
events (referred to as observations) present in the EEG, and by utilizing their
spatial and temporal patterns as represented by a probabilistic graph. Since
the generality of our model relies on the ability to customize the definitions
of specific dependencies described by the model, we have adopted a factor
graph-based setting to represent our model.
4.2.1 Definitions
Suppose that EEG data of a subject are recorded through M channels.
Initially, the data is discretized by dividing the recording duration into N
epochs. We represent the interactions between the channels at an epoch n
as a dynamic graph Gn = (V,En), where V is the set of |V | = M channels
and En ⊂ V × V is the set of undirected links between channels. The state
of a channel k in the nth epoch is denoted by Yn(k), which might represent a
phenomenon of interest. For example, in the case of SOZ localization, the
state might be a binary value representing whether the kth channel in the nth
epoch exhibits a SOZ-likely phenomenon. We also use Yn to denote the states
of all the channels at epoch n, and use Y to denote the set of all possible
values that Yn(k) can take. We refer to the EEG rhythm or discrete event
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present in the EEG as observations and use Xn(k) to denote the observation
present in the nth epoch of the kth channel. Depending on the number of
rhythms and/or events, Xn(k) could be a scalar or vector random variable.
The observations made in all the channels at epoch n are denoted by Xn.
4.2.2 Inference
Given a dynamic network Gn, and the observations Xn, our goal is to infer
the states of the channels at epoch n, i.e., Yn. In our approach, we derive the
inference model using a factor graph with factor functions defined as shown
in Table 4.1. The factor functions are defined using exponential relationships
so that they attain their maximum values when the exponents are zero, and



























































































































































































































































































































































































































































































































Current state of a 
brain region




Previous states of 
the same region
(a) Factors that explain the state of
a brain region.
(b) Dependencies as factor
functions.
Figure 4.1: The dependencies observed in brain activity and a representative
factor graph-model.
With these definitions, the state of a channel is spatially related to the
states of every other channel, temporally related to a function of all its
previous states, and, at the same time, explained by the current observation
of the channel. These dependencies and the factor functions that represent
them are illustrated in Figure 4.1a and 4.1b respectively. (Note that Figure
4.1b illustrates only the factor functions related to Channel 1 and that similar
factor functions exist for other channels although they are not shown in the
figure.) Provided with that information, for a particular state vector Y , we
can write P (Y |Gn) as in Eq. 4.1, where Z is a normalizing factor. In general,
it is infeasible to find the normalizing constant Z, because it would require
exploration of the space |Y|M .







g (Y (k), Y (i))× f (Y (k), φ(Xn(k)))× h (Y (k),Ωn−1(k))

(4.1)
Therefore, we define the following predictive function (Eq. 4.2) for inferring
Yn with the highest likelihood per Eq. 4.1.






g (Y (k), Y (i))× f (Y (k), φ(Xn(k)))× h (Y (k),Ωn−1(k))

(4.2)
Still, finding a Y that maximizes this objective function involves a discrete
optimization over the space |Y|M . A brute-force approach to finding an exact
solution is infeasible when M is large. Several methods, such as junction
trees [104], belief propagation [105], and sampling-based methods such as
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Markov chain Monte Carlo (MCMC) [106, 107], have been proposed to find
approximate solutions. However, we show that this can be calculated exactly
when the aforementioned definitions of the factor functions are utilized. We
can rewrite Eq. 4.2 using the definitions in Table 4.1 as follows.

















Now, representing the product terms as summations inside the exponent and
using the facts that the exponential function is monotonically increasing and
that maximizing a function is equivalent to minimizing the negative of that
function, we can rewrite Eq. 4.3 as:









(Y (k)−Y (l))2+(Y (k)−φ(Xn(k)))2+(Y (k)−Ωn−1(k))2
]
(4.4)
Although the individual components in this objective function are solvable
optimization problems, the combination of them makes it difficult to solve.
However, the objective function resembles that of a standard graph energy
minimization problem and hence can be solved using graph-cut algorithms
[108]. In this study, we describe a solution for minimizing this objective
function when |Y| = 2, i.e., the brain states are binary. Although that
is a limitation, the majority of the brain state classification problems can
be reduced to binary state cases when the time window of classification is
appropriately chosen. Regardless, potential solutions for |Y| > 2 are discussed
in Chapter 8.5.
4.2.3 Graph Inference using Min-cut for the Binary State Case
We constructed the graph shown in Figure 4.2a with two special nodes
in addition to the EEG channels as vertices. The additional nodes function
as source (marked by 1) and sink (marked by 0) nodes in the conventional
min-cut/max-flow problem. Weights in this graph are assigned as follows:
• Every channel is connected with every other channel, and the link
between channels k and l is assigned a weight of 1
d2kl
(Y (k)−Y (l))2 based
on the distance between them.
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(a) New graphical structure. (b) Min-cut partitioning.
Figure 4.2: Graph inference using the min-cut algorithm.
• Every channel is connected with the source node, and the link between
channel k and the source is assigned a weight of (1− Ωn−1(k))2 +
(1− φ (Xn(k)))2.
• Every channel is also connected with the sink node, and the link between
channel k and the sink is assigned a weight of Ω2n−1(k) + (φ (Xn(k)))
2.
Proposition 1. An optimal min-cut partitioning of the graph shown in
Figure 4.2a minimizes the objective function given in Eq. 4.4.
Proof: Suppose that we perform an arbitrary cut on the graph shown in
Figure 4.2a, resulting in two sets of vertices S and T . The energy of the















(Y (k)− Y (l))2
]
It can be seen that, for the same partition of vertices, the objective function
given in Eq. 4.4 attains the same quantity as Ecut. Therefore, since the
optimal min-cut partition minimizes the energy Ecut, it minimizes the objective
function given in Eq. 4.4.
Now suppose that we are given two sets of nodes {S∗, T ∗} as the optimal
partitioning of the graph. Without loss of generality, let us assume that S∗
contains the source and T ∗ contains the sink. Then, the other vertices in S∗
and T ∗, are assigned 1 and 0 as their respective states to obtain the optimal
Y that minimizes the objective function given in Eq. 4.4.
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4.3 Related Work in the EEG Literature
Identifying features (or biomarkers) that describe underlying neurophysio-
logical phenomena has been a major focus of research in the EEG literature
[88]. Spectral features [109], interictal spikes [110], high-frequency oscillations
[88], and phase-amplitude coupling [101] are some of the widely used features.
Although feature identification is an important step in any electrophysiologic
study, features alone often cannot completely describe the underlying phys-
iological phenomena. Researchers have also looked at spatial connectivity
between EEG channels as a means of describing neurophysiological activities
[100]. In recent times, because of the availability of long-term EEG recordings,
understanding of the temporal dependencies within various brain activities
has also advanced significantly [101]. A recent attempt at combining spatial
and temporal constraints has shown promise despite lacking comprehensive
validation [111]. Regardless, a throughly validated and general model that
captures all the factors, and is applicable to a variety of problems has not,
to our knowledge, been proposed in the EEG literature. Since the three
factors are complementary to each other, a model that jointly represents them
addresses an important research gap in the field of electrophysiology.
Graphical models have been widely used in medical informatics [112],
intrusion detection [113], social network modeling [114], and many other
areas. Although factor graphs are applicable in all these settings, their
applications in practice are still very much dependent on problem-specific
custom definitions of factor functions. Nevertheless, with some level of
customization, our approach provides a general framework to describe the
different dependencies observed in EEG signals. A similar framework for
emotion prediction is described in [114], where the authors used a factor
graph-based model to describe the influences of historical information, other
users, and dynamic status to predict a user’s emotions in a social network
setting. Although our factor functions are derived in a similar fashion, we show
that graph inference can be performed exactly using the proposed lightweight
algorithm, and that it outperforms the sampling-based inference method
utilized in [114]. Our algorithm for inference was inspired by [115], in which
the authors used an energy minimization-based approach for performing exact
graph inference in a Markov random field-based model.
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4.4 Application of the Model in Seizure Onset
Localization
4.4.1 Interictal SOZ Identification Methodology
The goal here is to identify a few channels that are likely to be in the
SOZ. Channels situated directly on or close to a SOZ exhibit different forms
of transient electrophysiologic events (or abnormal events) between seizures
[84]. The frequency of such abnormal neural events plays a major role in
determining the SOZ. However, capturing these abnormal neural events that
occur in distinct locations of the brain alone is often not sufficient to establish
an area in the brain as the SOZ. The reason is that insignificant artifacts
present in the EEG may show characteristics of those abnormal events that
are associated with SOZ (referred to as SOZ-likely events). In order to set
apart the SOZ-likely events, their spatial and temporal patterns could be
utilized. It is known that SOZ-likely events occur in a repetitive and spatially
correlated fashion (i.e., neighboring channels exhibit such events at the same
time) [103]. Hence, the factor graph-based model described in Section 4.2
can be applied to capture and utilize the spatial and temporal correlations in
isolating the SOZ-likely events.
4.4.2 Identifying Abnormal Neural Events
Spectral characteristics of iEEG measured in the form of power-in-bands
(PIB) features have been widely utilized to identify abnormal neural events
[116, 103, 109]. In this study, PIB features are extracted as spectral power
in the frequency bands delta (0–3 Hz), low-theta (3–6 Hz), high-theta (6–9
Hz), alpha (9–14 Hz), beta (14–25 Hz), low-gamma (30–55 Hz), high-gamma
(65–115 Hz), and ripple (125–150 Hz) and utilized to make observations
from channels. As described in Section 4.2, a φ function is used to relate
the observations to abnormal events. In Section 8.5, we evaluate different
techniques for obtaining a mapping from extracted PIB features to the
presence of an abnormal neural event. However, a mapping obtained using
observations alone is not sufficient to deduce SOZ because in addition to
SOZ-likely events, signal artifacts will also be captured by this mapping. This
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phenomenon is illustrated in Figure 4.3, in which PIB features show similar
characteristics for the events related to both SOZ and non-SOZ. Therefore, we
utilize the factor graph-based model presented in this study to further filter
the detected abnormal events based on their spatial and temporal patterns
and isolate the SOZ-likely events.







































































Figure 4.3: EEG events related to both SOZ and non-SOZ are captured by
PIB features because they possess similar spectral characteristics.
4.4.3 Spatial and Temporal Dependencies in SOZ Localization
Although artifacts show spectral characteristics similar to those of SOZ-
likely events, unlike the latter, the former do not occur in a spatially correlated
manner. This spatial correlation is measured with respect to the physical
distances between the electrodes placed in the brain. Therefore, the same
definition of the spatial factor function described in Section 4.2 is applicable.
If a channel’s observation is classified as an abnormal neural event and the
spatial factor function attains a large value with an adjacent channel, it
would mean that both channels likely show similar patterns of abnormalities,
which therefore must be SOZ-likely events. In addition, the SOZ-likely events
show a repetitive pattern, which artifacts usually do not. In Section 4.2,
we described the temporal correlation as a function of all previous states.
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As such, the temporal correlation here is established with the intuition that
a channel that previously exhibited a large number of SOZ-likely events is
likely to exhibit more because of the repetitive pattern. Hence, temporal
correlation is measured as the correlation between the state of a channel and
the observed frequency of SOZ-likely events in that channel until the previous
epoch, i.e., Ωn−1(k) =
∑n−1
i=1 Yi(k)
n−1 . Therefore, when Ωn−1(k) is close to 1 and
the observation made from channel k is classified as an abnormal neural event,
the event is more likely to be a SOZ-likely event than an artifact.
4.5 Experiments
This section describes the data used and the experiments performed to
demonstrate the application of this model to a crucial clinical task in epilep-
tology.
4.5.1 Data
The dataset consists of iEEG recordings collected from 29 epilepsy patients
(a subset of the participants described in Section 3.4). The iEEG sensors
were surgically implanted in potentially epileptogenic regions in the brain.
Patients were implanted with different numbers of sensors, and they all had
different SOZs. Ground truth (the true SOZ channels) was established from
clinical reports and verified independently through visual inspection of the
seizure iEEGs. During data collection, basic preprocessing was performed to
remove line-noise and other forms of signal contamination from the data.
4.5.2 Analytic Scheme
Two-hour between-seizure segments were chosen for each patient to repre-
sent a monitoring duration that could be achieved during surgery. The 2-hour
iEEG recordings were divided into non-overlapping 3-second epochs. This
epoch length was chosen because it would likely accommodate at least one
abnormal neural event that could be associated with the SOZ [103]. Spectral
domain features (i.e, PIB) were extracted in the 3-second epochs to capture
abnormal neural events [103]. Based on the features extracted in a 3-second
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Figure 4.4: A flow diagram illustrating the SOZ determination process.
recording of a channel, a binary value φ (Xn(k)) ∈ {0, 1} was assigned to that
channel, indicating whether or not an abnormal event was present. Section
8.5 provides a comparison of supervised and unsupervised techniques used
to create this mapping. In the case of supervised techniques, a classification
model was trained using the PIB features extracted from an existing corpus
of manually annotated abnormal neural events. In the case of unsupervised
techniques, channels were clustered into two groups based on the PIB features
extracted during an epoch, and the cluster with the larger cluster center (mea-
sured as the Euclidean distance from the origin) was labeled as the abnormal
cluster. Consequently, the respective epochs of those channels in the abnormal
cluster were classified as abnormal neural events. The factor graph-based
model was then used to filter the SOZ-likely events out of all the detected
abnormal neural events. A factor graph is generated using the observational,
spatial, and temporal factor functions described above specifically for this
application. The best combination of states that minimizes the objective
function given in Eq. 4.4, Yn, is found by using the min-cut algorithm. In
our approach, we used the Boykov-Kolmogorov algorithm [117] to obtain the
optimal partition of the graph. The states Yn here are binary values and
represent the presence or absence of SOZ-likely events in the channels. This
process is repeated for all the 3-second epochs, and the SOZ is deduced at
the end using a maximum likelihood approach (described in the following).
This whole process is illustrated in Figure 4.4.
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4.5.3 Maximum Likelihood SOZ Deduction
We model the occurrences of SOZ-likely events in channel k as independent
Bernoulli random variables with probability π(k). Here, π(k) denotes the true
bias of the channel’s being in the SOZ. We estimate π(k) using a maximum
likelihood approach and use π̂(k) to denote the estimate. Each Yn(k) that
results from the factor graph-inference is treated as an outcome of a Bernoulli
trial and the log-likelihood function after N such trials is defined as:







An estimate for π(k) that maximizes the above likelihood function (known







The ML approach generates a likelihood probability for each channel k
for being in the SOZ. We compared these probabilities against the ground
truth (binary values with 1 meaning that the channel is in the SOZ and
0 otherwise) to generate the area under the ROC curve (AUC), sensitivity,
specificity, precision, recall, and F1-score metrics. First, we evaluated a
number of techniques for generating a mapping from the extracted PIB
features to the presence of abnormal events. We evaluated three unsupervised
approaches, namely k-means, spectral, and hierarchical clustering methods
and two supervised approaches, namely support vector machine (SVM) and
generalized linear model (GLM), for this task. Second, we evaluated the
benefits of utilizing the min-cut algorithm for inferring instantaneous states.
Here we compared our results using the min-cut algorithm against those of
two sampling-based techniques [114]: Markov chain Monte Carlo (MCMC)
with random sampling, and MCMC with sampling per prior distribution.
Belief propagation-based methods are not suitable here because our factor
graph contains cycles [118]. Third, we compared our results against two recent
solutions for interictal SOZ localization, including a summation approach
[103] and a clustering approach [119]. In the summation approach, summation
of the features of a channel normalized by the maximum feature summation
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was used as the likelihood of that channel’s being in the SOZ. In the clustering
approach, the features of all the channels during the whole 2-hour period
were clustered into two classes by a k-means algorithm, and the cluster with
the larger cluster mean was chosen as the abnormal cluster. For each channel,
the fraction of all its features that were in the abnormal cluster was used as
the likelihood of that channel being in the SOZ. Both of these approaches
utilize only the observations and lack the additional information of the spatial
and temporal correlations.
4.6 Results and Discussion
Table 4.2 lists the results obtained for the experiments explained in Sec-
tion 4.5, performed using the aforementioned dataset containing non-seizure
(interictal) iEEG data from 29 epilepsy patients. First, a comparison of super-
vised and unsupervised techniques for the mapping from PIB features to the
presence of abnormal events was performed. The results indicate that using
a k-means clustering approach for mapping PIB features to abnormal events
is better than any other supervised or unsupervised approach, while other
approaches also prove useful. Second, a comparison between sampling-based
methods and the min-cut approach was performed for the task of graph
inference. Our results indicate that utilizing the min-cut approach to infer
instantaneous states is considerably better than a random sampling-based
MCMC approach (with a 10% higher AUC and 14% higher F1-score) and
marginally better than an MCMC approach with sampling per a prior dis-
tribution (with a 3% higher AUC and a similar F1-score), when used with
k-means algorithm for abnormal event classification. However, unlike this
approach, our method does not require a prior distribution to sample from.
Third, we show that our factor graph-based model for interictal SOZ localiza-
tion performs significantly better than either of the traditional approaches
(with 5% and 7% higher AUCs) when used with the k-means algorithm for









































































































































































































































































































































































































































































































































































































































































































































































































































Overall, the factor graph-based model with k-means clustering for abnormal
event classification and the min-cut algorithm for instantaneous state inference
outperforms all other methods for the application of interictal SOZ localization.
Utilization of spatial and temporal factor functions improves the localization
AUC by 5%–7%, relative to pure observation-based approaches (summation
and clustering). On the other hand, the runtime complexity of instantaneous
state inference is greatly reduced by the min-cut approach. The complexity of
a brute-force approach grows exponentially with the number of nodes in the
graph, while the min-cut approach has a reasonable runtime complexity of
O(|V ||E|2), where |V | is the number of nodes and |E| is the number of edges in
the graph. Although sampling-based methods are able to provide approximate
solutions with moderate complexity, the min-cut method provided superior





This chapter describes the application of another domain-guided model to
capture the transient abnormalities in the brain activity of epilepsy patients.
Specifically, it shows that combining multiple features of the transient ab-
normalities reduces the variance in SOZ classification and therefore achieves
better generalizability than single feature-based approaches. This study also
applies the developed model to a real EEG dataset collected from patients
who underwent epilepsy surgery at the Mayo Clinic, Rochester, Minnesota.
5.1 Introduction
A common practice undertaken in the literature investigating interictal
SOZ localization is to compare the incidence rates (events/time) of putative
pathological electrophysiological events associated with epileptic brain tissue
(known as electrophysiological biomarkers of epilepsy) detected in iEEGs
recorded from individual electrodes against the gold-standard SOZ electrodes
determined from spontaneous seizures. Among the potential electrophysiolog-
ical biomarkers, high-frequency oscillations (HFOs) [78, 120, 121, 122] and
interictal epileptiform discharges (IEDs) [123] have been the most widely inves-
tigated. Phase-amplitude coupling (PAC) and other forms of cross-frequency
coupling (CFC) have more recently been investigated as promising clinical
biomarkers for epilepsy [85]. HFOs are local field potentials that reflect short-
term synchronization of neuronal activity, and they are widely believed to be
clinically useful for localization of the epileptic brain [78, 97, 87]. Furthermore,
there is an extensive literature investigating IEDs as interictal markers of
SOZs, but they have met with limited success [124, 125, 126]. PAC (a measure
of cross-frequency coupling) [127] as an adjunct to ictal (seizure) biomarkers
was shown to be useful for SOZ localization [128], and more recently, PAC
51
has been evaluated as an interictal marker for determining SOZs [89]. Most of
the existing studies have utilized a simple counting of the above biomarkers
(detected either manually or using software) in fixed durations to classify
the electrodes that are in the SOZ [86]. Although some recent approaches
have utilized clustering methods [119] and dimensionality reduction methods
[129] as preprocessing steps in identifying pathologic interictal HFOs, the
determination of SOZs was still performed using simple counting of HFOs.
Furthermore, these approaches have predominantly utilized a single biomarker
to identify SOZs and have not considered the inter-patient variability nor the
temporal dynamics of the epileptic activity [86]. As a result, they have not
been able to generalize across multiple patients, and their overall accuracies
have been insufficient to bring them into clinical practice [91, 92].
Solution: The reasons for inter-patient variability might include electrode
placement, false-positive detections of biomarkers, signal artifacts, the varied
etiology of focal epilepsy, or the fact that some biomarkers are incident in
both physiologic and pathologic states [93, 94, 86]. Thus, utilizing a single
biomarker to identify SOZs of patients with potentially heterogeneous epilep-
togenic mechanisms may result in unsatisfactory accuracy for some individuals.
We hypothesize that it may be possible to reduce inter-patient variability
by combining the complementary values contained within different electro-
physiological biomarkers and thereby improve SOZ localization potential.
However, despite the growing interest in each of the above biomarkers, the
extent to which they provide independent predictive value for epileptogenic
tissue localization remains unclear. From a signal-processing perspective,
IED represents a relatively distinct electrophysiological phenomenon com-
pared to HFO and PAC. However, temporal correlations of HFO events and
PAC may be observed when short HFOs co-occur with IEDs [129]. Apart
from that specific instance, it is possible that each biomarker will consti-
tute specific electrophysiological information about the epileptogenicity of
brain tissue and might add predictive value when used together with other
biomarkers. However, the potential clinical utility of combining electrophysio-
logical biomarkers has received relatively little investigation [130]. In addition,
there is evidence that behavioral states play a role in altering the temporal
patterns of epileptiform activity in the brain [87, 88, 89]. As a result, the
occurrence of the biomarkers exhibits temporally varying rates when long
EEG recordings with mixed behavioral states are considered [90]. Hence,
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the common practice of simply counting HFOs or IEDs for a fixed duration
and using an average rate to determine the SOZ is likely suboptimal. We
had previously proposed a temporal filtering-based unsupervised approach
to utilize temporal characteristics of spectral power features to determine
SOZs interictally [9, 8]. However, more sophisticated models were needed to
effectively utilize multiple electrophysiological biomarkers and their temporal
characteristics to accurately determine SOZs. Modern artificial intelligence
(AI)-based methods facilitate (a) the ability to learn high-dimensional de-
cision functions from labeled training data and (b) the flexibility to define
customized features representing domain knowledge [131]. These properties
can be useful in harnessing multiple electrophysiological biomarkers and their
temporal characteristics for the interictal classification of SOZs. However, AI-
based approaches have been underexplored in the SOZ classification literature,
mainly because of the unavailability of large-scale iEEG datasets collected
during epilepsy-surgery evaluation. Fortunately, the availability of continuous
iEEG recordings collected from a large cohort of 82 patients (previously
described in Section 3.4) and approximately 5000 electrodes gives us a unique
opportunity to assess the potential utility of AI-based approaches in this
study. Although this dataset is still not large enough to automatically extract
class-specific electrophysiological patterns using deep-learning approaches,
comparable performance can be realized on this dataset using careful feature
engineering and appropriate model selection.
Study summary: In that context, the aim of this study is to develop an
AI-based analytic framework that utilizes multiple interictal electrophysiologi-
cal biomarkers (e.g., HFO, IED, and PAC) and their temporal characteristics
for interictal electrode classification and mapping of SOZs. To that end,
we developed a support vector machine (SVM)-based classification model
utilizing customized features (based on the above biomarkers) extracted
from 120-minute interictal iEEG recordings of 82 patients with drug-resistant
epilepsy to interictally identify the electrodes representing their seizure onset
zones. This approach achieved an average AUC (area under ROC curve) of
0.73 when the HFO, IED, and PAC biomarkers were used jointly, which is
14% better than the AUC achieved by a conventional biomarker incidence-
based approach using all three biomarkers, and 4%–13% better than that
of an SVM-based model that used any one of the biomarkers. This result
indicates that exploiting the temporal variations in biomarker activity can
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improve localization of the epileptic brain and that the biomarkers utilized in
this study have complementary predictive values. Our analysis of individual
patients reveals that the AUCs improve or remain unchanged for more than
65% of the patients when the composite, rather than any single biomarker,
is utilized, supporting the hypothesis that combining multiple biomarkers
can provide more generalizability than can individual biomarkers. Develop-
ment of this technology also enabled us to develop an understanding of the
recording durations required for interictal localization of SOZs. By analyzing
iEEG segments of different durations (10–120 minutes), we show that longer
iEEG segments provide better accuracy than do short segments, and that
the improvements become statistically insignificant for durations beyond 90
minutes.
5.2 Data and Approach
5.2.1 Data
Continuous 2-hour interictal segments of iEEG data, sufficiently separated
from seizures, were chosen for all 82 patients to represent a monitoring
duration that could be achieved during surgery. A total of 4966 electrodes
were implanted across the 82 subjects, and 911 of them were identified to be
in SOZs via ictal localization performed by clinical epileptologists caring for
the patients.
5.2.2 Data Preprocessing
Prior to analysis, continuous scalp and intracranial EEG recordings were
reviewed using a custom MATLAB viewer [98]. Electrode channels and time
segments containing significant artifacts or seizures were not included in
subsequent analyses. All iEEG recordings were filtered to remove 60-Hz
power-line artifacts.
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5.2.3 Overall Analytic Scheme
Selected 2-hour iEEG recordings were divided into non-overlapping 3-second
epochs. A 3-second epoch length was chosen to accommodate at least a single
transient electrophysiologic event (in the form of a PAC, HFO, or IED) that
could be associated with the SOZ. The HFO [86], IED [132], and PAC [89]
biomarkers were extracted using previously published detectors to measure
their presence in each 3-second epoch. Then, a clustering procedure was
performed to assign a binary observation of normal or abnormal to each
channel. This procedure was performed separately for each patient, and the
biomarker measures extracted in a 3-second recording of all the channels of
a specific patient were considered. These channels were clustered into two
groups based on their similarities with respect to each biomarker, and the
cluster with the larger average biomarker rate was considered the abnormal
cluster. This step was performed so that biomarker detections that had
strong magnitudes and showed strong spatial correlation were retained, and
electrodes with noisy detections were minimized. At the end of that procedure,
every 3-second recording of a channel was associated with three binary values
(one for each biomarker) representing the presence of the HFO, IED, and
PAC biomarkers. We refer to those binary values as observations. Since there
are 2400 3-second epochs in a 2-hour period, the total number of observations
made in a channel was 3 × 2400 = 7200. Since that number of features is
relatively large compared to the number of channels available in our study, we
reduced the number of observations by applying a straightforward summation
approach. Binary observations made within a 10-minute window (200 epochs)
were counted to arrive at a measure of the local rate of the biomarker incidence
for each 10-minute window of the 2-hour recording. Although the 10-minute
window length may appear to have been chosen arbitrarily, it is large enough
to have less noisy local biomarker incidence rates and yet not so large as to
mask the temporal variations in interictal biomarker activity. This method
reduces the number of observations for a channel to 36 (three local biomarker
rates × 12 windows). These observations, made across a 2-hour period of a
channel, were used to infer whether that channel belonged to an SOZ under a
supervised learning setting using a support vector machine (SVM) classifier.
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Figure 5.1: The overall analytic scheme of the SOZ detection algorithm
utilized in this study. A 2-hour data segment is analyzed for each patient.
PAC, HFO, and IED biomarkers are extracted in 3-second epochs, and a
clustering method is used to group channels based on similarities with
respect to the biomarkers. These groupings are converted to binary (0, 1)
observations and counted within a 10-minute window to obtain local
biomarker incidence rates. These local biomarker incidence rates for the three
biomarkers within all the 10-minute windows of a channel’s 2-hour recording
are utilized as the features of that channel in a machine learning setting. A
support vector machine (SVM) classifier, which was trained and tested using
labeled training data, is used to predict whether an electrode is in an SOZ.
5.2.4 Detection of Interictal Electrophysiological Biomarkers
The PAC measure was calculated by correlating instantaneous phase of the
low-frequency signal with the corresponding amplitude of a high-frequency
signal for a given set of low- and high-frequency bands (Figure 5.2a). In this
implementation, low- and high-frequency contents in the signal were extracted
using MORLET wavelet filters, and all frequency bands were correlated against
all others to create a so-called PAC-gram (Figure 5.2b). Based on the observed
high PAC content and the existing literature [129], 0.1–30 Hz was chosen
as the low-frequency (modulating) signal, and 65–115 Hz was chosen as the
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high-frequency (modulated) signal in the rest of the analysis. HFOs were
detected using a Hilbert transform-based method [86]. The data segments
were bandpass-filtered for every 1-Hz band step from 50 to 500 Hz. Then, the
filtered-data frequency bands were normalized (z-score), and the segments in
which the signal amplitudes were three standard deviations above the mean
for a duration of one complete cycle of a respective high frequency (in 65–500
Hz) were marked as HFOs (see Figure 5.2c) [93]. IEDs were extracted using
a previously validated spike-detection algorithm [132]. A detection threshold
of four standard deviations (of differential amplitude) around the mean was
used to mark IEDs in this algorithm (see Figure 5.2d). The HFO, IED, and










































Figure 5.2: Phase amplitude coupling (PAC), high-frequency oscillations
(HFO), and interictal epileptiform discharge (IED) detection. (A) Detailed
illustration of the PAC feature extraction algorithm. Low-(0.1–30 Hz) and
high-(65–115 Hz) frequency components are filtered out from the raw signal.
The phase of the slow wave is correlated with the high-frequency amplitude
envelope to measure coupling. (B) A PAC-gram representing the average
interictal PAC measured between different frequency bands. Highlighted
portion indicates the low- and high-frequency bands utilized in the rest of
our analysis. (C) Pictorial illustration of HFO detection. Oscillations that
have an amplitude of three standard deviations above the mean and lasting
for more than one complete cycle in low-gamma (30–60 Hz), high-gamma
(60–100 Hz), and ripple (100–150 Hz) bands are detected. (D) An illustration
of detected IEDs. Differential amplitude is standardized, and a threshold of
four standard deviations around the mean was used to mark IEDs.
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5.2.5 Prediction of SOZ Electrodes Using a Support Vector
Machine Classifier
The biomarkers extracted from a 2-hour recording of a channel were con-
verted to a 36-dimensional feature vector as shown in Figure 5.1. The features
represent the local biomarker incidence rates (with a separate rate for each
biomarker) within each 10-minute window of the 2-hour recording. These
features were standardized to eliminate any differences in scale. We took
two different approaches to perform cross-validation. First, we performed
tenfold cross-validation. The dataset, including standardized features of 4966
electrodes (including 911 SOZ electrodes), was divided into a 60% training
set and a 40% testing set, keeping the same proportion of SOZ and NSOZ
(non-SOZ) electrodes in both sets. Second, we performed leave-1-out cross-
validation. For every subject in the dataset, we used the data from the
rest of the subjects as the training data and the respective subject’s data
as the testing data. In each of the cross-validation iterations, training and
testing datasets were generated using one of the cross-validation approaches.
An SVM classifier was trained on the training set, whose hyper-parameters
(described below) we optimized by performing a grid search with a tenfold
cross-validation within the training set. The classifier trained on the best-
performing hyper-parameters was used to predict the labels of the channels
in the testing set. By comparing those predictions against the ground-truth
labels of the testing set channels, we calculated the metrics of model fitness.
This process was repeated 10 times with different combinations of training
and testing sets to obtain metrics of generalized performance. This process is
illustrated in Figure 5.3.
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Figure 5.3: A flow diagram illustrating the prediction framework. The input
is the whole dataset, including the 36 features extracted from 82 subjects
(4966 channels) and their gold-standard labels assigned by clinical
epileptologists. (A) tenfold cross-validation: first, the dataset is shuffled to
randomize the order of channels in it. After randomization, the dataset is
partitioned into two sets, a 60% training set and a 40% testing set, keeping
the same proportion of NSOZ and SOZ channels in both sets. (C) Inner CV
loop: A set of optimal hyper-parameters is selected for the SVM classifier
based on a tenfold cross-validation within the training set. (D)
Goodness-of-fit metrics: The classifier learned in the previous step is tested
on the testing dataset, and measures of its performance are generated. This
whole procedure is repeated 10 times (i.e., tenfold CV) or 82 times (i.e.,
leave-1-out CV) to produce generalized performance metrics, eliminating any
bias introduced by a specific split of training and testing sets.
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A support vector machine is a binary classifier that finds the maximum
margin hyper-plane that separates the two classes in the data [133]. The data
being classified are denoted by X ∈ RN×P (N channels and P features), and
the data from channel i are denoted by X(i) ∈ RP . The class labels for all
the channels are denoted by Y ∈ {−1, 1}N (where −1 and 1 are numerical
labels for the two classes), and the class label for channel i is denoted by
Y (i) ∈ {−1, 1}. The optimization problem to find the optimal hyper-plane





||W ||2 subject to Y (i)(W TX(i) + b) ≥ 1, i ∈ 1, . . . , N (5.1)
Once the optimal hyper-plane [Wopt, bopt] is found, the predicted class label
for channel i is obtained as the sign of W ToptX
(i) + bopt. This formulation
assumes that the data have a clear separation between the two classes. When
that is not the case, slack variables and a tolerance parameter (box-constraint)
can be introduced to obtain separating hyper-planes that tolerate small
misclassification errors [134].
Dual formulation of SVM has received considerable interest because it
enables use of different kernel transformations of the original feature space
without altering the optimization task and because of its advantages in
complexity when the data are high-dimensional [133]. Specifically, this allows
for the features to be transformed from the original feature space to a kernel
space. With this transformation, the cases in which the original data are
not linearly separable may be solved because transformation of the data to
higher dimensions may introduce linear separation in the transformed domain.
Linear, radial basis function (RBF), and polynomial kernels are widely used
kernels in this context.
Goodness of fit of the SVM classifier is evaluated by predicting the classes
of the test dataset by using the classifier that was trained on the training
dataset and comparing the predictions against the true class labels of the test
dataset. This comparison is performed using standard performance metrics
such as receiver operating characteristics (ROC) curve analysis, area under
ROC curve (AUC), sensitivity, specificity, accuracy, precision, recall, and
F1-score. Because of heterogeneity in the data, choosing one partition of
training and test datasets is not sufficient to credibly evaluate the performance
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of a classifier. A common practice to obviate the effect of heterogeneity in
the data is to perform several iterations of training-testing cross-validation of
the dataset. One run of this procedure is carried out by choosing a subset
of the dataset as training data, and testing on the rest of the dataset. This
approach allows the calculation of generalizable performance metrics for the
analyzed classifier.
5.3 Results
5.3.1 Nonlinear Classification Boundary between SOZ and
NSOZ Electrodes
Understanding the nature of the separation between the two classes in
feature space is important to achieve the maximum classification performance
in binary classification. If the separation is linear, a linear classifier should be
sufficient (and preferable due to the Occam’s razor principle) to achieve the
maximum attainable classification performance. On the other hand, when
the separation is nonlinear, linear classifiers perform poorly compared to
nonlinear classifiers. However, when the feature space is high-dimensional,
visualizing the boundary between classes can be difficult. An option is to
use linear and nonlinear classifiers to classify the two classes and plot the
histograms of likelihood probabilities predicted by the classifier to understand
the degree of separation achieved by linear and nonlinear boundaries [135].
We performed this analysis for our dataset by using an SVM classifier with
linear and RBF kernels. Furthermore, we used the tenfold cross-validation
approach to perform this analysis because the individual AUCs obtained using
the leave-1-out cross-validation approach were highly variable across patients.
We trained two SVM classifiers with linear and RBF kernels, respectively,
using the framework shown in Figure 5.3 with 60% of all the electrodes and
all the biomarkers. These classifiers were used to predict the class labels for
the rest of the electrodes (40%). We then compared the distribution of the
likelihood probabilities generated by the two SVM classifiers against the true
class labels. Figures 5.4a and 5.4b show the histograms of the likelihood
probabilities obtained using an SVM classifier with linear and RBF kernels,
respectively, for SOZ and NSOZ electrodes in the testing set. The nonlinear
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boundary achieved through an SVM classifier with an RBF kernel clearly has
a better separation between the two classes, as can also be seen in Figure 5.4c.
To quantify this observation, we plotted ROC curves (which are shown in
Figure 5.4d) for the predictions obtained using linear and RBF kernels. The
linear-SVM classifier obtained an AUC value of 0.57, while the RBF-SVM
classifier obtained an AUC of 0.79 when all the biomarkers were utilized.
Hence, we conclude that the boundary between SOZ and NSOZ electrodes is
nonlinear in the feature space in which the features are derived as described
in Figure 5.1, and the rest of our analyses focus on the results obtained by













































































































Figure 5.4: Results obtained using a support vector machine with interictal
electrophysiological biomarkers to classify seizure onset zone (SOZ)
electrodes. (A) and (B) show the probability densities of the likelihoods
predicted by an SVM classifier for SOZ and NSOZ electrodes in the testing
set for linear and RBF kernels, respectively. The RBF kernel results in less
overlap between the SOZ and NSOZ probability densities. (C) Boxplot
showing the range of likelihood probabilities obtained for SOZ and NSOZ
electrodes when all biomarkers were used as features in an SVM classifier
with an RBF kernel. (D) A comparison between the ROC curves when an
SVM classifier was used with an RBF kernel for individual biomarkers and
their combination, and when it was used with a linear kernel with a
combination of all biomarkers. (E) A comparison between the AUCs
obtained using conventional unsupervised methods that use overall rates of
biomarker incidence to predict SOZ electrodes, and those obtained using our
SVM-based supervised approach.
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5.3.2 A Supervised Learning Approach Improves the SOZ
Localization Accuracy
This study proposes a supervised-learning-based approach that uses an
SVM classifier to predict electrodes in an SOZ by using interictal iEEG data.
In order to understand whether our supervised approach is better than simply
using biomarker rates, we implemented biomarker rate-based SOZ electrode
classification for HFO, IED, and PAC separately and in combination. (We
simply added the individual biomarker incidence rates to obtain an overall
biomarker incidence rate.) Figure 5.4e shows a comparison between the
ROC curves obtained for the unsupervised biomarker incidence rate-based
approach and the supervised approach that uses an SVM classifier with
an RBF kernel when all biomarkers were utilized. Predictions using the
unsupervised approach were performed on the same testing set electrodes that
were used in the supervised approach. The SVM-based supervised approach
outperformed the unsupervised approaches with a 17%–23% gain in the AUC
value. Notably, the performance of the SVM classifier with a linear kernel was
comparable to that of the unsupervised approach, with an AUC value of 0.57,
as seen in Figure 5.4D. This highlights the ability to significantly improve
the correct classification of previously unseen SOZ electrodes by utilizing the
right machine learning method (in this case, SVM with an RBF kernel) to
learn the characteristics of SOZ electrodes.
5.3.3 Goodness-of-fit Metrics for SOZ Electrode Classification
Other goodness-of-fit metrics, as specified previously, were calculated for
the different combinations of biomarkers and methods and are listed in Table
5.1. For all the metrics other than AUC, the likelihood probabilities assigned
by the classifier were applied with a threshold to classify SOZ and NSOZ
electrodes. In order to compare the different approaches, this threshold was






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.4 Combining Multiple Electrophysiological Biomarkers
Improves the Localization Accuracy
The classification framework depicted in Figure 5.3 was utilized with the
features relevant to HFO, IED, and PAC biomarkers separately to reveal the
predictive ability of individual biomarkers. Then the individual classification
performances were compared against the performance obtained when all
the biomarkers were used together. Figure 5.4D shows the ROC curves
obtained for the different runs of the classification framework. While the
PAC biomarker had the best predictive ability individually (AUC: 0.74 –
tenfold CV, 0.69 – leave-1-out CV), the classification obtained using all the
biomarkers together performed better than any of the individual biomarkers,
providing an AUC of 0.79 with the tenfold CV approach and an AUC of 0.73
with the leave-1-out CV approach. These findings support the idea that the
different interictal electrophysiological biomarkers used in this study possess
complementary information that can be harnessed to achieve a superior
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Figure 5.5: Improvements in patient-specific SOZ classification achieved by
means of combining multiple biomarkers as opposed to utilizing a single
biomarker in the SVM framework. (A), (B), and (C): Improvements
obtained in AUCs for patient-specific SOZ classification when the
combination of multiple biomarkers was utilized compared to when HFO,
IED, or PAC, respectively, was utilized alone. (D) Histogram densities of the
patient-specific AUCs for the prediction of SOZ electrodes using HFO, IED,
PAC, and their composite.
To determine whether the combination of multiple biomarkers can reduce
the inter-patient variability, we analyzed the improvements in SOZ electrode
classification potential in each individual by calculating the AUC for each
individual separately. We predicted the SOZ electrodes of each individual
patient using HFO features, IED features, and PAC features separately and
then their composite, within the SVM-based framework described previously
using a leave-1-out cross-validation approach. Figures 5.5A–C illustrate the
respective improvements in the AUCs of individual patients obtained when
the combination of the three biomarkers was utilized instead of HFO, IED,
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or PAC by itself. Our analysis indicates that the AUCs of individual patients
improved or remained unchanged for more than 65% of the patients when
the composite was utilized compared to any individual biomarker. Then we
plotted the histograms of the AUCs of individual patients for each biomarker
and their composite separately, and approximated the densities by using
kernel density estimation. Figure 5.5D shows that the histogram density
of AUCs of individual patients becomes skewed towards higher AUC values
when the composite is utilized to predict SOZ electrodes. This indicates
that the utilization of multiple biomarkers with complementary information
reduces the overall variability across patients in the ability to classify SOZ
electrodes—variability that is apparent with any single biomarker.
5.3.5 Recording Durations Between 90 and 120 Minutes May
be Sufficient for Interictal SOZ Localization
The ability to localize seizure-generating brain tissue is a cornerstone of
clinical epileptology. We investigated how the duration of interictal iEEG
recording impacted the the localization of the SOZ (as illustrated in Figure
5.6A). Here we applied our AI-based framework on a range of recording
durations between 10 and 120 minutes. Figure 5.6 shows the mean ROC
curves obtained using a tenfold cross-validation for different durations when
an SVM classifier with an RBF kernel was utilized with all the biomarkers. To
quantify the different runs, we plotted the AUC metric against the recording
length used for SOZ electrode classification prediction. That is shown in
Figure 5.6C, where the error bars indicate the standard deviations of the
AUCs based on a tenfold cross-validation. Statistical significance tests using
two-sided paired t-tests indicate that the AUCs obtained using 90-, 100-,
and 110-minute recordings are not statistically very different from the AUCs
obtained using a 120-minute recording. This finding indicates that recording
durations between 90 and 120 minutes may be sufficient for interictal SOZ
identification with clinically relevant accuracies.
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NS: P<0.05 : Not significant
Figure 5.6: Evaluation of the length of recordings and interictal SOZ
localization. (A) ROC curves obtained when shorter interictal segments of
durations ranging from 20 to 120 minutes were utilized for analysis. (B)
AUC values obtained with short interictal segments. Longer interictal
segments result in better AUC values; however, the AUCs obtained using
segments longer than 90 minutes are statistically indifferent (based on
two-sided paired t-tests between AUCs).
5.4 Contributions of the Study
5.4.1 Main Contribution
This study describes a ML method for classification of SOZ and NSOZ
electrodes using multiple electrophysiological biomarkers extracted from inter-
ictal iEEG data collected in a clinical setting. This study, to our knowledge,
is the first to utilize the complementary information provided by multiple
electrophysiological biomarkers and their temporal characteristics as a way
of reducing variability across patients to improve interictal SOZ localization.
Using 2-hour wide-bandwidth intracranial EEG recordings of approximately
5000 electrodes from 82 patients, this study provides a large-scale evaluation
of an artificial intelligence-based approach for interictal SOZ localization and
shows that when used in concert with multiple interictal biomarkers, it can
outperform single biomarker approaches. The ability to perform real-time
feature processing and SOZ determination with clinically relevant accuracy,
with a maximum monitoring duration of 2 hours, supports the feasibility of
SOZ determination using interictal intracranial EEG data. In addition to the
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above specific contributions, this study also exemplifies the role of artificial
intelligence in augmenting clinical workflows.
5.4.2 The Value of Combining Multiple Biomarkers
Interictal SOZ localization techniques have been widely discussed, with the
main focus being on the search for and validation of a single biomarker that
can be used in all patients [78, 136, 137, 138, 121]. Conventional methods have
focused on HFO biomarker detection algorithms and on HFOs themselves
[139, 140, 141]. However, the generalizability of such single biomarkers has
been insufficient for clinical practice [91, 92, 86], primarily because of inter-
patient variability, and it appears that one biomarker may not be sufficient
to identify SOZs in all patients. While there have been multiple attempts to
automate SOZ localization [115, 142, 143], very little work has attempted to
improve localization potential by means of combining multiple biomarkers.
This study shows that combining multiple interictal electrophysiological
biomarkers within a rigorous, supervised machine learning setting can be
more accurate in performing interictal SOZ localization than can utilization
of a single biomarker, essentially by reducing inter-patient variability. This is
evident from our individual patient-based analysis (Figure 5.5), in which we
show that SOZ electrode classification AUCs improve or remain unchanged
for more than 65% of patients when the combination of the three biomarkers
is utilized instead of single biomarkers. This finding indicates that combining
multiple biomarkers reduces the variance in SOZ electrode classification
and therefore achieves better generalizability than single-biomarker-based
approaches. Figure 5.5 also shows that combining multiple biomarkers reduces
the accuracy in SOZ electrode classification for some patients when compared
with any of the individual biomarkers. The reason for this could be that
there are more disagreements within the different biomarkers than agreements
with respect to SOZ electrodes. The situations in which combining multiple
biomarkers is detrimental can be explored and tested by comparing the
individual predictions provided by the biomarkers.
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5.4.3 Exploiting the Temporal Variability in Epileptic Activity
to Improve Classification Potential
We showed in this study that utilizing a machine learning approach that
uses local rates of biomarkers within 10-minute subintervals for classifying
SOZ electrodes improves the AUC by 19% compared to traditional unsu-
pervised approaches that primarily utilize the overall rates of biomarkers.
We believe that the improvement is due to the inability of the overall-rate-
based approaches to account for the temporal variations in epileptic activity.
Recent studies have reported that the rate of epileptiform activity changes
significantly between different behavioral states [88, 89]. Since our study uses
night segments with mixed behavioral states, the ability to differentiate SOZ
electrodes from NSOZ electrodes using rates of epileptiform activity varies
depending on the portion of the segment. Hence, looking at the overall rates
of epileptiform activity might average out the variations between subinter-
vals and hence degrade performance, and result in accuracy lower than the
maximum attainable. This study also shows that a nonlinear classification
technique provides significant improvements in AUC compared to a linear
classification technique and that the performance provided by the latter is
similar to that of commonly used unsupervised approaches. Although a linear
classifier considers each subinterval for classification, it is impractical to assign
a particular subinterval a higher weight because the exact subintervals in
which the epileptiform activity is highly discriminative may not be the same
across different patients. Therefore, when trained across multiple patients, the
linear classifier perceives each subinterval as equally important and assigns
all of them equal weights. As a result, its performance is similar to that of
the approaches that use overall epileptiform activity rates to classify SOZ
electrodes. On the other hand, an RBF kernel measures similarities (Eu-
clidean distances) between a channel and selected SOZ and NSOZ channels
(known as support vectors) with respect to their local rates of epileptiform
activity. Therefore, regardless of the position of the subinterval that is highly
discriminative between SOZ and NSOZ channels, that discriminative ability
will be reflected in the overall distance between those channels.
That is shown in Figures 5.7A–D using an example. Figure 5.7A shows that
there is a large variation in the local rates of PAC (in 10-minute windows)
across channels of a selected patient. Figure 5.7B shows the overall PAC
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rates for each channel, and shows that classifying SOZ electrodes simply
by thresholding the overall rates results in poor sensitivity and specificity.
Figure 5.7C shows that transforming the local rates to a kernel space using a
linear kernel does not produce any major changes compared to the previous
approach with regard to efficiency (in terms of sensitivity and specificity);
whereas, Figure 5.7D shows that transforming the local rates using an RBF
kernel produces a more favorable transformation because it provides improved
sensitivity and specificity. As shown in Figures 5.7C and 5.7D, kernel distances
between feature vectors of individual channels and average feature vectors of
the SOZ channels were calculated using linear and RBF kernels. This example
elucidates the utility of a nonlinear machine learning classification approach
and its relationship to the underlying physiology. It is also noteworthy that a
nonlinear classification approach is suitable in this case due to the manner in
which the features of channels were derived, and that linear classifiers may
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Figure 5.7: Temporal variability in the rates of epileptiform activity (with
respect to PAC) and its relation to nonlinear classification. This figure
illustrates that the RBF kernel is more specific in capturing the similarities
between electrodes with regards to their epileptiform activity patterns. (A)
Normalized local PAC rates in different 10-minute intervals of SOZ and
NSOZ channels of a selected patient. (B) Overall PAC rates (obtained by
summing local rates) for the channels and their poor ability to classify SOZ
electrodes. (SS is sensitivity, SP is specificity, and a dashed line indicates
application of a threshold). (C) Features after application of a
transformation using the linear kernel. This transformation does not provide
any notable improvement compared to the summation approach. (D)
Features after application of a nonlinear transformation using the RBF
kernel. It is evident that this transformation provides better discrimination
between SOZ and NSOZ channels.
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5.4.4 Identifying SOZs During Long and Short Recordings of
Night Segments
This study showed that localizing an SOZ using multiple features identified
in 120 minutes of mixed behavioral state data provided accuracy similar to
that obtained with shorter segments. There is a clear relationship between
the utility of this platform and the time of the recording used in analysis.
Segments of 120 minutes were arbitrarily chosen to be the maximum amount
of time a neurologist could use during an operating room recording to identify
the SOZ. Interestingly, results as measured by the AUC did not significantly
differ for recording durations between 90 and 120 minutes. It appears that,
given satisfactory recording conditions, less than one hour may be all that
is needed to achieve high SOZ identification accuracy with this platform.
The relationship between the sleep-wake cycle and epileptiform discharges is
well known [144, 87, 145]. Investigation of PAC, HFO, and IED using both
short-term and long-term iEEG data shows an increment of the HFO rate
with the non-rapid eye movement (NREM) sleep stage, especially in subjects
with temporal lobe epilepsy [146, 89, 147]. In addition, recent work has shown
that the PAC localization potential increases in slow-wave sleep [89]. Our
results suggest that obtaining sleep recordings of a sufficient duration can be
beneficial to quantitative SOZ localization.
5.4.5 Contributions Towards Advancing the Current State of
Clinical Decision Making
We demonstrated that our approach can identify electrodes in an SOZ with
an accuracy of approximately 80% (AUC) on a large cohort of 82 patients,
using interictal iEEG recordings of durations less than two hours. The idea
of utilizing artificial intelligence to augment clinical workflows has become
central in the era of “big data.” Studies have shown the utility of deep learning-
based approaches in augmenting clinical diagnosis of skin cancer and diabetic
retinopathy, primarily using imaging measurements [23, 22]. These studies
have benefited considerably from the availability of a) huge image databases
and b) substantially validated artificial neural network-based classification
models. Our study, on the other hand, embodies an alternative approach that
utilizes feature engineering as a remedial option for the unavailability of large
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datasets at the scale of the currently available imaging datasets (with millions
of medical images). The insights drawn from this study will be particularly
useful for tasks that lack an abundance of labeled training samples, which





This chapter is organized as follows. It first introduces the long-term changes
that can be observed in the human brain and the multiple measurement
modalities that can be used to measure those changes. It then describes a
mathematical framework to quantify the decline in brain health when those
long-term changes manifest in the brain and the potential clinical implications
of such a framework. Finally, it summarizes two contributions based on the
proposed mathematical framework and DGML to enable the early detection
of neurological diseases such as, epilepsy and Alzheimer’s disease. Following
this chapter, Chapters 7 and 8 describe those two contributions in more detail.
Furthermore, Chapter 9 builds on the findings in Chapter 8 and describes
a clinically useful tool for predicting the progression from mild cognitive
impairment to Alzheimer’s disease.
6.1 Long-term Changes in Brain Activity and
Structure
The primary cause of long-term changes in the brain is aging. Those
changes are persistent and impact the brain’s electrical activity, anatomy,
and behavior. Several studies have demonstrated that rhythmic activity
in the brain (e.g., delta, theta, alpha, beta, and gamma) changes as a
function of age [148, 149, 150]. For instance, the power of alpha rhythms
(8–13 Hz) in healthy subjects decreases with age. However, a different age
dynamic is seen for frequency of alpha rhythms. The frequency reaches
the highest values at around 20 years of age and slowly declines [151]. On
the other hand, the anatomical changes associated with brain aging include
the macroscopic (e.g., ventricular enlargement, cortical thinning, decreased
post-mortem weight, the accumulation of white matter hyperintensities), the
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cellular (e.g., synaptic pruning, axonal loss, mitochondrial changes, alterations
to glial cell numbers), through to the molecular (e.g., altered gene expression,
disrupted calcium signalling, epigenetic changes) [152, 153, 154]. Furthermore,
behaviorally, brain aging is associated with cognitive decline (commonly
described as cognitive aging, which particularly affects cognitive domains such
as information processing speed, memory, reasoning, and executive function),
decreased well-being and increased symptoms of low mood [155, 156].
6.2 Measuring Long-term Changes in the Brain
Electrophysiology: EEG offers a very inexpensive and portable way to
measure the brain electrophysiological activity. As explained previously, the
rhythmic activity in the brain, especially the alpha rhythm, changes as a
function of age [148]. The alpha rhythm is considered a potential biomarker
of brain health in adults, as its frequency and power decrease with age [151].
Structural Neuroimaging: Structural magnetic resonance imaging (SMRI)
measures brain structure and can quantify neurodegeneration resulting from
healthy aging as well as diseases. As age-related neuronal loss and gliosis
result in progressive neurodegeneration, measures of cerebral atrophy as
measured by SMRI are highly reflective of anatomical brain health. As
a result, there is a preponderance of studies focusing on quantifying the
biological brain age using SMRI data obtained from healthy individuals. The
models, generally using data from T1-weighted MRI scans of brain structure,
are informed by learning the relationship between age and brain structure in
large samples of healthy adults. These models can then be used to generate a
biological age from neuroimaging data, a brain-predicted age. Following the
established biogerontological model of determining the discrepancy between
the chronological and biological age of an organism [157], if an individual’s
brain-predicted age is greater than their chronological age, this indicates
that their brain structure more closely resembles a healthy person who is
older than they are. The assumption is that greater discrepancies between
brain-predicted age and chronological age reflect poorer brain health, for a
given age.
Cognitive Battery: Cognitive testing can be used to define the magnitude
and pattern of changes in cognition associated with normal aging, and in
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distinguishing clinically abnormal from normal cognitive changes. These tests
include a battery of standardized tests measuring key cognitive abilities such
as attention, learning, memory, language, visuospatial abilities, and executive
functions. Neuropsychological evaluations often include measures of mood
and affect as well as information on well-being and quality of life.
6.3 Approach for Quantifying Long-term Changes in
the Brain
The approach for quantifying long-term changes in the brain relies on an
underlying model of instantaneous brain health. The National Institute of
Aging defines brain health as the ability to remember, learn, plan, concentrate,
and maintain a clear, active mind. Neurological diseases and several other
chronic diseases cause permanent decline in brain health regardless of an
individual’s age, as illustrated in Figure 6.1. Our goal is to develop models
that can quantify brain health based on quantitative measurements. Such
models can be used to track the long-term changes in an individual’s brain
health and, therefore, can be clinically useful in the characterization and early
detection of neurological diseases and in quantifying improvements of certain
treatments for neurological diseases.
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Figure 6.1: Brain health decline in young and elderly populations.
6.3.1 Generic Model Description
Suppose that we use X to denote a form of measurement taken from the
brain (e.g., EEG, sMRI) and use Y to denote a measure of brain health.
In addition, we use the binary variable D ∈ {0, 1} to denote normal (0)
or abnormal (1) brain health decline. The goal is to identify a function
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f that relates X and Y , i.e., Y = f(X), either via domain knowledge or
using a machine learning approach. This is also equivalent to identifying
the conditional probability distribution P (Y |X). Now suppose that the





Figure 6.2: The distribution of brain health given a measurement of the
brain.
Then, the individuals whose brain health values are greater than the mean
of the distribution (y0) are likely healthy or have normal brain health (D = 0).
Those individuals whose brain health values are less than the mean are either
very healthy or likely have abnormal brain health (D = 1). Our goal is to
identify individuals who have abnormal brain health. We use the logistic
function on the difference between the estimated brain health value and
the mean of conditional distribution to determine the probability of having
abnormal brain health (Eq. 6.1).
P (D = 1|Y = y) = 1
1 + e(y−y0)
(6.1)
6.4 Clinical Implications of Modeling Brain Health
6.4.1 Biomarkers of Diseases
A number of neurological and psychiatric diseases have been proposed to
result in premature or accelerated aging, based on clinical observations and
behavioral or biological research. These include schizophrenia, depression,
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epilepsy, HIV infection, and traumatic brain injury [158, 159]. Neurodegener-
ation is one of the four key components of aging proposed by [160]; therefore,
models of brain aging offer a possible window into the relationship between
aging and disease. If a disease can be shown to accelerate the aging-related
phenotype of brain structure, this provides information about the potential
mechanisms involved and highlights possible commonalities across diagnos-
tic categories. Importantly, it also enables the measurement of individual
differences in disease groups, with prognostic implications for future brain
health.
6.4.2 Early Detection of Neurological Diseases
However, it has been shown that the changes in brain activity and anatomy
precede behavioral changes in the presence of neurological diseases [161].
Therefore, the ability to model brain health using quantitative measurements
can help detect abnormal conditions prior to their manifestations as cognitive
disorders. Specifically, longitudinal measurements of brain anatomy and
activity can be helpful in detecting abnormal trends in brain health decline,
and such early evidence can be the basis for taking preventive measures and
preemptively treating the disease.
6.4.3 Continuous Monitoring of Brain Health under
Treatments
Models of brain health are essential to evaluate the improvement and/or
worsening of a neurological disease under a therapeutic option. The ability
to continuously monitor brain health can provide continuous feedback to the
provider and can allow dynamically changes in the treatments. For instance,
modern invasive treatments such as cortical and deep-brain stimulation greatly
depend on the ability to quantify brain health continuously. Such continuous
measurements are used to control the stimulation parameters of the underlying
feedback control system providing the treatment.
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6.5 Examples of Brain Health Models
The following summarizes two different models of brain health: a) a
electrophysiology-based model developed using the data collected from a
young population, and b) a neuroimaging-based model developed using the
data collected from an elderly population. These examples demonstrate how
models of brain health can be useful in detecting neurological diseases early.
Chapters 7 and 8 describe those two examples in more detail.
6.5.1 Modeling Brain Health using EEG
This study describes a model that combined alpha rhythm-related features
from scalp EEG recorded from major brain regions to quantify the brain
health of health individuals. This study shows that deviations in the EEG
features representing brain health of healthy individuals, such as the alpha
rhythm, can indicate the potential for epilepsy and help lateralize seizure focus,
even when commonly recognized epileptiform features are absent. Hence, an
automated approach that utilizes alpha rhythm-related features to classify
1) whether an EEG was recorded from an epilepsy patient, and 2) if so, the
seizure-generating side of the patient’s brain was developed. Such ability to
diagnose epilepsy at the earliest possible time can avoid significant delays
in treatment, and can more efficiently triage patients to costly in-hospital
monitoring studies.
6.5.2 Modeling Brain Health using Neuroimaging
This study describes a joint model of brain-age and cognition using struc-
tural neuroimaging data. By leveraging the relationship between brain age,
brain structure, and cognition, a multitask learning-based joint model of
brain age and cognition was developed, which exposed the brain-aging model
to a larger dynamic range of neurodegeneration. This model proved to be
more generalizable in brain-age prediction and was able to differentiate neu-
rodegenerative patients from healthy individuals with much better accuracy.
In addition, this study showed that the individuals who had much higher
brain age compared to their chronological ages, and who at the time were
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cognitively normal, had a higher likelihood of becoming cognitively impaired
in the future. This result shows that the proposed brain-age model can be
used to detect cognitive impairment much earlier than symptoms appear.
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CHAPTER 7
MODELING BRAIN HEALTH USING EEG
This chapter describes a brain health model-based on scalp EEG data and
describes its application to diagnose epilepsy at the earliest possible time.
The model and its utility are demonstrated via a study conducted at the
Mayo Clinic, Rochester, Minnesota, using a scalp EEG dataset collected from
healthy individuals and epilepsy patients.
7.1 Introduction
Epileptologists assess the potential for epilepsy and related conditions by
identifying visual clues of abnormal activity (also known as epileptiform
activity) in a short scalp electroencephalography (EEG) recording session
( 20–60 minutes). A positive screen, identifying abnormal epileptiform EEG
transients, may lead to starting an anti-seizure medication trial. However, this
initial assessment is not always successful, i.e., epileptogenic activity may not
be recorded in a short EEG session. Unfortunately, such scenarios are very
common in clinical settings to the extent that even some patients with drug-
resistant epilepsy have inconclusive EEGs on expert visual review (i.e., the
EEGs did not contain any epileptogenic activity) [162]. The inability to find
evidence for epilepsy at the earliest possible time can cause delay in delivering
clinical care [163]. In fact, even after deciding to start anti-seizure medications
approximately 1/3 of people will not completely respond and continue to have
seizures despite multiple different medication trials. Each medication trial can
take months, and thus puts the patient at continued risk for epilepsy-related
injuries and comorbidities [164]. Furthermore, and in patients determined to
have DRE a more comprehensive evaluation is indicated to determine if they
are candidates for non-pharmacological therapies, e.g., surgery and electrical
stimulation. Thus, more rapid diagnosis of epilepsy, and in particular drug-
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resistant epilepsy, is needed. We conjecture that even short EEG recordings
might contain subtle electrophysiological abnormalities that can indicate a
possibility of epilepsy, even when commonly known epileptogenic activity are
absent.
Most common abnormalities in the brain activity associated with epilepsy
are interictal spikes and sharp waves (IIS) [165]. Interictal spikes and sharp
waves represent the summated excitatory and inhibitory postsynaptic po-
tentials of a large population of neurons [166] and have similar underlying
physiological causes. The difference in their appearances reflects the rapidity
of neuronal synchronization and the way in which the epileptiform discharge
spreads through cortex. In addition to providing evidence for epilepsy, the
spatial distribution of these events can indicate the classification of epilepsy as
generalized or focal epilepsy. In focal epilepsy, the distribution of IIS can be
used to spatially map the epileptic brain hemisphere, lobe, and region [167].
However, these abnormalities may not be observed in short EEG recordings
for multiple reasons, e.g., they may be very infrequent and not captured
in a short recording, they may originate from deeper brain structures like
cingulate, hippocampus etc., they are activated only during sleep that was not
recorded, or they involve an insufficient amount of cortex to be measurable
on the scalp [168].
Hypotheses: Pathologic changes such as neuronal loss and gliosis are com-
mon in chronic epilepsy, and the same neuronal-glia circuits underlying seizure
generation may subserve normal brain functions, e.g., the hippocampus is a
common site of focal epilepsy and is known to be critical for memory function
[169]. Therefore, we hypothesize that the cellular changes associated with
epilepsy may cause decline in EEG-based measures of normal brain function
in epilepsy patients. The alpha rhythm observed in the EEG is considered as
a potential biomarker of normal brain function in adults and its frequency and
power decrease with age [170]. It is theorized to arise through cortico-thalamic
interactions and to reflect processes that subserve a vast number of cognitive
processes, including attention and memory [171]. Alterations in the alpha
rhythm have been observed in many neurological diseases including epilepsy,
where it typically slows down and loses its characteristic anterior-to-posterior
gradient, which are reported to be in line with clinical severity [172]. Although
the alpha rhythm-related abnormalities are well-known in epilepsy, they are
not used as part of the diagnostic criteria because they lack specificity to any
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neurological disease [173, 174]. In addition, the analysis of alpha rhythm in
the EEGs of epilepsy patients is further complicated by its changes related to
aging [170] and antiepileptic medications, antidepressants, and antipsychotics
[175, 176, 177]. However, we propose that alpha rhythm-related abnormalities
can suggest a higher pre-test potential for epilepsy when an individual is
screened for epilepsy for the first time and therefore can be used to warrant
additional tests when the EEG does not contain epileptogenic activity, e.g.,
more prolonged EEG recordings that ensure sleep recordings. In addition,
there is evidence that people with epilepsy who have seizures originating
from their dominant hemisphere can experience relatively more disruptions
in their normal brain function, compared to those with seizure foci in their
non-dominant hemispheres [178]. Therefore, we further hypothesize that in ad-
dition to indicating the potential for epilepsy, the alpha rhythm-abnormalities
can also help lateralize the origin of epilepsy in focal epilepsy. In summation,
this study investigates whether we can extract subtle clues of epilepsy in
EEGs which would be considered inconclusive in current clinical practice.
Study summary: To test our hypotheses, we analyzed the scalp EEG
recordings of age matched 144 healthy individuals and 48 individuals with
drug-resistant focal epilepsy (DRFE) who went through clinical evaluations
at the Mayo Clinic, Rochester, Minnesota. The EEGs of DRFE individuals
did not contain any epileptogenic activity based on expert visual review
performed by board-certified epileptologists. We preprocessed the EEGs to
remove artifacts and performed Fourier analysis to extract EEG features
representing the fraction of spectral powers contained within the alpha band
across the four major brain regions. We then analyzed using the extracted
features i) the extent to which DRFE patients deviated from healthy and
ii) whether there are differences within the DRFE patients based on the
hemisphere generating seizures. Furthermore, we used those differences to
determine whether an EEG is likely to have been recorded from a DRFE
patient, and if so, their epileptic hemisphere, using a tenfold cross-validation
approach. Furthermore, we analyzed whether these differences are significant
when compared with confounders such as the individual’s age and antiepileptic
drugs.
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7.2 EEG Data and Preprocessing
This section describes the datasets used in this study and the preprocessing
steps.
Data of healthy individuals: The LEMON dataset consisted of scalp EEG
recordings from 203 healthy individuals (median age 39, age range 20–77, 82
females) [179]. The participants were stratified between young and old groups
with age ranges 20–35 and 59–77, respectively. The EEGs were recorded
using 62 channels according to the standard 10-10 localization system [180].
The data were originally recorded at a sampling rate of 2500 Hz and then
downsampled to 250 Hz, and each EEG session comprised eight eyes-closed
(EC) and eight eyes-open (EO) segments, each 60 seconds long. We rejected
the channels that were determined as outlier channels by the investigators
of the LEMON study [179]. We excluded the data of 59 individuals from
our study because some channels required for our analyses were either not
available or deemed outlier channels.
Data of epilepsy patients: We obtained scalp-EEG recordings from 48
individuals with DRE (median age 39, age range 18–66, 25 females) that were
performed as part of their clinical evaluations, and our study was approved by
the Mayo Clinic Institutional Review Board. The EEGs were recorded with
31 channels according to the standard 10–20 localization system [181] at a
sampling rate of 256 Hz. The EEGs were visually reviewed by board-certified
epileptologists and found to be free of any epileptiform activity. We selected
EC and EO segments based on the annotations made by EEG analysts.
Stratification of participants for analyses: Our first analysis focused on
differences between epilepsy patients and healthy individuals. We utilized
the data of all 144 healthy individuals from the LEMON study and 48 Mayo
patients for this analysis. Our second analysis focused on differences based
on the seizure-generating side of the brain in epilepsy patients. In addition
to the EEG features, we utilized handedness (right or left) to determine the
dominant hemisphere. Of the 48 epilepsy patients, 43 were right-handed and
5 were left-handed. Furthermore, although there is evidence that dominant
hemisphere of right-handed individuals is generally deterministic (i.e., the left
side), the dominant hemisphere of left-handed individuals is nondeterministic
(can be left or right side) [182]. Therefore, we excluded the a) left-handed
patients, because of insufficient sample size and the nondeterministic nature
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of their dominant hemisphere, and b) one right-handed patient who had a
central midline (non-lateralized) seizure onset, from this analysis. As a result,
the second analysis utilized the EEG data of 42 right-handed DRFE patients
(28 patients with seizure focus on the left side, and 14 patients with seizure
focus on the right side).
EEG preprocessing: Further preprocessing was done in EEGLAB for
MATLAB [183]. First, the EEGs were bandpass-filtered within 1–45 Hz (8th
order, Butterworth filter). Next, an independent component analysis was
performed, components reflecting eye movement, eye blink, or heartbeat-
related artifacts were removed, and bad channels were rejected, all according
to the widely recognized Makoto’s EEG preprocessing pipeline [184]. The
retained independent components were back-projected to sensor space for
further analysis.
Selection of EEG channels: Because the EEG data of healthy individuals
were recorded using a 62-channel 10–10 system, we selected a subset of
channels that matched the 10–20 system used to record the EEG data from
epilepsy patients. Within the EEG data of selected channels from the healthy
and patient populations, we selected four bipolar pairs of electrodes from
each hemisphere, producing eight channels of EEG data for each participant.
Table 7.1 shows the electrodes that were used to form the bipolar montage
representing each major brain region and hemisphere.
Table 7.1: Channels used to form the bipolar montage representing each
major brain region and hemisphere. The electrode names conform to the
standard 10–20 EEG system labels.





Extracting spectral features: We first separated EC and EO EEG seg-
ments of each participant, standardized (z-scored) each channel separately
within each segment, and divided each segment into 10-second non-overlapping
windows (Figure 7.1A-B; Figure 7.1A shows only 5-second-long EEGs for
visual clarity). Note that the number of 10-second windows was different
for each participant in the DRE population. We then computed the power
spectrum for each window using the multi-taper spectral estimation methods
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implemented in the Chronux toolbox [185]. In order to eliminate the subject-
specific differences in total signal power, we also normalized all the calculated
power values by using the total power of the signal within 0.5–40 Hz (Figure
7.1C-D). We then separately aggregated the normalized power within two
frequency bands: low-alpha (7.5–10.5 Hz) and high-alpha (10.5–13.5 Hz); such
a division of the alpha band allows the detection of slowing (more power in
low-alpha than in high-alpha) as well as the overall reduction in alpha power.
As a result, each calculated feature was a fraction of the total power within
one of the alpha bands and each 10-second window produced 16 features
(eight channels × two frequency bands). Furthermore, each participant’s
EEG data produced NEC × 16 EC features and NEO × 16 EO features, where
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Figure 7.1: Extraction of spectral features: (A) and (B) illustrate sample EC
and EO segments (length: 5 seconds) of a healthy participant’s EEG. (C)
and (D) illustrate normalized power spectrums of EC and EO segments,
where the solid line indicates average values calculated across all the healthy
participants and the shaded areas indicate 95% confidence intervals.
For further analysis, we selected an equal number (N(i)) of EC and EO
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windows for each participant such that EC and EO features can also be com-
bined to form pairs of (EC,EO) windows, where N(i) = min(NEC(i), NEO(i)),
and i is the participant number. As a result, participant i has N(i) number
of (EC,EO)-window pairs each with 16 EC and 16 EO features, i.e., a total
of 32 features. After this operation, the healthy data consisted of an average
of 47 (EC,EO)-window pairs (min=42, max=48) and the DRFE patient data
consisted of an average of 10 (EC,EO)-window pairs (min=2, max=34).
7.3 EEG-based Model of Brain Health
Characterizing normal brain function: We performed a log transforma-
tion of the features and used the cumulative density function (CDF) of the
log-transformed features in the healthy population to characterize normal
brain function. An example of this is shown in Figure 7.2A-C. Suppose
that the CDF of a single log-transformed feature xk (k ∈ {1, . . . , 32} is the
feature number) in the healthy population (considering all participants) is
denoted by F (xk), where xk ∈ [−∞, 0] and F (xk) ∈ [0, 1]. We hypothesize
that the samples representing abnormal brain function will fall near the
lower limit of xk. Therefore, the probability-of-normality for such samples
will be close to zero, while the probability-of-normality for samples that are
near the upper limit of xk will be close to one. With this intuition, we use
the CDF of xk to estimate the probability-of-normality for a new sample
x′k, i.e., P (x
′
k ∈ Normal) = F (x′k), as the CDF satisfies the aforementioned
requirements. However, note that this estimation of probability-of-normality
is based on a single feature xk.
Calculating probability-of-normality for an (EC,EO)-window pair:
To combine the values of all 32 features in an (EC, EO)-window pair, we
assume that the individual estimations can be independently combined. By
applying the independence assumption, we now derive a combined probability-
of-normality as shown below.
P (x′ ∈ Normal) = 32
√√√√ 32∏
k=1









Note that we use the geometric mean of the product of the individual feature-
based estimations as the combined estimate because the multiplication of 32
fractional numbers will produce a very small probability value. Furthermore,
we calculated P (x′ ∈ Normal) described in Eq. 7.2 in the log domain to
avoid numerical instability. This derivation provides a single probability value
P (x′ ∈ Normal) for each pair of (EC,EO)-windows. As a result, we now
have window-level probability-of-normality values for all (EC,EO) pairs of all
participants.
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Figure 7.2: Characterizing normal brain function and classification
framework: (A) Histogram of low-alpha (7.5-10.5 Hz) power fraction in
(F7-F3) in the EC windows of healthy individuals. (B) and (C) illustrate the
histogram and the cumulative density of the log transformation of the same
features, respectively. (D) A random sample of 96 healthy participants is
selected for characterizing normal brain function. The data of the rest (48
healthy and 48 DRFE) are utilized to evaluate the classification potential.
Cumulative density functions of the 32 features representing alpha power
fractions in the (EC,EO)-window pairs are computed. Window-level
probability-of-normality estimates were aggregated to obtain participant-level
probabilities. Goodness-of-fit metrics were computed by comparing
participant-level probabilities with ground truth, separately for classifying a)
healthy vs epilepsy and b) hemisphere with seizure focus. This procedure
was repeated ten times to estimate average metrics and standard deviations.
Individual-level probability estimation: To estimate whether a partic-
ipant’s EEG is normal, we use a maximum likelihood estimation based on
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the window-level probability-of-normality values. We model the window-
level estimates of a participant Pi as independent observations made from a
Bernoulli trial with an unknown probability πi, where πi is the probability-
of-normality for participant Pi, i.e., πi = P (Pi ∈ Normal). Suppose that we
use x′(i, n) to denote the nth window of participant i, and Y (i, n) to denote













Classification framework: Figure 7.2D illustrates the classification ap-
proach we utilized to evaluate our hypotheses. During each cross-validation,
we selected a random sample of 96 healthy participants to generate the feature-
specific CDFs characterizing normal brain function (i.e, training set). We used
the data of the rest of the participants (48 healthy and 48 DRFE) to evalute
the classification potential of our approach (i.e., testing set). This scheme
ensured that the training and testing datasets consisted of two disjoint sets of
participants and that the testing set is class-balanced. First we computed the
CDFs of the 32 features representing alpha power fractions in the (EC,EO)-
window pairs using the healthy sample in the training set. Then, we computed
the window-level probability-of-normality values for each (EC,EO)-window
pair in the testing set. Then, we aggregated the window-level values to obtain
individual-level values as described previously. By comparing individual-level
probabilities with ground truth, we computed goodness-of-fit metrics for the
classification task, separately for classifying a) healthy vs epilepsy and b)
hemisphere with seizure focus.
Performance evaluation: We first plotted receiver operating characteristic
(ROC) curves and calculated the area under ROC curve (AUC) to compare
model performances. An optimal threshold on the ROC curve was selected
using the convex hull method [186]. That threshold was used to calculate
precision, recall, and F1-score. The classification procedure was repeated
ten times to calculate the mean and standard deviations of the metrics. In
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addition, because frontal and temporal lobe epilepsy are the most common
forms of focal epilepsy, we performed the classification approach using the
features from those two regions alone and compared the results with those
obtained from the approach using features extracted from all regions.
7.5 Results
7.5.1 Characterizing Normal Brain Function in The Healthy
Population
We used the features based on the alpha rhythm to characterize normal
brain function. Figure 7.3A illustrates the CDFs of log-transformed alpha
power fractions in the healthy population in EC and EO windows. The
figure also highlights the differences between the four major brain regions
with respect to the same features, where the CDF of each brain region was
generated by taking the average of the CDFs of the respective regions in the
left and right hemispheres. Our observations agree with the commonly-known
characteristics of the alpha rhythm; i.e., a) it is posteriorly dominant and b)
its presence is amplified when the eyes are closed [173]. In addition, Figures
7.3B and 7.3C show the spatial patterns of the differences between EC and EO
conditions in the two alpha bands, based on Wasserstein distances between
the CDFs. We find that the differences are stronger in the posterior regions
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Figure 7.3: Characterizing normal brain function in the healthy population:
(A) Cumulative density functions of log-transformed spectral power fractions
in low-alpha (7.5-10.5 Hz) and high-alpha (10.5-13.5 Hz) bands, grouped
based on eyes-closed and eyes-open conditions. Solid lines indicate average
values across 10-second windows and shaded areas indicate 95% confidence
intervals. Note that the window-level features were averaged between left
and right hemispheres to generate the CDF plots. (B) and (C) are head plots
illustrating the location-specific Wasserstein distances between the CDFs of
EC and EO windows in low-alpha (7.5-10.5 Hz) and high-alpha (10.5-13.5
Hz) bands, respectively. The pins indicate approximate locations of the
bipolar channels.
7.5.2 Evidence for Disrupted Brain Function in Inconclusive
EEGs of DRFE Patients
The primary goal of this study is to understand whether there are subtle
abnormalities in the inconclusive EEGs of DRFE patients. To study this, we
analyzed how the distributions of the log-transformed alpha power fractions
in the healthy and DRFE individuals differed using a) their CDFs and b)
the probability-of-normality values. Figure 7.4A illustrates the differences
between the log-transformed alpha power fractions of healthy and DRFE
94
individuals, based on the Wasserstein distance between CDFs. Note that those
differences were calculated separately for EC and EO conditions. We observed
that the differences are notable in frontal and temporal regions. Particularly,
the alpha power values were significantly lower in the DRFE population
when compared with the healthy population, and this was highlighted in the
frontal and temporal regions. To demonstrate this objectively, we used the
probability-of-normality values described in Section 7.3. Figure 7.4B shows
the boxplots of the window-level probability-of-normality values in the healthy
and DRFE populations. We found that the probability-of-normality values
are significantly lower in the DRFE population compared to the healthy
population (p<0.05 based on the Wilcoxon rank sum test).
Eyes Closed Eyes Open
7.5-10.5 Hz 10.5-13.5 Hz 7.5-10.5 Hz 10.5-13.5 Hz
7.5-10.5 Hz 10.5-13.5 Hz 7.5-10.5 Hz 10.5-13.5 Hz


































* = Statistically significant
Figure 7.4: Disrupted normal brain function in the DRFE population. (A)
Head plots illustrating the location specific Wasserstein distances between
the CDFs of log-transformed alpha power features of healthy and DRFE
individuals. (B) Boxplots of window-level probability-of-normality estimates
for healthy and DRFE individuals. (C) Head plots illustrating the
location-specific Wasserstein distances between the CDFs of log-transformed
alpha power features of right-handed DRFE individuals who had
right-hemispheric seizures and those who had left-hemispheric seizures. (D)
Boxplots of window-level probability of normality estimates for healthy and
right-handed DRFE individuals where the DRFE individuals are further
stratified based on the hemisphere generating seizures. In (B) and (D) the
numbers N=n indicate the number of participants whose data were used in
generating the boxplot.
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7.5.3 The Side of Seizure Focus Impacts the Extent of Brain
Function Disruptions in Focal Epilepsy
To understand the contribution of seizure focus towards disruptions in
brain function, we analyzed how the distributions of the log-transformed
alpha power fractions within the right-handed DRFE patients differed based
on the hemisphere generating seizures. As described previously, the left
side is generally the dominant hemisphere in right-handed DRFE patients.
Figure 7.4C illustrates the spatial patterns of the differences between the log-
transformed alpha-power fractions of right-handed DRFE individuals who had
right-hemispheric seizures and those who had left-hemispheric seizures, based
on the Wasserstein distance between CDFs. We found that the differences are
emphasized notably in frontal and temporal regions. Similar to the differences
observed between healthy and DRFE patients, the alpha power values were
significantly lower in the individuals with left-hemispheric seizures compared
to those with right-hemispheric seizures. We again utilized the probability-
of-normality values to demonstrate this. Figure 7.4D shows the boxplots
of the window-level probability-of-normality values between the two groups.
We found that the probability-of-normality values are significantly lower in
right-handed DRFE patients who had left hemispheric seizures compared to
those with right-hemispheric seizures (p<0.05 based on the Wilcoxon rank
sum test).
7.5.4 Inconclusive EEGs Can Help Diagnose Drug-resistant
Focal Epilepsy and Lateralize Seizure Focus
Next, to evaluate the potential to diagnose DRFE and lateralize seizure
focus using the alpha rhythm-related features, we performed two classification
experiments: a) classifying healthy and DRFE individuals and b) classifying
the seizure-generating side of the brain, both using the classification framework
described previously. Figure 7.5A and 7.5B illustrate the ROC curves for the
two classification tasks.
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Figure 7.5: Receiver operating characteristic (ROC) curves for the two
classification tasks. (A) ROC curves for classifying healthy individuals and
DRFE patients. (B) ROC curves for classifying seizure generating side of the
brain in right-handed DRFE patients. In both (A) and (B), red and blue
curves indicate classifications using features from all regions and frontal and
temporal regions, respectively. Furthermore, solid lines indicate average
values obtained using the tenfold crossvalidation and shaded areas indicate
95% confidence intervals.
Furthermore, Table 7.2 displays the goodness-of-fit metrics for the clas-
sification tasks, calculated based on the ROC analysis. We found that the
probability-of-normality values derived based on a healthy sample can be used
to differentiate previously unseen healthy and DRFE patients (AUC=0.79–0.83).
Similarly, we found that the same probability values can also be used to differ-
entiate the seizure-generating side of the brain in a previously unseen DRFE
population (AUC=0.68–0.71). In both cases, the classification performance
was significantly better than chance (AUC>0.5) and showed minimal variation
in a tenfold cross-validation scheme. We also found that the probability-of-
normality values based on the frontal and temporal alpha features provided
marginally better results in both the classification tasks compared to the
probability values based on all regions (average AUC improvements of 0.04
















































































































































































































































































































































7.5.5 Pathological Disruptions in the Alpha Rhythm Are More
Significant than Those Related to Aging and
Antiepileptic Medications
Finally, we sought to distinguish the effect of chronic drug-resistant epilepsy
in the alpha rhythm from the effects of aging and antiepileptic drugs (AEDs).
Effects of aging vs DRFE: In this analysis, we used the alpha features
of healthy-young individuals (age: 20–35, N=97) for characterizing normal
brain function based on CDFs. Then, using those CDFs, we computed the
window-level probability-of-normality values for healthy-old individuals (age:
59–77, N=47) and DRFE patients (N=48). Figure 7.6A illustrates the results
of multiple comparisons performed on those probability-of-normality values
between the different groups. Note that we used the data of healthy-young
individuals as a reference in this analysis. We found that the differences be-
tween young- and old-healthy individuals, and the differences between healthy
and DRFE individuals, were both significant (p<0.01). We also observed
that the mean window-level probability-of-normality of DRFE patients was
significantly lower than the means of other two groups.
Effects of AEDs vs DRFE: In this analysis, we used the alpha features of all
healthy individuals (N=144) for characterizing normal brain function. Then,
using those CDFs, we computed the window-level probability-of-normality
values for two groups of DRFE patients: patients not taking any AEDs
(N=5) and patients taking AEDs (N=43). Figure 7.6B illustrates the results
of multiple comparisons performed on those probability-of-normality values
between the different groups. Similar to all previous analyses, we used the
data of healthy individuals as a reference in this analysis. We found that the
difference between DRFE individuals based on whether they took AEDs or















































* Statistically significant * Statistically not significant
Figure 7.6: Multiple comparisons between our study participants who were
stratified based on their age and the number of consumed antiepileptic drugs
(AEDs). Figures show the point estimates and comparison intervals of mean
probability of normality values. (A) Multiple comparisons between healthy
and DRFE individuals where the healthy individuals are stratified based on
the age group: Young (Healthy-Y): 20–35, and Old (Healthy-O): 59–77). (B)
Multiple comparisons between healthy and DRFE individuals where the
DRFE individuals are stratified based the number of AEDs consumed at the
time of EEG. The numbers N=n indicate the number of participants whose
data were used in the analyses.
7.6 Interpretation of Results
7.6.1 Main Contribution of the Study
In this study, we investigated whether such inconclusive EEGs contain subtle
abnormalities that can help improve their diagnostic value. We conducted this
retrospective study using the inconclusive scalp EEG recordings of 48 patients
with drug-resistant focal epilepsy and the scalp EEGs of 144 age-matched
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healthy individuals. We extracted alpha rhythm-related characteristics from
the healthy population and used them to represent normal brain function.
We then analyzed how the same alpha rhythm-related characteristics in the
DRFE population differed from the representation of normal brain function.
Our analyses indicate that a) alpha power is significantly reduced in DRFE
compared to healthy and b) alpha power of right-handed DRFE patients
with left-hemispheric seizures is significantly lower compared to those with
right-hemispheric seizures. We also utilized these findings in a classification
framework to classify a) whether an EEG was recorded from an epilepsy
patient, and b) if so, the seizure generating side of the patient’s brain, by
using EEG recordings that do not contain any epileptiform activity. A tenfold
cross-validation approach achieved mean AUC values of 0.83 and 0.71 for
the respective classification tasks. These findings suggest that EEG-based
measures representing normal brain function can help in the diagnosis of
epilepsy even when the EEG does not contain any epileptiform activity.
This finding is significant because the ability to diagnose epilepsy at the
earliest possible time can prevent significant delays in treatment, and can
support more efficient triage of patients to costly in-hospital monitoring
studies. In that context, our study presents a promising research direction in
the treatment of epilepsy.
7.6.2 The Spatial Patterns of the Alpha Abnormalities in
DRFE
Our results indicate significant alpha rhythm-abnormalities in the frontal
and temporal regions of DRFE patients, and such abnormalities were observed
in both EC and EO conditions (Figure 7.4A and 7.4C). This observation was
further highlighted in the classification tasks; we found that using the alpha
features extracted from frontal and temporal regions provided marginally
better classification performances compared to using the same features ex-
tracted from all brain regions. These observations suggest that that the alpha
abnormalities in DRFE are of focal nature and display frontal spreading. We
surmise that such characteristic changes in the alpha rhythm could have been
modulated by the specific epilepsy syndrome because the majority of the
DRFE patients (38 out of 48) had frontal or temporal seizure onset. Prior
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studies have also reported similar findings indicating a frontal spread of alpha
rhythm alterations in focal epilepsy and suggested that this effect could be
commensurate with the extent of cortico-thalamic dysfunction [172].
7.6.3 Analysis of Confounders
Alpha rhythm abnormalities related to neurological diseases are typically
confounded by age-related changes and changes induced by certain medications
[170]. In this study, we showed that the alpha abnormalities we observed in
the inconclusive EEGs of DRFE patients were significant when compared with
changes related to aging and AEDs, using a multiple comparison approach.
This finding suggests that the EEGs which were determined to be inconclusive
based on visual review, in fact, contain strong pathological correlates of DRFE
that may be sufficient to support clinical use. However, we note that our
analysis comparing the effects of AEDs can benefit from additional samples
to increase the statistical power of the finding.
7.6.4 Methodological Contributions
This study developed a probabilistic approach to characterize normal brain
function using alpha rhythm-related features extracted from eight bipolar
channels. This involves computing the CDFs of log-transformed alpha power
features in the individual channels of 10-second EEG windows and using
those CDFs to assign a window-level probability-of-normality estimate to a
new window. We combined the individual channel-based values to obtain a
combined probability-of-normality estimate for each window. Furthermore,
we applied a maximum-likelihood approach to aggregate the window-level
probability-of-normality values of a participant’s entire EEG recording to
obtain a probability-of-normality estimate for the participant. These values
were then used for classification purposes. Our approach can be seen as an
anomaly detection technique using which we estimate whether a new sample
is anomalous compared to the reference population. An advantage of this
approach is that it can be developed using the data of the reference population
alone without requiring data from anomalous samples. Furthermore, our ap-
proach presents a general paradigm for EEG-based anomaly detection, which
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can be beneficial for other EEG applications such as seizure forecasting [187].
In addition, our approach to characterize the health of brain functionality
using the alpha rhythm can form the basis for the growing area of research
on EEG and brain health [188] and can be used to study a variety of other
neurological conditions.
7.6.5 Study Limitations and Future Work
Our participants, in this study, were limited to healthy individuals and
DRFE patients alone. An inconclusive EEG in the clinic could imply a wide
range of possibilities including healthy, epilepsy (and its many subtypes), and
a number of other neurological diseases. A population-level study including
EEGs from a heterogeneous sample is necessary to accurately evaluate the
clinical value of our findings. Specifically in the context of epilepsy, the abili-
ties to differentiate a) drug-resistant epilepsy patients from drug-responsive
epilepsy patients and b) focal epilepsy patients from generalized epilepsy
patients, would be potentially very useful because they would allow clinicians
to individualize treatments based on disease subtype.
Our analysis relied on expert EEG annotations regarding EC and EO
conditions, awake and sleep, and bad channels. Such annotations are time-
consuming, costly, susceptible to human error, and clearly not scalable.
Fully automated approaches using deep neural networks that can analyze
raw EEG data without requiring expert annotations of specific events can
provide multiple benefits: a) enable large-scale studies, b) eliminate individual
biases, and c) help identify novel EEG features and advance our scientific
knowledge. Such automated approaches can also augment the visual review of
epileptologists by providing focused inputs and help reduce physician burnout
[189].
Another limitation of our study is that the EEGs of two populations, healthy
and DRFE, were acquired using different systems under different conditions.
Therefore, the difference between the acquisition systems/environments is a
potential confounder in our analyses between healthy subjects and DRFE
patients. To address this limitation as best we could, a) we undertook the
same preprocessing steps for both the EEG datasets and b) we used the
fraction of alpha power within the wideband of 0.5-40 Hz to mask the subject-
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specific differences in total signal power. However, EEGs of both controls and
patients recorded using the same acquisition system are necessary to fully
eliminate this confounder. Our future efforts will investigate this possibility.
7.7 Summary
EEG-based diagnosis of epilepsy, which is the gold-standard approach,
relies on visual identification of epileptiform activity. However, epileptiform
activity may not be recorded in a short EEG recording session, and that can
cause delays in the delivery of clinical care. Unfortunately, such scenarios are
common in the clinic; approximately 50% of the EEGs recorded from patients
with seizures are deemed inconclusive based on expert visual review. In this
study, using a semi-automated approach, we investigated the possibilities
of diagnosing DRFE and lateralizing seizure focus based on inconclusive
EEGs. Our results support the hypothesis that EEG-based measures of
normal brain function, based on the alpha rhythm can help diagnose DRFE
and lateralize seizure focus when an EEG does not contain any epileptiform
activity, recorded seizures, or other non-specific abnormalities. Based on
these findings, we further hypothesize that such findings in an inconclusive
EEG can suggest a higher pre-test potential for epilepsy when an individual
is screened for epilepsy for the first time. In addition, our findings also
suggest that automated analyses of scalp EEG can help in developing scal-
able and cost-effective approaches for advancing the current state of clinical
electrophysiology. However, prospective studies and addressing the identified
limitations of our work are necessary to fully understand the clinical value
of these hypotheses. Going forward, our efforts will focus on expanding
the study to population-level datasets including EEGs from heterogeneous
samples, developing fully automated methods, and addressing systemic biases
introduced by EEG acquisition systems.
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CHAPTER 8
MODELING BRAIN HEALTH USING SMRI
This chapter describes a domain-guided brain health model based on
structural MRI data and describes its application to detect brain health
decline in elderly individuals. The model and its utility are demonstrated
via a study conducted at the Mayo Clinic, Rochester, Minnesota, using a
population-level structural MRI dataset collected as part of the Mayo Clinic
Study of Aging.
8.1 Introduction
Age-related neurodegenerative diseases, such as Alzheimer’s disease (AD),
impose a growing burden on society. Hence, there is great interest in under-
standing and modeling the brain health, with the goal of detecting age-related
neurological abnormalities ahead of time. Brain age and cognitive perfor-
mance are two widely used measures in the study of brain health. Brain age
estimates the biological age of an individual’s brain based on the extent of
cerebral atrophy [190]; whereas, cognitive performance represents an individ-
ual’s intellectual functions and processes, such as attention, the formation of
knowledge, memory, judgment, reasoning, problem solving, comprehension,
and language. In other words, brain age and cognitive performance measure,
respectively, the structural and functional health of an individual’s brain. In
this study, we sought to develop a machine learning-based model to jointly
describe these two measures of brain health.
Models describing these two measures have typically been developed using
statistical or machine learning approaches based on neuroimaging data (e.g.,
structural magnetic resonance imaging). Although the two measures are
related to each other through brain structure, researchers have chosen to
study them in isolation from each other for the following reasons. First,
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brain-age models are developed entirely using data on healthy individuals,
because ground-truth brain age is defined only for healthy individuals. More
concretely, the brain ages of healthy individuals are conjectured to be close to
their chronological ages [191]. Therefore, the brain ages of individuals with
neurodegenerative diseases are unknown. On the other hand, cognitive per-
formance can be measured regardless of an individual’s health, and therefore
the study populations are not restricted to healthy individuals. Second, brain
age, by definition, depends entirely on brain structure. On the other hand,
cognition depends not only on brain structure but also on cognitive reserve
and the presence or absence of pathological mechanisms related to diseases
such as Alzheimer’s disease (AD) [192]. Therefore, models of cognition require
a careful consideration of these two factors.
However, despite those complexities, we identified two benefits to developing
a joint model of the two factors. First, the brain-age models developed based
entirely on healthy populations have limited generalizability, because the
dynamic range of cerebral atrophies in the study populations is typically small.
Extreme levels of cerebral atrophy will not be present in healthy populations.
A brain-age model developed jointly with a cognitive-performance model
will have improved generalizability because the populations used to model
cognitive performance contain larger dynamic ranges of cerebral atrophy. A
joint model can effectively share information between the two models and
inform the brain-age model about extreme levels of cerebral atrophy. Second,
a joint model can inform scientists about the relations of regional atrophies
with respect to structural and functional health. Despite decades of research,
there is still a notable level of ambiguity within the scientific community
about the regions involved in cognitive processing and the sensitivity of brain
functions to age-related regional cerebral atrophy. We hope that by using the
joint model, we can elucidate the ambiguities by quantifying the importance
of brain regions in predicting the two measures of brain health.
Approach: Hence, the goal of this study has been to develop a joint model
of the two measures by explicitly defining the commonalities and differences
between them based on domain knowledge. Our model builds upon the fact
that both brain age and cognitive performance depend on brain structure. A
conceptual diagram of our joint model is shown in Figure 8.1. We derived an
abstraction of the model by representing the relationships between the two
measures as edges of a graphical model. We then represented the edges using
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artificial-neural-network layers to derive a learning model. In this study, we
used structural magnetic resonance imaging (SMRI) data, years of education,
and APOE-ε4 genotype to quantify brain structure, cognitive reserve, and
AD-related pathological features, respectively. Furthermore, we used the mini-
mental state examination (MMSE) score to measure cognitive performance.
This approach results in a multitask learning model that takes SMRI data,




















Figure 8.1: A conceptual diagram of our joint model. The functional
mappings between inputs and outputs were learned using
artificial-neural-network layers.
The model consists of 1) a function that learns a shared representation
of brain structure using SMRI data, 2) an output that predicts brain age
based on brain structure, and 3) an output that predicts MMSE score using
brain structure and cognition-specific inputs. The training of the model is
performed by partitioning the training data into healthy individuals and
individuals with neurodegenerative diseases. The parts of the model specific
to brain-age prediction are trained using the data of healthy individuals,
and the parts of the model specific to MMSE prediction are trained using
the data of both healthy individuals and individuals with neurodegenerative
diseases. Note that the shared representation of brain structure is trained
using the data from every participant in the study regardless of his or her
health. Therefore, the joint model exposes the brain-age predictor to a larger
dynamic range of inputs.
Study summary: We evaluated our model using data collected as part
of the Mayo Clinic Study of Aging (MCSA). These data included SMRI
107
images, demographics, and cognitive-performance measures collected from
2809 individuals between the ages of 50 and 90 (818 of whom were healthy).
SMRI images were preprocessed to extract the cortical thicknesses of brain
regions of interest (ROIs). Our joint model took cortical thickness measures of
41 ROIs, years of education, and APOE-ε4 genotype as inputs and predicted
brain age (in years) and MMSE score (0–30). A fivefold cross-validation
using an 80%/20% split of the study data indicated that the joint model
improved the prediction accuracy of the brain-age model by 12% (an 8-month
improvement in mean absolute error) and provided a 5% improvement in
predicting the accurate order of brain-age values based on serial SMRI images
(referred to as the longitudinal stability) compared to a conventional model.
Furthermore, we identified distinct, scientifically meaningful brain regions
related to the structural and functional aspects of brain health by evaluating
the importance of input features in the joint model. Our major contributions
are the following:
1. A joint model describing structural and functional measures of brain
health. Previous studies have studied those measures in isolation using
different study populations.
2. An improved brain-age predictor. Our joint model improved the gen-
eralizability of a conventional brain prediction approach because the
joint setting enabled the brain-age model to learn from a much larger
dynamic range of inputs.
3. Identification of distinct brain regions that are representative of struc-
tural and functional brain health. We found that insular atrophy is
tightly correlated with structural brain health, and that atrophy in
temporal regions is tightly correlated with cognitive processing.
4. We present a general paradigm by which measurements of other brain
functions can be used to improve brain-age prediction. For instance,
motor-function-related measurements, such as the Unified Parkinson’s
Disease Rating Scale (UPDRS) [193], can be used to train a joint model
by using data from individuals with movement disorders.
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8.2 Model Description
Here we describe a mathematical formulation of our model that jointly
predicts brain age and cognitive performance based on SMRI data and
demographic information.
8.2.1 Definitions
We use XMRI ∈ Rd to denote SMRI features, XE ∈ R to denote years of
education, and XA ∈ {0, 1} to denote APOE-ε4 genotype, where d is the
number of ROIs. In addition, we use YA and YM to denote the ground-truth
values with respect to brain age and MMSE score, respectively. Similarly, ŶA
and ŶM denote the predicted brain age and MMSE score, respectively.
8.2.2 Dependency Graph
Figure 8.2a illustrates the relationships between inputs and outputs. As
discussed previously, brain age depends entirely on brain structure as derived
from structural MRI data; whereas, cognitive function depends also on
cognitive reserve and the presence or absence of pathological mechanisms
related to conditions like Alzheimer’s disease. We use years of education
and the APOE-ε4 genotype to quantify cognitive reserve and AD-related
pathological features, respectively. The same relationships are illustrated
as dependencies in the graphical model shown in Figure 8.2b, in which the
intermediate variable R denotes brain structure.
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(a) Relationship among










Figure 8.2: Model derivation based on domain knowledge.
8.2.3 Learning
Given XMRI , XA, and XE, we are interested in estimating YA and YM .










We can then estimate ŶA and ŶM in the following manner.
ŶA = arg max
YA
P(YA|XMRI)
ŶM = arg max
YM
P(YM|XMRI,XA,XE)
Those mappings can be learned using a machine learning approach as
illustrated in Figure 8.2c. Parts A, B, and C denote functions that can be
learned using training data. For instance, they can be implemented using
dense neural-network layers. Furthermore, it is possible to learn linear and
nonlinear functions by using an appropriately chosen activation function.
Part A takes XMRI as input and generates a feature map representing brain
structure. Part B takes that feature map as input and predicts brain age.
The feature map generated by part A is concatenated with [XA,XE] and given
as input to part C. Part C then predicts the MMSE score using that input.
8.2.4 Training
The model can be trained using the back-propagation algorithm. Specif-
ically, parts A and B can be trained using the data on healthy individuals.
Similarly, parts A and C can be trained using the data of every individual
regardless of his or her health. The loss function that was used to train
our model consists of two parts, L1 and L2, which are for the brain-age and
MMSE predictions, respectively. Because both brain age and the MMSE
score are real values, we used mean-squared losses for L1 and L2. The overall











where B denotes a batch of training data, and BT1 and BT2 denote subsets
of the training batch B that can be used to train the brain-age (T1) and
MMSE (T2) parts of the model, respectively. The overall training approach is
described using pseudocode in Algorithm 1, where WA, WB, and WC denote
the weights associated with parts A, B, and C. Note that part A is trained
regardless of the specific task being trained.
111
Algorithm 1 Training algorithm
1: procedure TrainingLoop(N,WA,WB,WC)
2: for n ∈ 1....N do
3: B← training-batch(n)
4: for k ∈ 1, 2 do
5: BTk ← B[Task == k]




7: WA ←WA − αk ∂L∂WA
8: if k = 1 then
9: WB ←WB − αk ∂L∂WB
10: else if k = 2 then
11: WC ←WC − αk ∂L∂WC
8.3 Data
This study utilized data from the Mayo Clinic Study of Aging (MCSA), an
epidemiologic study of Olmsted County, Minnesota, residents [15]. The data
represent 2809 participants who had multiple follow-ups. The following data
were collected at each visit of each participant.
8.3.1 Demographics
Sex and years of education were obtained at the first clinical visit. Age
was recorded at the time of the MRI scan. In addition, recently existing
cardiovascular and metabolic conditions (CMC) (hypertension, hyperlipidemia,
cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes
mellitus, and stroke) were extracted from health care records.
8.3.2 Structural MRI Acquisition and Preprocessing
Cortical thickness measurements were made using a previously published
method for standard structural MPRAGE (magnetization-prepared rapid
acquisition gradient echo) scans [194]. The median thicknesses of bilateral
ROIs (except the cerebellum) were computed using the Mayo Clinic Adult
Lifespan Template (MCALT) atlas.
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8.3.3 APOE-ε4 Genotype
The greatest genetic risk for late-onset Alzheimer’s disease is associated
with alleles of the apolipoprotein E (APOE ) gene. With an allele frequency
of 14%, APOE-ε4 is present in approximately 25% of the United States
population and associated with increased risk of Alzheimer’s disease [195].
APOE-ε4 individuals have an earlier average age of AD onset by 10–15 years
per allele [195]. Most of the genetic effect on age of onset of AD is accounted
for by inheritance of APOE alleles [196]. We utilized the APOE-ε4 genotype
to quantify the risk of having AD-related etiologies in an individual’s brain.
8.3.4 Mini-Mental State Examination (MMSE)
The MMSE [197] is a widely used cognitive screening test, for which scores
from 24 to 30 are considered to be within the normal range. Items address
orientation, memory, recall, attention, naming of objects, following of verbal
and written commands, writing of a sentence, and copying of a figure.
8.3.5 Healthy Sub-population and Ground-truth
A healthy sub-population was extracted from all the participants of the
study based on the following conditions: 1) their clinical diagnoses were
cognitively unimpaired; 2) they did not have abnormal levels of amyloid
deposition in their brains (i.e., they were amyloid-negative [198]); and 3) they
did not have more than two cardiovascular and metabolic risk factors [199].
Since those criteria ensured that those participants in that sub-population
did not have any neurodegenerative etiologies, we treated their chronological
ages as the ground-truth brain ages. On the other hand, all participants had
ground-truth information on their MMSE scores.
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8.4 Experiments
8.4.1 Inputs and Outputs
Model inputs included cortical thickness measures of 41 ROIs, the APOE-ε4
genotype (binary), and years of education (6–14 years) [200]. Model outputs
were brain age and MMSE scores, which were predicted as real numbers.
8.4.2 Training and Validation
The training and validation procedure we undertook is illustrated in Figure
8.3. The data associated with the two tasks were divided prior to model
training and validation. A dataset with only healthy individuals was assembled
for the brain-age task, and another dataset with all the participants was
assembled for the MMSE task. Note that the first dataset was a subset of
the latter. The participants in each dataset were split into training (80%)
and validation (20%) groups, and all follow-up data on the participants in
the training set were appended to the training set during model training.
However, the training and validation data used for model evaluation contained
only the baseline data, ensuring that the evaluation metrics were not affected

















































































































































We performed a fivefold cross-validation by randomly shuffling the partici-
pants in each dataset and repeating the training-validation split described
above to evaluate the performance of our model. Table 8.1 lists the numbers
of training and validation samples that we utilized for each task. Note that
the number of training data samples was slightly different in the different
cross-validations depending on the participants selected for the training set
and the amount of follow-up data available for each participant. Each train-
ing epoch consisted of two steps: 1) a batch of healthy-participant data was
retrieved from the training set of the first dataset and was used to train the
brain-age task, and 2) a batch of data from the training set of the second
dataset was retrieved and was used to train the MMSE task (described in
Algorithm 1).
Table 8.1: Training and validation datasets.
Task Training Validation
# subjects # samples # subjects # samples
Brain age 652 ∼1265 166 166
MMSE 2231 ∼5250 558 558
8.4.3 Models
We implemented linear and nonlinear models based on the description
provided in Section 8.2. Both models were implemented with the same number
of neurons in all of the layers, but the hidden layers of the linear model were
implemented with linear activation functions; whereas, the hidden layers
of the nonlinear model were implemented with ReLU activation functions.
The representation of brain structure (R) was implemented using one hidden
layer with 32 neurons (i.e., part A in Figure 8.2c had 41×32 weights and
32 bias units). Parts B and C in Figure 8.2c were implemented with dense
layers with one output neuron each (i.e., part B had 32×1 weights and 1 bias
unit, and part C had 34×1 weights and 1 bias unit). The output layers were
implemented with linear activation functions for the linear model and with
leaky ReLU activation functions for the nonlinear model. Optimizations were
performed using the Adam optimizer with α = 0.001 and default values for
other parameters. The models were trained for 200,000 epochs with a batch
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size of 128, and the learning curves were inspected to avoid over fitting and
to ensure convergence of training.
8.4.4 Software and Hardware
We implemented our software using the TensorFlow API [201] version 1.12
and Python version 3.7, and we performed all the experiments on a Linux
server with four NVIDIA Tesla-P100 graphics processing units.
8.4.5 Evaluation Metrics
We used mean absolute error (MAE) and mean-squared error (MSE) to
measure the prediction accuracy of both the outputs. In addition, we evaluated
the longitudinal stability (LS) of brain-age prediction by comparing the
order of brain ages in pairs of predicted brain-age values. We performed
this evaluation based on the fact that brain age is strictly increasing with
chronological age. The metric we used for the evaluation (LS) measures what







I[ŶA1 < ŶA2 ],
where a1 and a2 are two inputs such that the data a1 were collected prior
to a2, ŶA1 and ŶA2 are predicted brain-age values for the respective inputs,
M is the number of pairs of inputs with the condition that a1 < a2, and I
indicates the indicator function.
8.4.6 Model Comparisons
First, we evaluated the benefits of developing a joint model rather than
separate models of brain age and cognitive performance. We did so by
developing isolated brain-age and MMSE-score predictors with the same
model architectures, but without sharing the representation of brain structure.
As a result, a network with one hidden layer of size 32 was used to predict
brain age, and a network with one hidden layer of size 32 and with the
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additional cognition-related inputs was used to predict the MMSE score, both
trained and validated separately. Furthermore, we performed this experiment
separately for the linear and nonlinear approaches.
8.4.7 Differentiating Cognitively Impaired and Normal
Subjects
We compared the predicted brain-age values against true chronological ages
in the cognitively impaired and unimpaired groups to test the hypothesis that
in a group of people with the same chronological age, a cognitively impaired
person is likely to have a higher brain age than a healthy individual.
8.4.8 Evaluating SMRI Feature Importance
After our model was trained, we used the integrated-gradients [3] approach
to evaluate the importance given to the SMRI features. This experiment was
performed to identify brain regions that are predictive of age-related cerebral
atrophy and cognitive performance. Here we provide a brief summary of the
integrated-gradients approach.
8.4.9 Integrated Gradients
Suppose that we use F to represent the function approximated by our model.
An attribution of the prediction at input x ∈Rd (where d denotes the input
dimensionality) relative to a reference input x′ ∈Rd is a vector AF(x, x′) ∈Rd,
and the ith element of it is defined as follows.
AFi(x, x
′) = (x− x′)×
∫ 1
α=0
∂F(x′ + α(x− x′))
∂xi
dα
We used the d-dimensional zero vector [0, 0, . . . , 0]d as the reference input,




The accuracy metrics of our models are listed in Table 8.2. We use the
abbreviations J-NL, I-NL, J-L, and I-L to denote a joint nonlinear model, an
isolated nonlinear model, a joint linear model, and an isolated linear model,
respectively. In addition, we use the abbreviations MAE and RMSE to denote
mean absolute error and root mean-squared error, respectively. All measures
are provided in the form of means (standard deviations), and all values have
been rounded to two decimal places. Our conclusions below are based on
the results obtained on the validation dataset, which included only the data
from healthy individuals. We observe that our joint model performed better
than isolated models in predicting brain age and MMSE score. This was
true in both the linear and nonlinear approaches we considered. The linear
and nonlinear joint models provided significant improvements with respect to
MAE and RMSE in both brain-age and MMSE-score predictions compared to
isolated models. We also find that the best accuracy obtained by our model
compares favorably with that of previous brain-age models developed with

























































































































































































































































































































































The results with respect to the longitudinal stability of brain-age prediction
are listed in Table 8.3. The LS (longitudinal stability) metric indicates that
the joint models (linear and nonlinear) perform better in predicting the order
of brain-age values than do isolated models.






8.5.3 Differentiating Cognitively Impaired and Normal
Subjects
Figure 8.4 shows that subjects with cognitive impairment were predicted to
have higher brain ages than those who were unimpaired. We used the analysis
of covariance (ANCOVA) to find that the intercepts of the two regression
models are significantly different (p < 0.05) when they are conditioned on the
















Figure 8.4: Brain age vs. chronological age.
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8.5.4 SMRI Feature Importance
Figure 8.5 illustrates the feature importance (in descending order) of SMRI-
ROIs in predicting brain age and MMSE score. We combined the 41 ROIs
we used in our analysis to form the scientifically meaningful 11 regions that
Figure 8.5 displays. The insula was given the highest weight in predicting
brain age, and some temporal regions (lateral and medial) were given high











































































































































































(b) SMRI-ROI importance in MMSE
prediction.
Figure 8.5: The importance of SMRI ROIs in predicting brain age and
MMSE score. (SMA is the supplementary motor area)
8.6 Discussion
Brain age and cognitive performance are two popular measures of age-
related brain health. We developed a joint learning-based model to predict
these two measures using structural MRI data and demographic information.
We hypothesized that a brain-age model developed jointly with a cognitive-
performance model will have improved generalizability because the populations
used to model cognitive performance contain larger dynamic ranges of cerebral
atrophy, and a joint model would be able inform scientists about the relations
of regional atrophies with respect to structural and functional health.
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8.6.1 Generalizability of Prediction
Our results suggest that combined prediction of brain age and MMSE score
provides substantial improvements in the accuracy of brain-age prediction in
the validation dataset relative to results obtained with the isolated models.
The improvements were 0.7 in MAE and 1.01 in RMSE for the nonlinear
model, and 0.17 in MAE and 0.13 in RMSE for the linear model. Although
those improvements are not large in absolute terms, they are significant im-
provements relative to the respective MAE and RMSE values. Furthermore, it
is important to note that all the improvements were observed for the validation
dataset, which included only the data of healthy individuals. That means that
the information from the data of individuals with neurodegenerative diseases
improves the generalizability of brain-age prediction even within the range
of cerebral atrophy seen in healthy individuals. Although the same effect
may be achieved by training the brain-age model using additional data on
healthy individuals, we note that most of the data collected as part of clinical
studies are for individuals with diseases, and it is often infeasible to obtain
large samples of data from healthy individuals. Similarly, we observed notable
improvements in the longitudinal stability of brain-age prediction when the
joint model was used. The improvements were 5% and 2% for the nonlinear
and linear models, respectively. In addition, we observed that the joint model
also provided better accuracy in predicting MMSE scores. We believe that
this phenomenon is due to the regularizing effect of the joint model (i.e., a
regularizing effect was obtained by training of the shared brain-structure rep-
resentation using data from the brain-age task). Those observations suggest
that a joint model is more beneficial than isolated models.
8.6.2 Specific Brain Regions Representative of Brain Health
Furthermore, we sought to identify brain regions that are representative of
structural and functional brain health by evaluating the importance given
to SMRI ROIs in predicting brain age and MMSE score. The integrated
gradients approach indicated that the insula was given the highest weight in
predicting brain age, and that temporal regions (lateral and medial) were given
large weights in the prediction of MMSE scores. The insula has previously
been associated with age-related functions such as planning and prospective
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thinking, and it has been shown that nonplanning impulsivity reduces with
age [203]. Furthermore, the temporal lobe has been associated with cognitive
function and cognitive impairment in multiple studies [204, 205]. One of the
concerns in studying structural and functional brain health together has been
that the differences between the two concepts might be washed away in a
joint model. However, our model has the ability to jointly describe structural
and functional brain health and to distinguish the differences between them.
8.7 Study Summary
SMRI-based models of brain age and cognitive performance have been
studied extensively in the literature [190, 206]. Significant progress has
been made in brain-age modeling using preprocessed SMRI features as well
as raw images [190, 202]. Models of cognition have also been developed
using surrogates of cognitive ability, such as Mini-Mental State Examinations
(MMSE), Montreal Cognitive Assessment (MoCA) tests, and the Alzheimer’s
Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) [207]. However,
the scope of the previous studies was limited to a specific aspect of brain
health (either structural or functional) and the relationship between them was
not exploited. This study is the first to use a joint model to combine the two
semantically different but biologically related measures. A major difference
between our approach to brain-age prediction and existing approaches is that
our model allows the brain-age model to learn from the data of both healthy
individuals and individuals with neurodegenerative diseases.
On the other hand, it can be seen that our joint model is a realization
of the multi-task-learning paradigm [208]. However, most applications of
multitask learning have focused on scenarios in which tasks are drawn from
the same distribution, i.e., the tasks can be predicted using the same set of
inputs [209]. This study, on the other hand, presents a unique application
of multi-task learning to partially related tasks, a largely under-explored
topic [210]. Specifically, the uniqueness of our model is in the specification
of explicit definitions of the commonalities and differences between the two
outputs of the model based on domain knowledge, and that allowed us to
specify how the two tasks interacted with each other. That is significantly




This chapter describes a tool for predicting the progression from mild
cognitive impairment to Alzheimer’s disease, and a study conducted using the
multimodal dataset collected as part of the Alzheimer’s disease neuroimaging
initiative to demonstrate the tool’s efficacy.
9.1 Introduction
Alzheimer’s disease (AD) progresses through a preclinical phase with un-
derlying biomarker abnormalities, then a prodromal state of mild cognitive
impairment (MCI), and finally frank AD dementia [211]. Annually, 10%–15%
of patients diagnosed with MCI progress to AD dementia [212]. Identification
of factors contributing to progression from MCI to AD is crucial for clinical
prognostication and risk stratification to guide counseling and selection of
potential treatments.
In the last decade, biomarkers from cerebrospinal fluid (CSF), positron
emission tomography (PET), and magnetic resonance imaging (MRI) have
been increasingly used in AD clinical and research studies to assess the degree
of AD related pathology. Increased amyloid pathology measured by decreased
CSF Aβ42 and increased cerebral amyloid on PET, as well as increased
neuronal injury assessed by increased CSF tau, hypometabolism on FDG-
PET, and atrophy on structural MRI, are important factors in assessing the
degree of brain changes due to AD pathology and as a surrogate for prediction
of progression in individuals with MCI [211]. In addition, clinical measures
such as the Mini-Mental State Examination (MMSE) and Alzheimer’s Disease
Assessment Scale-Cognition (ADAS-Cog), which reflect the current level of
impairment in individuals, have been shown to be useful for prediction of
MCI progression [179, 213, 163].
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Research gaps: Two additional important factors in the context of MCI
progression to AD are genetic factors and cognitive resilience. AD is a geneti-
cally complex disorder, with susceptibility thought to reflect the collective
influences of multiple genetic risk and protective factors [164]. Other than
the apolipoprotein E ε4 (APOE-ε4 ) allele, individual genetic variants asso-
ciated with AD have shown modest population-level effect sizes, in keeping
with current hypotheses about the genetic architecture of the disease [214].
Although the heritability of AD is thought to be 60%–80%, beyond the well-
studied effect of the APOE-ε4 allele [165], relatively little is known about the
genetic factors specifically related to MCI-to-AD progression [166], particu-
larly regarding their added value above known biomarker profiles. Cognitive
resilience represents the ability of an individual to delay the deleterious effects
of neurodegenerative pathologies on onset of cognitive symptoms [167]. While
cognitive resilience has been widely used to explain the pathology-cognition
disconnect in cognitively unimpaired individuals with AD pathology (and
normal cognition), its relative influence specifically on MCI-to-AD progression
has not been fully evaluated [168]. Furthermore, the complex relationships
among the well-known AD biomarkers, cognitive resilience, and genetic factors
remain largely unknown and estimating the independent predictive values
provided by each of these factors may open the door to alternative strategies
to delay or prevent the onset of dementia.
Several machine learning (ML)-based approaches have been proposed for
predicting MCI-to-AD progression [179, 213, 169, 170] and clinical stage clas-
sification [172] utilizing high-dimensional clinical and biomarker data among
the potential predictors. A limitation of the ML-based approaches that utilize
high-dimensional data is the potential for overfitting, such that the classi-
fiers are so optimally trained to fit the primary dataset that they perform
poorly on previously unseen test data, ultimately limiting the generalizability
and wider interpretability [172] of the predictive model. This is particularly
important in this study because both a) an unbiased estimation of the contri-
butions of cognitive resilience and genetic factors in predicting MCI-to-AD
progression and b) the successful clinical translation of this technique would
require a generalizable model. However, prior studies on the predictability
of MCI-to-AD progression have not performed satisfactory assessments of
generalizability [179, 213, 169, 170]. These approaches utilize nonlinear classi-
fications methods such as multi-kernel learning and artificial neural networks
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without establishing the need for nonlinear models. Nonlinear classification
models are more susceptible to overfitting compared to linear classification
models in problems involving high-dimensional data since they optimize rela-
tively higher numbers of model parameters [173]; whereas, a pitfall associated
with linear models is that they provide suboptimal prediction performance
when the data is not linearly separable. Therefore, our goals in this study
with respect to the development of a predictive model are a) to understand
whether linear classifiers are sufficient to provide clinically relevant accuracies
in predicting MCI-to-AD progression based on a set of features derived from
multiple modalities and b) to develop an analytical method that evaluates the
generalizability of different classifiers and to aid model selection in clinical
settings.
Study summary: In this study, we used a machine learning-based approach
and data from a well-characterized clinical cohort to identify individuals
with MCI who rapidly progress to AD versus those with a more protracted
course. Specifically, using a set of features derived from the ADNI multi-
modal biomarker and clinical dataset along with genetic factors and cognitive
resilience measures, a linear model-based ML framework was developed for
predicting MCI-to-AD progression. Based on a test of linear-separability [174],
we show that linear classification models perform just as good as non-linear
models in this setting and a support vector machine classifier with a linear
kernel provides the most generalizable performance with a test-set area under
ROC curve (AUC) value of 0.93. Using this framework, we evaluated the
predictive values of previously underexplored factors of cognitive resilience
and genetic factors and gauged their relative importance compared to com-
monly used CSF and imaging predictors. We found that, while the markers
of AD pathophysiology (amyloid, tau, and neuronal injury) provided very
high predictive values, the genetic factors and brain regions associated with




This report utilized data from the Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI), a multisite longitudinal study of older adults representing
clinical stages along the continuum from normal aging to AD [178]. All study
participants provided written informed consent, and study protocols were
approved by each local site’s institutional review board. Further information
about ADNI, including full study protocols, complete inclusion and exclusion
criteria, and data collection and availability can be found at http://www.adni-
info.org/. All methods as stated on the website were performed with the
relevant guidelines and regulations. Since all the analyses were performed on
de-identified ADNI data which is publically available for download, IRB review
was not required. In addition, all methods were carried out in accordance
with the approved guidelines.
In choosing ADNI participants to study, we used these inclusion criteria: a)
the person had at least three years of follow-up; b) the person had all the data
modalities of interest (as specified below); and c) the person was diagnosed
with MCI at the baseline evaluation. We identified 135 participants who met
those criteria. A total of 39 of the 135 progressed to AD within three years of
the MCI diagnosis (and are referred to as the MCI-P group); the remaining
96 progressed to AD after three years or remained in MCI until their last
follow-up after three years (and are referred to as the MCI-NP group).
9.2.2 Predictive Factors
Figure 9.1 illustrates potential factors that may impact progression from
MCI to AD. Below we describe the specifics of the individual biomarkers
utilized in this work.
All the biomarkers utilized in this work were downloaded from the LONI
data archive (https://ida.loni.usc.edu/) where the pre-processed ADNI data
are hosted.
Cerebrospinal fluid (CSF) biomarkers: CSF levels of amyloid beta (Aβ)
and total (T-tau) and phosphorylated (P-tau) tau proteins were assayed by
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Figure 9.1: Factors that can predict progression from MCI to AD. The extent
of Aβ-deposition, clinical decline, and neuronal injury at baseline represent
the clinical severity of the disease in the MCI subjects. Cognitive resilience,
genetic traits, and demographic factors are measures of heterogeneity within
the cohort. Aβ-deposition is generally measured using CSF-Aβ and PET
amyloid imaging. Neuronal injury is measured using CSF-Tau, FDG-PET,
glucose uptake, and MRI atrophy measures. Clinical cognitive decline is
measured via clinical scores such as Mini-Mental State Examinations
(MMSE). Cognitive resilience in a subject can be measured using IQ and
level of education. The genetic traits of an individual can be measured using
gene expression (RNA) measures. Demographic factors like age, gender, and
disease risk factors can also influence the progression. Indicated using solid
arrows are factors that influence MCI-to-AD progression and broken lines
indicate measurements that were used to measure those factors. Factors and
measurements highlighted in red are those that have not been studied in
previous MCI-to-AD progression studies in conjunction with the rest.
the ADNI biomarker core as previously described [180].
Magnetic resonance imaging biomarkers: Structural MRI (SMRI) scans
at baseline were downloaded and processed as described previously [181].
FreeSurfer v5.1 was used to obtain volume and thickness measures for standard
regions of interest (ROIs) as surrogates for cerebral atrophy. We scaled the
volumes by total intracranial volume. In addition, we also included volumetric
measurements of hippocampal subfields.
Positron emission tomography (PET) biomarkers: Fluorodeoxyglu-
cose (FDG) and F-florbetapir PET imaging from the baseline visit were
analyzed as surrogates for neuronal injury and amyloid pathology, respec-
tively [178]. For FDG-PET, AD-specific ROIs representing the temporal,
angular, and posterior cingulate gyri were utilized [183]. For F-florbetapir
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PET, we included regional amyloid deposition assessed by standardized up-
take value ratio (SUVR) in the temporal, parietal, and cingulate cortex, as
well as a composite global measure of multiple regions [184].
Cognition: Scores on the Mini-Mental State Examination (MMSE) [185] at
baseline were utilized as measures of cognitive performance.
Cognitive resilience: The number of errors on the American National
Adult Reading Test (ANART) (which is an estimate of pre-morbid verbal
IQ) and years of education were utilized as surrogate measures of cognitive
resilience.
Genetic factors: Genotype and gene expression data from peripheral blood
samples in ADNI were obtained as previously described [215]. In this study,
we specifically analyzed APOE-ε4 allele status (carrier vs. non-carrier) as
well as expression data for the top genes with validated associations to AD
(APOE, BIN1, CLU, ABCA7, CR1, PICALM, MS4A6A, CD33, and CD2AP)
as listed in the AlzGene database [216].
Demographics: Gender and age at the baseline visit were utilized in the
predictive model.
Data aggregation and ML preprocessing: A total of 94 potential pre-
dictive factors were included for analysis. A matrix was generated with
135 rows (representing study participants) and 94 columns (representing the
potential predictive factors for MCI-to-AD progression). Prior to further
analysis, we centered and standardized all data on a feature-by-feature basis
by subtracting the mean and then dividing by the standard deviation.
9.3 ML-based Prediction Framework
Figure 9.2 shows a flow diagram of the prediction framework developed for
this study. The framework consists of four major steps: information-theoretic
feature selection, classifiers and hyper-parameter optimization, goodness-of-fit
evaluation, and generalized performance evaluation. They are explained in
the following paragraphs. A unique aspect of this workflow is the ability to
specify the number of parameters optimized in the classification model by
using an information-theoretic feature selection method. This is particularly
useful in assessing the generalizability of a classifier as a function of the
number of model parameters.
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Full dataset:
N = 135 subjects (MCI-P – 39, MCI-NP – 96)
P = 94 features
Randomized shuffling
Training – 80% Testing – 20%
Choose n features using JMI criterion
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Figure 9.2: A flow diagram illustrating the prediction framework. The
framework uses a machine learning-based approach to learn a classifier using
80% of the full dataset and to test its performance on the remaining 20% of
the data. Specific details of each step in the framework are as follows. (A)
Stratified data partitioning: After the order of the subjects is randomized,
the MCI-NP and MCI-P groups are separately partitioned with an
80%-training/20%-testing split. The respective training and testing sets from
MCI-NP and MCI-P groups are combined to form the overall training and
testing data for a single cross-validation. (B) Feature select loop: The top n
out of 94 features that best jointly correlate with the class labels (P-MCI or
MCI-NP) are selected using the joint mutual information (JMI) criterion.
(C) Inner CV loop: A combination of hyper-parameters is selected for each
classifier based on a tenfold cross-validation. (D) Goodness-of-fit metrics:
The classifier learned in the previous step is tested on the testing dataset and
measured on its performance. (E) Outer CV loop: A fivefold cross-validation
is utilized to produce generalized performance metrics accounting for
non-uniformly distributed data.
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9.3.1 Feature Reduction using Joint Mutual Information (JMI)
Mutual information between two random variables quantifies the amount of
information shared between them. Mutual information is a more comprehen-
sive measure of the relationships between random variables than statistical
correlation-based approaches, which measure linear relationships only. Math-
ematically, mutual information is denoted by and defined for discrete random
variables Q and R as shown in Eq. 9.1, where Q and R denote the alphabets










When Fk is one of the attributes in a set of attributes {F1, F2, . . . , Fk}
and is an outcome or class that can be predicted by the attributes, mutual-
information-based approaches can be used to select the most predictive
attributes. One such approach is to treat the attributes as independent random
variables, rank them in descending order based on their mutual information
with respect to the outcome Y , and select the top n number of attributes. One
limitation of that approach is that useful and parsimonious sets of features
should be both a) individually relevant and b) not highly correlated with
each other. Joint mutual information shared between {F1, F2, . . . , Fk} and Y
is defined as shown in Eq. 9.2, where Fk and Y denote the alphabets of Fk
and Y respectively.






p(f1, f2, . . . , fk, y)log
p(f1, f2, . . . , fk, y)
p(f1, f2, . . . , fk)p(y)
(9.2)
A JMI-based feature selection method starts with an empty set of attributes
and iteratively adds Fis that, when added, provide the maximum increase
in the joint mutual information shared between the set of attributes and the
outcome [175]. It has been shown to be the most stable and flexible feature
selection method [217] among all the information-theoretic feature selection
methods developed to date.
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9.3.2 Classification Methods
We evaluated a number of classifiers in this study to understand the concepts
of linear separability and generalizability in the context of predicting MCI-
to-AD progression. Support vector machine (SVM), multiple kernel learning
(MKL), and generalized linear models (GLM) with elastic-net regularization
are the classifiers used in this study. SVM classifier, because it allows the
transformation of features using linear and nonlinear kernels, provides us the
ability to evaluate the suitability of linear and nonlinear classifiers for this
problem. On the other hand, MKL allows the application of different kernel
transformations for features from different modalities while optimizing more
model-parameters than an SVM classifier. Although MKL and SVM are
similar classification paradigms, MKL facilitates the integration of multiple
modalities at the expense of potential overfitting. Finally, GLM classification
with elastic-net regularization is an extension of the commonly known logistic
regression classifier with additional regularization to minimize overfitting. In
this study, we evaluated the overall generalizability of these classifiers that
have distinct optimization objectives. A description of SVM classification is
provided in Section 5.2.5.
Multiple kernel learning is a classification technique that builds upon the
dual transformation of SVM and introduces additional variables in order to
weight the kernel transformation of individual features [218]. It does so by re-




where Km is the kernel function of the m
th feature and βm is its weight. This
technique is particularly useful when the data contain different modalities of
features that need to be weighted differently. In a standard kernel-SVM, either
the kernel transformation is uniformly weighted, or the weights are determined
manually. It has been shown that the same dual formulation of SVM can be
utilized to find the optimal weightings of the kernel transformation under the
constraint that
∑P
m=1 βm = 1.
Logistic regression is a subclass of generalized linear models (GLM) and
is well-suited for binary classification tasks [182]. It models the response
variable as a binomially distributed random variable whose parameters are
described by predictor variables and model parameters. Regularization of
the model parameters is utilized to avoid effects related to overfitting. The







[Y (i)log(X(i)) + (1− Y (i))log(1− (X(i)))] + λPα(β) (9.3)
where h(x) is the logistic function defined as 1
1+e−x
and Pα(β) is the regulariza-
tion term with the elasticity parameter α. The regularization term in general
might contain both L1-norm terms and L2-norm terms, a situation that is com-




[219]. The elasticity parameter α ranges in (0, 1] with values of α → 0
approaching ridge regression and α→ 1 approaching LASSO regression.
9.3.3 Hyper-parameter Optimization
The hyper-parameters of the three classifiers are SVM’s kernel, kernel scale
σ, and box-constraint C, MKL’s kernel, and GLM’s penalty term λ and
elastic-net parameter α. The optimal values of hyper-parameters are chosen
by performing a grid-search of parameter values with a k-fold cross-validation
within the training dataset.
9.3.4 Goodness-of-fit Evaluation and Generalized Performance
Metrics
Goodness-of-fit of a classifier is evaluated by i) predicting the classes of the
test dataset by using the classifier that was trained on the training dataset
and ii) comparing the predictions against the true class labels of the test
dataset. The comparison is performed using standard performance metrics
such as receiver operating characteristics (ROC) curve analysis, area under
ROC curve (AUC), sensitivity, specificity, accuracy, precision, recall, and
F1-score.
Because of heterogeneity in the data, choosing one partition of training
and test datasets is not sufficient to credibly evaluate the performance of a
classifier. A common practice to obviate the effect of heterogeneity in the
data is to perform an k-fold training-testing cross-validation of the dataset.
One run of this procedure is carried out by randomly choosing a subset of
the dataset as training data, and testing on the rest of the dataset. That is
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repeated different times, and the performance metrics of all evaluations are
averaged. In addition to this, the proportion of the different classes in the
randomly chosen training dataset was kept constant in our approach via a
stratified data-partitioning to eliminate any variability in the performance
of the classifiers due to class imbalances in the data [173]. We performed
those extra steps to obtain a generalizable set of performance metrics for the
analyzed classifier.
9.3.5 Implementation of the Prediction Framework
We utilized a standard fivefold cross-validation with 80% training data and
20% testing data to evaluate the performance of the classifiers. Training and
testing data selection was performed using the stratified data-partitioning
approach explained previously. The JMI criterion was used to identify features
based on the training dataset and corresponding labels. Using the reduced
dataset, we trained SVM with a linear kernel, SVM with an RBF kernel, MKL
with a linear kernel, LR with elastic-net regularization, and RF. The highest
average AUC obtained with a tenfold cross-validation within the training
set was used as the selection criterion for the optimal hyper-parameters. We
generated performance metrics for each classifier with the best identified
hyper-parameters by predicting the labels of the test set and comparing them
against the true class labels of the test set. The performance metrics of all
five of the (outer) cross-validation runs were averaged to generate generalized
performance metrics.
9.3.6 Test for Linear Separability
Linear separability of a dataset with two classes signifies that a linear
classifier (or a hyperplane) can separate the two classes in the data as well as
nonlinear classifiers can. We show that by using a slight modification of the
histogram-of-projections [174] method, which is considered a test for class
separability using SVM classification. The histogram-of-projections method
[174], is as follows. An SVM classifier is trained using the training data and a
chosen kernel. Then, the test samples are projected on the 1-dimensional line
perpendicular to the maximum margin hyperplane learned by the SVM model.
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Histograms of these projections for the two different classes are compared to
evaluate the degree of separation achieved by the classifier. In our approach,
we applied a sigmoid transformation to the projections of the test samples to
obtain likelihood probabilities, and then, based on the likelihood probabilities,
we created histograms of the two classes. This modification was performed in
order to eliminate the effects of scaling when different kernel transformations
are applied in SVM classification and to maintain the range of histograms
within a closed set [0, 1].
9.4 Results
Our results are organized as follows. Table 9.1 represents the overall
summary statistics of the dataset analyzed in this study with some important
demographic factors. First, we present the results of our evaluation of whether
linear models are sufficient to classify this dataset. Second, we report the
analytic method we developed to evaluate generalizability and the results on
the generalizability of the analyzed linear classifiers. Third, we report the
relative importance of the biomarkers and clinical variables utilized in this
study evaluated using the most generalizable classifier selected based on the
previous result. Finally, we report the analysis based on LASSO regression
[186] and a set of identified features that provide independent information in
predicting MCI-to-AD progression.
Table 9.1: Summary characteristics of participants at baseline.
MCI-P (n = 39) MCI-NP (n = 96)
Average age (range of ages) 72 (55–84) 71 (55–88)
Number of females (percent female) 19 (49%) 48 (50%)
Average years of education (range) 16 (9–20) 16 (12–20)
Number of APOE carriers (percent) 6 (15%) 3 (3%)
9.4.1 Linear Separability
First, we evaluated the linear separability of the data in order to under-
stand whether linear classifiers, which are less susceptible to overfitting, were
sufficient to perform prediction of MCI-to-AD progression. We applied the
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modified histogram-of-projections method to our dataset by training two
SVM classifiers with linear and RBF kernels and by plotting histograms of
sigmoid transformations of the projections of test samples.
Figure 9.3: An illustration of the method that evaluates linear separability of
the data. We utilize a slightly modified version of the histogram of
projections method to evaluate linear separability of the data. (A) A
maximum margin hyperplane is learned using SVM with a choice of kernel.
All samples are projected onto the line perpendicular to the hyperplane to
obtain the projections. The projection lengths are transformed to a
probability value via the sigmoid function. Histograms of the probabilities
for the two classes are plotted separately. (B) Histograms of the probabilities
of the MCI-P and MCI-NP samples in our dataset obtained using a linear
kernel. (C) Histograms of the probabilities of the MCI-P and MCI-NP
samples in our dataset obtained using an RBF kernel. (D) A grouped scatter
plot of the probabilities obtained using linear and RBF kernels for MCI-P
and MCI-NP classes. The similar histogram shapes and similar
misclassification errors in (B) and (C), and the high correlation (ρ = 0.99,
p<1E-6) between the probabilities obtained using the two kernels, indicate
that linear and nonlinear kernels result in similar boundaries for
classification; hence, this dataset is linearly separable.
Figure 9.3A shows a generic illustration of our approach based on the
histogram-of-projections method. Figures 9.3B and 9.3C show the histograms
obtained using our approach for linear and RBF kernels, respectively. The two
histograms have similar shapes, and the misclassification errors obtained by
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choosing an appropriate threshold are also close (20.52% for the linear kernel
and 19.78% for the RBF kernel). Figure 9.3D shows a grouped scatter plot
of the probabilities obtained using linear versus RBF kernels for the MCI-P
and MCI-NP classes. There is a significantly high correlation between the
probabilities obtained using the two kernels ( ρ= 0.99, p<1E-6), indicating
that the classification boundaries learned using the linear and nonlinear
kernels are similar. This experiment suggests that the dataset being analyzed
is linearly separable. Hence, we limited our analyses to linear classification
techniques for the rest of this study.
9.4.2 Generalizability of Classifiers
Second, we evaluated the overfitting characteristics of the linear classifiers
in order to identify models that were likely to provide highly generalizable
performance on this dataset. Three linear classifiers—multiple kernel learning
(MKL) with linear kernels, support vector machine (SVM) with linear kernel,
and generalized linear model (GLM) with elastic-net regularization—were
trained using 80% of the whole dataset as the training set but using only
a subset of all the features. We selected the subset (out of a total of 94
features) using the joint mutual information (JMI) criterion, by varying the
number of features used each time as 5, 10, 15, . . . , 85, 90, 94. We utilized
tenfold stratified cross-validation to obtain average training and testing area
under ROC curve (AUC) metrics and their respective standard deviations
on each occasion. Figure 9.4 shows plots of the cross-validated AUCs with
their standard deviations against the ratio number of features used in training
number of training samples
for both
training (9.4A) and test (9.4B) sets. On the training set, the AUCs of all
the classifiers showed better performance with increasing numbers of features
used in training. But on the test set, only SVM and GLM showed a relatively
steady trend in the AUC. MKL, on the other hand, showed a decreasing
testing AUC trend with increasing numbers of features used in training. Those
data suggest that the MKL classifier may be overfitting the training data
when the ratio number of features used in training
number of training samples
is not small (it is > 0.14 in this
case).
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Figure 9.4: An evaluation of generalizability of linear classifiers. Three linear
classifiers—multiple kernel learning (MKL) with linear kernels, support
vector machine (SVM) with a linear kernel, and generalized linear model
(GLM) with elastic-net regularization—were trained multiple times using
80% of the data as the training set but with a variable number of features
each time. We plotted the cross-validated AUCs with their standard
deviations against the ratio number of features used in training
number of training samples
for both training (A)
and testing (B) sets. While all the classifiers show an increasing AUC trend
on the training set with increased numbers of features used in training, only
SVM and GLM show a relatively steady trend on the test set. MKL on the
other hand, shows a decreasing testing AUC trend with increased numbers of
features used in training.
Those results suggest that both SVM with a linear kernel and GLM with
elastic-net regularization have good generalizability (with a consistent AUC
value of approximately 0.9) regardless of the ratio of the number of features to
the number of training samples, and MKL had good generalizable performance
only when this ratio was small. Further, particularly for this dataset, all
linear classifiers showed a reasonable test set predictability when the number
of features was appropriately chosen during the training phase.
9.4.3 Prediction Performance of Linear Classifiers
The subset of features that provided the most generalizable predictive
performance for each linear classifier were selected. Table 9.2 lists all the
cross-validated goodness-of-fit metrics (AUC, sensitivity, specificity, accuracy,
precision, recall, and F1-score) obtained using MKL with linear kernels, SVM
with a linear kernel, and GLM with elastic-net regularization, with their
respective subsets of features. All linear classifiers produced comparable















































































































































































































































































































9.4.4 Predictive Ability of Individual Modalities
To understand the predictive ability of individual modalities in a statistically
impartial manner, we restricted our analysis in this subsection to only one
linear classifier. Based on Table 9.2, we chose the SVM classifier with a
linear kernel, as it provided the best performance in terms of the AUC
metric. Then, we repeated our classification procedure using a stratified
tenfold cross-validation for each of the modalities (using all the variables in
the respective modality each time). Figure 9.5A shows a bar-chart of the
average AUCs obtained by individual modalities. CSF proteomic markers
(including Aβ, total-tau, and phosphorylated-tau) provided the best individual
prediction capability, followed by the imaging markers in the order amyloid
PET, FDG-PET, and SMRI. Gene expression, clinical, cognitive resilience,
and demographic markers showed lower predictive ability than did CSF
and imaging-based markers. Figure 9.5B shows a different bar-chart of the
average AUCs obtained by iteratively removing the respective features of
the individual modalities in a descending order based on their individual
predictive abilities seen in Figure 9.5A. A gradual decline in the AUC is























































































































Figure 9.5: An evaluation of the relative predictive abilities of modalities.
(A) The cross-validated AUCs obtained using an SVM classifier with a linear
kernel separately for each of the modalities. (B) The AUCs obtained by
iteratively removing the modalities in a descending order based on AUCs
obtained in (A). (Modalities with high AUC values per (A) were removed
first.) In (B), “∼X” indicates that modality X was removed while the
modalities that are less predictive than X were kept.
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9.4.5 Best Predictors of MCI-to-AD Progression
Next, we sought to identify a minimal set of predictors required to model
MCI-to-AD progression. This was motivated by an observation about Figure
9.5: although CSF features provided the best individual AUC (Figure 9.5A),
the removal of CSF features from the data (Figure 9.5B) did not result in
a substantial drop in the AUC (the reduction in AUC is within the error
limits). That suggests that other modalities provide overlapping information
that may be correlated with the CSF markers, and also indicates that all the
modalities might have a notable level of correlation with each other. We used
a generalized linear model (GLM) classification method with L1 regularization
(known as LASSO regression) to identify a sparse set of features with minimal
within-correlation and maximal prediction potential of clinical progression
[186]. We chose to use LASSO regression instead of SVM classification for this
task because the feature weights assigned by the SVM classifier with a linear
kernel do not represent the independent predictive values of individual features
when the features themselves are correlated with each other. However, the
L1-norm-based regularization of LASSO regression may enable identification
of the smallest possible set of predictors, since it penalizes the classifiers
that utilize a large number of features in the resulting predictive function.
Table 9.3 shows the results from this approach, identifying the factors that
provided the best spread of independent information to predict MCI-to-AD
progression. This model included PET, MRI, and CSF variables in addition
to age and expression of CR1 (complement receptor 1) and was able to predict



















































































































































































































































































































































































































































































































9.5 Interpretation of Results
In this study, we developed an accurate and generalizable machine learning-
based methodology for predicting short-term progression of MCI to AD
dementia in a well-characterized clinical cohort. A unique aspect of this
work was our evaluation of important genetic markers and cognitive resilience
markers in addition to the neuroimaging biomarkers and clinical examination.
The results suggest that a combination of selected neuroimaging, blood and
CSF biomarkers, and demographic traits reflect the underlying pathophysi-
ology and factors that drive clinical progression in the AD spectrum. The
methodology allowed us to discover that expression of CR1 and AD-pattern
neuropathology and neurodegeneration (MRI measures in the frontal lobes) in
brain regions associated with cognitive resilience added independent predictive
values in predicting MCI-to-AD progression. We also evaluated the relative
importance of individual predictors and identified a minimal set of predictors
that are important for predictive modeling of MCI progression to AD.
9.5.1 Predictors of MCI Progression to AD
The broad pathogenesis of AD has been well-described conceptually, from
initial alterations in molecular and cellular pathology to neurodegeneration
and eventually to clinical impairment sufficient to cause dementia [179].
However, it is not yet fully understood what specific factors “shift the curve”
to either promote or inhibit the development of dementia. As a result, we
initially approached our study in a relatively unbiased fashion, casting a
broad net for potential predictive factors out of multidimensional clinical,
neuroimaging, and other biomarker data. Through our ML approach, we
found that measures of AD neuropathology (CSF amyloid and tau and cerebral
amyloid assessed by PET) and neuronal injury (assessed by FDG-PET and
structural MRI) explained the most variance in separating fast versus slow
progression from MCI to AD dementia. The importance of biomarkers in
predicting progression has been studied in the past, but the approach we took
allowed us to rank various predictors (including the biomarkers) as well as
identify the minimal predictor set that are key to the overall models. When the
biomarkers were excluded, predictors such as cognitive performance, cognitive
resilience, and expression of selected genes individually explained less of the
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outcome variance and collectively appeared to offer less new information to
the predictive model. Our results support the hypothesis that CSF biomarkers
and imaging can be used as surrogates for neuropathology and brain health
and can serve as key indicators of future MCI prognosis.
9.5.2 Information Added by Genetic Factors and Cognitive
Resilience
An important aspect of this work is the incorporation of genetic factors and
cognitive resilience into our predictive model. Most cases of AD are thought
to be genetically complex, with multiple factors presumed to contribute to
susceptibility and protection, with the largest known factor being the APOE-
ε4 allele [220]. Understanding of the genetic architecture of AD has greatly
expanded over the last decade as a result of genome-wide and rare-variant
association studies, among other approaches [164]. However, the specific
genetic factors that influence progression at various clinical stages of AD are
still not well-characterized. Our ML approach identified expression of CR1
as a key factor in predicting fast versus slow progression to AD dementia,
which is a novel finding of this study. Interestingly, our final minimal set
model included CR1 expression but did not include APOE-ε4 allele status,
suggesting that the former provided unique information for clinical course
prediction while the latter was already represented by surrogate biomarkers,
specifically amyloid deposition [187]. Polymorphisms (genotype variations) in
CR1 have been associated with AD status and endophenotypes in numerous
large-scale studies [188, 171, 162, 189, 221, 222]. CR1 encodes a receptor
involved in complement activation, a major immune mechanism with a wide
array of functions; it has been proposed that it impacts the clearance of
amyloid in AD [223]. Previous findings on CR1 have been illuminated by a
more recent and extensive body of work highlighting immune system pathways
as potential cruxes in AD pathophysiology [224, 225, 226, 227, 54]. Our new
findings relating CR1 expression to progression from MCI to AD dementia
provide further validation of that previous work and argue for greater focus
on CR1-and on genetic variation in MCI-to-AD progression more broadly
[57]-to enable better understanding of the mechanisms underlying AD and
its clinical trajectories.
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It is not unexpected that in our ML-based prediction model for MCI to
AD progression, CR1 gene expression contributed relatively less to explaining
variance than biomarkers of neuropathology and neuronal injury. Surrogates
of pathology (fluid biomarker and neuroimaging) reflect the extent of disease
related changes and are likely more proximal to clinical manifestations of
disease compared to gene expression which may be upstream of these changes
and thus possibly modifiable by concomitant forces over time. An example
is the relationship between APOE-ε4 and amyloid: while APOE-ε4 is a key
driver of amyloidosis, the measured effect of amyloid load on cognition is
significantly stronger than the impact of APOE-ε4 on cognition [187, 49].
Complementary methods to incorporate collective effects of multiple genes,
including pathway analyses and polygenic risk scoring [52, 50, 51, 53], could
be incorporated into our ML approach in future. In addition, for this study
we analyzed microarray gene expression (rather than genotype) data, which
offers the conceptual advantage of being a dynamic (rather than static)
marker of late-life conditions but which has the disadvantage of representing a
downstream effect of influences earlier in life with the potential to be modified
by interactions with other heritable and non-heritable factors. Finally, for this
study we limited the focus to the AlzGene top 10 list1, but other genes with
less well-known population-level effects on case-control status may have larger
contributions to late-life clinical progression which could be discovered with
an unbiased genome-wide approach. Despite these constraints, our approach
serves as a proof of concept that incorporating genetic data can add value to
ML-based clinical prediction models and highlights CR1 for further study on
its potential effects at the inflection of MCI to AD progression.
Although cognitive resilience has been shown to contribute significantly to
delaying the onset of clinical impairment, neither education nor verbal IQ
was identified as a key predictor of MCI progression. There are two possible
explanations for those results. First, preservation of structure or lack of
atrophy, as observed via MRI, may be a better surrogate of resilience than
are estimates of pre-morbid IQ or educational attainment. It has been shown
that cognitive resilience is captured well by greater volume and metabolism,
especially in the frontal and cingulate regions [55]. Second, cognitive resilience
may be more relevant before the onset of cognitive symptoms or impairment
1http://www.alzgene.org/TopResults.asp, accessed 11/22/2020
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[168], and thus may be of less importance in cognitively impaired individuals,
who are the focus of this study.
9.5.3 Strengths of the Computational Approach
Our results indicate that linear classifiers are sufficient to identify patients
who have the potential to progress from MCI to AD within three years, via
the use of multimodal measurements including imaging, CSF, genetic, and
clinical data. The reason for this might be all the features were engineered
prior to application of machine learning in such a way that a dichotomy
within a feature correlates with disease progression. Linear classifiers are
particularly useful they are less susceptible to overfitting and thus can be
appropriate for clinical translation. In addition, we also developed an analytic
method for evaluating the generalizability of three different linear classification
approaches, namely GLM-ElasticNet, multi-kernel SVM with linear kernels,
and standard SVM with a linear kernel. Multi-kernel SVM showed slightly
greater tendency to overfit than the other linear classifiers in our experiments.
Because multi-kernel SVM optimizes twice as many model parameters as
standard SVM or GLM, it seems that the number of samples used in this
study was not enough to train multi-kernel SVM in a generalizable manner.
However, as indicated in the experiments, when the number of features used
in the classification was small, multi-kernel SVM seemed to provide a more
generalizable performance compared to when more features were used in the
classification, since there were fewer optimized model parameters in the former
scenario. Even so, standard SVM and GLM provided better generalizability
and achieved higher classification accuracies with more features. In comparison
with previously published predictors of MCI-to-AD progression, our approach
achieves superior predictive performance, with a 0.93 area under ROC curve
providing a 6% improvement over the current best predictor [179]. Although
Korolev et al. [179] utilized only CSF and imaging modalities, the AUC in
their approach was evaluated on the whole dataset (including 90% training
data and 10% testing data), while we evaluated it only on the testing dataset




Machine learning for healthcare is an emerging field in the broad area of
data science and has received strong interest in recent times. Applications
of machine learning in healthcare hold significant promise in enhancing a
clinician’s ability to diagnose and treat a disease. In addition, such approaches
can also enable new directions of research, identification of novel treatments,
and reduce the overall cost of the healthcare system. However, the progress
in this field has been hindered by the lack analytical tools that can handle
relatively smaller datasets, the need for highly interpretable models, and
incorporation of heterogeneous healthcare datasets. This dissertation intro-
duced a new analytical framework named domain-guided machine learning
(DGML) that incorporates domain expertise with machine learning using
probabilistic graphical models as the basis.
In essence, the framework uses probabilistic graphical models to represent
the domain-driven relationships between different information sources and
transforms them into discriminative models to infer the state of an underly-
ing biological phenomenon. Because DGML is based on domain expertise,
the development of a DGML-based predictive model is less reliant on data
volume. In other words, the domain-based design provides a meaningful
initialization for a machine learning model, which can then be fine-tuned
using the limited data available. This allows DGML-based models to achieve
desired performance levels even with a small number of training data sam-
ples. Furthermore, by design, the DGML framework allows the integration of
multimodal healthcare data taking their inter-dependencies also into account.
In fact, such inter-dependencies are obtained from domain experts and the
model is designed in such a way that the combination of multiple data sources
is meaningful from a biological perspective. In addition, DGML-based models
are easily interpretable for clinicians because clinical intuitions are the basis
for the development of a DGML-based model.
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Because DGML models have firm biological foundations, they also al-
low the development of accurate predictive models even when the available
ground-truth information is limited or error-prone. This is evident from the
applications that demonstrated DGML, which have shown the promise for
clinical translation: 1) the technology developed for epileptic seizure forecast-
ing is currently undergoing a human clinical trial at the Mayo Clinic; and 2)
the technology developed for seizure onset localization has resulted in a joint
patent between the Mayo Clinic and the University of Illinois and is under
consideration for a prospective trial [228]. In summation, this dissertation
proposed an analytical framework known as domain-guided machine learning
and described several research studies, which demonstrated the analytical
methods developed using the proposed framework in important clinical appli-
cations. Furthermore, the contributions made in this dissertation are relevant
to several research disciplines including neural engineering, computational
neuroscience, artificial intelligence, and translational health data science.
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